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Cardiomyopathies are an important cause of heart disease, affecting an estimated 
40,000 (0.25%) individuals in the Netherlands.1 They are characterised by abnormal 
myocardial structure and/or function. Other non-genetic causes that could result 
in the observed myocardial abnormality must first be excluded in order to make 
the diagnosis. Examples of these are coronary artery disease, hypertension, valvu-
lar disease, myocarditis and congenital heart disease. Different cardiomyopathy 
subtypes can be recognised: hypertrophic, dilated, arrhythmogenic, and restrictive 
cardiomyo pathy.2 According to the classification system proposed by the European 
Society of Cardiology, it is not clear whether left ventricular non-compaction cardio-
myopathy (NCCM) is a separate cardiomyopathy. However, the classification system 
proposed by the American Heart Association includes NCCM as a separate entity 
and also includes cardiac ion channel disorders and channelopathies.2,3 
In 1990, the first mutation underlying cardiomyopathy was identified in the 
β-myosin heavy chain (MYH7) gene in a large family with hypertrophic cardiomyo-
pathy (HCM).4,5 Since then, mutations in over 60 genes have been associated with 
















figure 1 Total number of genes associated with one or more cardiomyopathy subtype reported since 1990. 
The total number of associated cardiomyopathy genes is shown by the black line. Per cardiomyopathy 
subtype the novel associated genes are listed since the first publication in 1990 of a mutation in the 
MYH7 gene in HCM by Geisterfer-Lowrance et al.5 Since many genes have been associated with multiple 
cardiomyopathy subtypes, the line of the total number of associated genes is not the sum of all lines of 
the cardiomyopathy subtypes (see Table 1).
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Table 1 Genes associated with one or more cardiomyopathy subtypes
Gene Name Locus OMIM HCM DCM ACM RCM NCCM References
ABCC9 ATP-binding cassette 9 12p12.1 601439 x 67
ACTC1 Actin, alpha cardiac muscle 15q14 102540 x x x x 68-77
ACTN2 Actinin, alpha 2 1q43 102573 x x 78-80
ANKRD1 Ankyrin repeat domain-containing protein 1 10q23.3 609599 x x 81-83
BAG3 BCL2-associated athanogene 3 10q26.11 603883 x 84,85
CALR3 Calreticulin 3 19p13.11 611414 x 86
CASQ2 Calsequestrin 1p13.1 114251 x x 77,86
CAV3 Caveolin 3 3p25.3 601253 x x 87-89
CRYAB Crystallin alpha-B 11q23.1 123590 x 90
CSRP3 Cysteine- and glycine-rich protein 3 11p15.1 600824 x x 70,78,80,91-94
DES Desmin 2q35 125660 x x x 29,48,49,95-103
DMD Dystrophin Xp21.2 300377 x 104-107
DSC2 Desmocollin 2 18q12.1 125645 x 22,25,26,28,31,108-112
DSG2 Desmoglein 2 18q12.1 125671 x x 21,24-26,28,31,38,111,113-116
DSP Desmoplakin 6p24.3 125647 x x x 19,24-26,28,31,62,113,116-120
DTNA Dystrobrevin alpha 18q12.1 601239 x 121
EMD Emerin Xq28 300384 x 122
EYA4 Eyes absent 4 6q23.2 603550 x 123
FHL2 Four-and-a-half LIM domains 2 2q12 602633 x 124
FKRP Fukutin-related protein 19q13.32 606596 x 125-128
FKTN Fukutin 9q31.2 607440 x 129
GATAD1 GATA zinc finger domain-containing protein 1 7q21.2 614518 x 130
GLA Galactosidase alpha Xq22.1 300644 x 131-135
ILK Intergrin-linked kinase 11p15.4 602366 x 136
JPH2 Junctophilin 2 20q13.12 605267 x 137,138
JUP Junction plakoglobin 17q21.2 173325 x x 16,23-25,28,113,139
LAMA4 Laminin alpha-4 6q21 600133 x 136
LAMP2 Lysosome-associated membrane protein 2 Xq24 309060 x x 140-146
LDB3 LIM domain binding 3 10q23.2 605906 x x x 77,78,94,121,147-149
LMNA Lamin A/C 1q22 150330 x x x 54,77,150-154
MYBPC3 Myosin-binding protein C 11p11.2 600958 x x x 69-72,77,152,155-168
MYH6 Myosin heavy chain 6 14q11.2 160710 x x 152,166,169
MYH7 Myosin heavy chain 7 14q11.2 160760 x x x x 5,69-72,74,94,152,153,158, 162-167,170-176
MYL2 Myosin light chain 2 12q24.11 160781 x x 158,163,177-179
MYL3 Myosin light chain 3 3p21.31 160790 x x 70,71,158,163,177,179,180
MYLK2 Myosin light chain kinase 2 20q13.3 606566 x 181
MYOZ2 Myozenin 2 4q26 605602 x 182
MYPN Myopalladin 10q21.1 608517 x x x 183,184




thies is most commonly autosomal dominant, but autosomal recessive, X-linked 
and mitochondrial inheritance patterns have also been observed. Inherited cardio-
myopathies are characterised by incomplete and age-related penetrance. The pro-
portion of individuals carrying a mutation (genotype) with associated clinical symp-
toms (phenotype) increases with age, but virtually never reaches 100%. Incomplete 
penetrance implies that some mutation carriers will remain unaffected during their 
entire life. The onset of symptoms is usually after adolescence or in early adulthood, 
but children with severe forms of cardiomyopathy have been described. Some of 
these cases have been associated with multiple mutations.6,7 A selection bias has 
led to the situation that the first publications described the most severely affected 
cardiomyopathy patients. However, subsequent studies also included patients with 
Table 1 Genes associated with one or more cardiomyopathy subtypes (continued)
Gene Name Locus OMIM HCM DCM ACM RCM NCCM References
PDLIM3 PDZ and LIM domain protein 3 4q35.1 605889 x 187
PKP2 Plakophilin 2 12p11.21 602861 x x 20,24-26,28,31,113,116,188-191
PLN Phospholamban 6q22.31 172405 x x x x 77,86,192-196
PRKAG2 Protein kinase AMP-activated, gamma-2 7q36.1 602743 x 69,143,197,198
PSEN1 Presenilin 1 14q24.2 104311 x 199
PSEN2 Presenilin 2 1q42.13 600759 x 166,199
RBM20 RNA-binding motif protein 20 10q25.2 613171 x 153,200-202
RYR2 Ryanodine receptor 2 1q43 180902 x x 42,203
SCN5A Sodium channel, type V, alpha subunit 3p22.2 600163 x x x 94,152,166,204-209
SGCD Sarcoglycan, delta 5q33.3 601411 x 210,211
TAZ Tafazzin Xq28 300394 x x 77,121,149,212-215
TBX20 T-box 20 7p14.2 606061 x 216
TCAP Titin-cap 17q12 604488 x x 78,92,94,217
TGFB3 Transforming growth factor, beta 3 14q24.3 190230 x 41
TMEM43 Transmembrane protein 43 3p25 612048 x 218
TMPO Thymopoietin 12q23.1 188380 x 219
TNNC1 Troponin C 3p21.1 191040 x x 152,220-224
TNNI3 Troponin I 19q13.42 191044 x x x x
68-72,74,75,77,152,153,158, 
162,163,171,175,225-230
TNNT2 Troponin T2 1q32.1 191045 x x x x
68-71,75-77,94,152,153,158, 
162,165,166,171,173,222,231-234
TPM1 Tropomyosin 1 15q22.2 191010 x x x x 68,70,72,77,152,168,171,179,231,232,235-237
TTN Titin 2q31.2 188840 x x x 50-53,238-240
TXNRD2 Thioredoxin reductase 2 22q11.21 606448 x 241
VCL Vinculin 10q22.2 193065 x x 78,242-244
HCM indicates hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; ACM, arrhythmogenic 
cardiomyopathy; RCM, restrictive cardiomyopathy; NCCM, non-compaction cardiomyopathy.
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a milder phenotype, pointing out that these disorders may not be as severe as ini-
tially believed, although the course can still be very grave. The range in both type and 
severity of the disease between individuals carrying the same mutation, even within 
the same family, is called variable expression.8 
Inherited cardiomyopathies are not only clinically variable; the genetic back-
ground is also heterogeneous. For each cardiomyopathy, multiple disease genes 
have been identified. Mutations in several genes, especially in those genes coding 
for sarcomeric proteins, can cause different cardiomyopathy subtypes (Table 1 and 
Figure 2). Since 1990, the number of genes associated with one or multiple forms 
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figure 2 Genetic heterogeneity and overlap in genes causing cardiomyopathies. This figure shows the 
genes underlying hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic 
cardiomyopathy (ACM), restrictive cardiomyopathy (RCM), and non-compaction cardiomyopathy 
(NCCM). The genes correspond with Table 1. The figure is based on Van Spaendonck et al. (2008)65 and 




of cardiomyopathy has increased rapidly (Figure 1). This thesis focuses on the 
genetic and clinical aspects of arrhythmogenic cardiomyopathy (ACM), which will 
be discussed in more detail below.
Arrhythmogenic cardiomyopathy
In 1982, Marcus et al. described a comprehensive series of patients diagnosed with 
“right ventricular dysplasia”. These patients were characterised by life-threatening 
ventricular arrhythmias, originating from the right ventricle (RV).9 The cause of the 
disease was believed to be a developmental defect of the myocardial tissue of the 
RV, resulting in the use of the term “right ventricular dysplasia”. However, the find-
ing that the RV myocardium is subject to cell death and is subsequently replaced by 
fibrous and fatty tissue, which interferes with electrical conduction of the heart and 
results in arrhythmias, later led to the concept of arrhythmogenic right ventricular 
cardiomyopathy (ARVC).10 In addition to this classic form of ARVC, biventricular 
and left-dominant forms have been recognised.11,12 Nowadays, the encompassing 
term “arrhythmogenic cardiomyopathy” (ACM) is increasingly used. Men are more 
frequently affected than women and the estimated prevalence in the general popula-
tion ranges from 1 in 1,000 to 1 in 5,000.13
An international task force proposed diagnostic criteria for ARVC in 1994.14 These 
clinical criteria comprise six different categories, including structural and histologi-
cal findings, depolarisation and repolarisation abnormalities, arrhythmias, and fam-
ily history. Major and minor criteria were defined for each category. A diagnosis can 
be made if a patient fulfils two major criteria, one major and two minor criteria, or 
four minor criteria, all from different categories. These 1994 criteria were found to 
be highly specific but not sensitive enough. To overcome this issue, the criteria were 
modified in 2010, while maintaining the six different categories and including the 
results of genetic studies (Table 2).15
16
Table 2 Revised task force criteria for the diagnosis of ARVC#
Major Minor
i. Global or regional dysfunction and structural alterations*
By 2D echo:
•	 Regional RV akinesia, dyskinesia, or aneurysm
•	 and 1 of the following (end diastole):
-  PLAX RVOT ≥32 mm (corrected for body size [PLAX/
BSA] ≥19 mm/m2)
-  PSAX RVOT ≥36 mm (corrected for body size [PSAX/
BSA] ≥21 mm/m2)
- or fractional area change ≤33%
By MRI:
•	 	Regional RV akinesia or dyskinesia or dyssynchronous 
RV contraction
•	 and 1 of the following:
-  Ratio of RV end-diastolic volume to BSA  
≥110 mL/m2 (male) or ≥100 mL/m2 (female)
- or RV ejection fraction ≤40%
By RV angiography:
•	 Regional RV akinesia, dyskinesia, or aneurysm
By 2D echo:
•	 Regional RV akinesia or dyskinesia
•	 and 1 of the following (end diastole):
-  PLAX RVOT ≥29 to <32 mm (corrected for body size [PLAX/
BSA] ≥16 to <19 mm/m2)
-  PSAX RVOT ≥32 to <36 mm (corrected for body size [PSAX/
BSA] ≥18 to <21 mm/m2)
- or fractional area change >33 to ≤40%
By MRI:
•	 	Regional RV akinesia or dyskinesia or dyssynchronous RV 
contraction
•	 and 1 of the following:
-  Ratio of RV end-diastolic volume to BSA ≥100 to <110 mL/m2 
(male) or ≥90 to 100 mL/m2 (female)
- or RV ejection fraction >40% to ≤45%
ii. Tissue characterisation
•	 	Residual myocytes <60% by morphometric analysis (or 
<50% if estimated), with fibrous replacement of the 
RV free wall myocardium in ≥1 sample, with or without 
fatty replacement of tissue on endomyocardial biopsy
•	 	Residual myocytes 60% to 75% by morphometric analysis (or 
50% to 65% if estimated), with fibrous replacement of the 
RV free wall myocardium in ≥1 sample, with or without fatty 
replacement of tissue on endomyocardial biopsy
iii. repolarisation abnormalities
•	 	Inverted T waves in right precordial leads (V1, V2, and 
V3) or beyond in individuals >14 years of age (in the 
absence of complete right bundle-branch block QRS 
≥120 ms)
•	 	Inverted T waves in leads V1 and V2 in individuals >14 years of 
age (in the absence of complete right bundle-branch block) or 
in V4, V5, or V6
•	 	Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 
years of age in the presence of complete right bundle-branch 
block
iV. depolarisation/conduction abnormalities
•	 	Epsilon wave (reproducible low-amplitude signals 
between end of QRS complex to onset of the T wave) in 
the right precordial leads (V1 to V3)
•	 	Late potentials by SAECG in ≥1 of 3 parameters in the absence 
of a QRS duration of ≥110 ms on the standard ECG
•	 Filtered QRS duration (fQRS) ≥114 ms
•	 	Duration of terminal QRS <40 µV (low-amplitude signal 
duration) ≥38 ms
•	 Root-mean-square voltage of terminal 40ms <20 µV
•	 	Terminal activation duration of QRS ≥55 ms measured from 
the nadir of the S wave to the end of the QRS, including R’, in 





Genetic aspects of ACM
ACM is a familial disease in at least 50% of cases.13 This has led to the assumption 
that ACM is a genetically determined cardiomyopathy, but it was not until 2000 that 
a homozygous mutation in the gene encoding the desmosomal protein plakoglobin 
(JUP) was identified in patients with a recessive form of ACM with skin abnormali-
ties, i.e. palmoplantar keratosis and woolly hair. This was called Naxos disease, after 
the Greek island where these patients were living.16 In the same year, a homozygous 
mutation in desmoplakin (DSP), encoding another desmosomal protein, was identi-
fied in patients from Ecuador with dilated cardiomyopathy and comparable skin 
abnormalities to Naxos disease.17 This disease is called Carvajal syndrome and is 
named after the physician who first described these families.18 In 2002, a mutation in 
the same DSP gene was identified in an autosomal dominant form of ACM.19 Since 
then, screening of other genes encoding desmosomal proteins in non-syndromal 
Table 2 Revised task force criteria for the diagnosis of ARVC# (continued)
Major Minor
V. Arrhythmias
•	 	Non-sustained or sustained ventricular tachycardia 
of left bundle-branch morphology with superior axis 
(negative or indeterminate QRS in leads II, III, and aVF 
and positive in lead aVL)
•	 	Non-sustained or sustained ventricular tachycardia of RV 
outflow configuration, left bundle-branch block morphology 
with inferior axis (positive QRS in leads II, III, and aVF and 
negative in lead aVL) or of unknown axis
•	 500 ventricular extrasystoles per 24 hours (Holter)
Vi. family history
•	 	ARVC confirmed in a first-degree relative who meets 
current Task Force criteria
•	 	ARVC confirmed pathologically at autopsy or surgery in 
a first-degree relative
•	 	Identification of a pathogenic mutation† categorised 
as associated or probably associated with ARVC in the 
patient under evaluation
•	 	ARVC confirmed in a second-degree relative who meets 
current Task Force criteria
•	 	History of ARVC in a first-degree relative in whom it is not 
possible or practical to determine whether the family member 
meets current Task Force criteria
•	 	Premature sudden death (<35 years of age) due to suspected 
ARVC in a first-degree relative
•	 	ARVC confirmed pathologically or by current Task Force 
criteria in second-degree relative
PLAX indicates parasternal long-axis view; RVOT, RV outflow tract; BSA, body surface area; PSAX, 
parasternal short-axis view; aVF, augmented voltage unipolar left foot lead; and aVL, augmented voltage 
unipolar left arm lead. Diagnostic terminology for the revised criteria: definite diagnosis: 2 major, or 1 
major and 2 minor criteria, or 4 minor crtieria from the different categories; borderline: 1 major and 1 
minor, or 3 minor criteria from the different categories; possible: 1 major or 2 minor criteria from different 
categories.
*  Hypokinesis is not included in this or subsequent definitions of RV regional wall motion abnormalities 
for the proposed modified criteria.
†  A pathogenic mutation is a DNA alteration associated with ARVC that alters, or is expected to alter, the 
structure or function of the encoded protein or that has demonstrated linkage to the disease phenotype 
in a conclusive pedigree and is unobserved or rare in a large non-ARVC control population.
#  Adapted from Marcus et al. (2010).15
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ACM cases has resulted in the identification of mutations in plakophilin 2 (PKP2), 
desmocollin 2 (DSC2), desmoglein 2 (DSG2), and plakoglobin (JUP).20-23
The proper function and structure of cardiac myocytes, and also epithelial cells 
of the skin, is preserved by cell adhesion junctions in the intercalated discs, located 
between adjacent cells. The intercalated disc contains three different intercellular 
connections: gap junctions, responsible for electric coupling between cells, adhe-
rens junctions, and desmosomes, which provide mechanical coupling by linking 
the cytoplasmic actin and intermediate filaments, respectively. Furthermore, the 
desmosome plays a crucial role in organising and maintaining the intercalated disk 
itself, thereby also preserving the electrical coupling between cells (Figure 3).
The identification of a mutation in a patient with ACM is of great importance, 
since it has several consequences. It can confirm the diagnosis and it is also the 
starting point for cascade family screening for the identified mutation. Family mem-
bers who are found to be a carrier of the mutation should be screened at regular 
intervals to pick up early symptoms and/or signs attributable to the disease. These 
individuals can then benefit from appropriate treatment such as medication or an 
implantable cardioverter defibrillator (ICD). Family members who are found not to 
carry the identified pathogenic mutation can be dismissed from frequent follow-ups 
figure 3 Schematic representation of the molecular organisation of cardiac desmosomes. A model of the 
relative organisation of major desmosome components is presented. The plasma membrane-bound (PM) 
desmocollin 2 (DSC2) and desmoglein 2 (DSG2) proteins interact via their extracellular domains at the 
dense midline (DM) in the extracellular space between adjacent cells. Their cytoplasmic domains interact 
with plakoglobin (PG) and plakophilin 2 (PKP2) in the outer dense plaque (ODP). Also in the ODP, PKP2 
and PG interact with the N-terminal domain of desmoplakin (DSP). The C-terminus of desmoplakin 




and reassured about their own risks as well as those for their children. The identifi-
cation of a mutation could also confirm a suspected diagnosis of ACM in a patient 
whose clinical features are inconclusive.
desmosomal genes in ACM
An overview of the results of comprehensive desmosomal screening in nine differ-
ent cohorts is listed in Table 3.24-32 Taken together, a mutation in one or more of the 
desmosomal genes can be identified in 44% of patients with ACM, with the large 
majority found in the PKP2 gene. Notably, multiple mutations in the same gene or 
in different genes can be identified in 6% of ACM patients, but often it is not clear 
whether all these identified mutations are truly pathogenic. It is important to realise 
that a sequence variant in one of the desmosomal genes is not by definition a patho-
genic mutation. Numerous single nucleotide polymorphisms are present in these 
genes and the pathogenicity of many novel variants is unclear, leading to the terms 
“variant of unknown significance” and “unclassified variant”. Nonsense mutations, 
both in-frame and frame-shift insertion or deletion mutations, and splice site muta-
tions are generally considered pathogenic unless identified as polymorphisms. To 
determine whether missense mutations can be classified as pathogenic, several 
aspects need to be considered: the absence of the mutation in ethnically matched 
controls, co-segregation with the phenotype in pedigrees, considerable differences 
in physico chemical properties of the amino acids, evolutionary conservation of 
amino acids across several species, their presence in an evolutionary conserved 
Table 3 Comprehensive screening of desmosomal genes in ACM cohorts
Cohort results of mutational analysis
Country Year no. of patients PKP2 DSC2 DSG2 DSP JUP >1 Total
United States24 2009 82 39% 0% 4% 1% 1% 7% 52%
Denmark25 2010 55 11% 5% 4% 2% 2% 9% 33%
France/Switzerland26 2010 135 30% 1% 7% 4% 0% 4% 46%
Canada27 2010 23 22% 0% 4% 4% 0% 13% 43%
United States/Italy28 2010 198 11% 2% 3% 2% 1% 8% 26%
Germany29* 2010 12 42% 8% 17% 0% 0% 0% 67%
Finland30 2011 29 10% 0% 3% 3% NS 0% 17%
The Netherlands31 2011 149 51% 1% 3% 1% 0% 2% 58%
United Kingdom32† 2011 97 8% 58%
Total 780 28% 2% 4% 2% 1% 6% 44%
NS indicates not studied. Single mutations are listed per gene. The percentage of multiple mutations in 
the same gene (compound heterozygosity or homozygous) or in different genes (digenic inheritance) is 
indicated by ‘>1’. * in this chohort, one mutation in DES was also found. † single genes mutations not 
specified.
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region, and localisation in a domain predicted or proven to be functionally impor-
tant. Several software programs are available to predict the effect of a mutation, 
such as Sorting Intolerant From Tolerant (SIFT) and Polymorphism Phenotyping 
(PolyPhen).33,34 These programs, however, often yield contradictory results, thereby 
hampering the interpretation and classification of variants.35 
Kapplinger and colleagues screened PKP2, DSC2, DSG2, DSP, and TMEM43 
in 427 unrelated, ostensibly healthy, subjects from various racial and ethnic back-
grounds. They found a mutation in 69 of them (16%).36 They annotated any variant 
uniquely identified in one control as a “mutation”, as well as any variant observed 
in only ACM cases but absent in the controls. In the ACM cases a mutation was 
identified in 102 of 175 (58%). However, the percentage of missense mutations in 
the control cohort and the ACM cohort was 16% and 21%, respectively, and not 
significantly different. Truncating mutations and multiple mutations were found 
to be likely ACM-associated, but so-called radical mutations were also present in 
0.5% of the control subjects.36 In a Finnish population sample of 6,334 individuals, 
31 (0.5%) were found to carry a PKP2 mutation that had been identified in ACM 
patients.30 A truncating mutation in DSC2 (p.Ala897LysfsX4), previously reported 
as pathogenic,22 was later identified in multiple control cohorts and may now be 
considered a rare variant, insufficient to cause ACM, but possibly affecting pheno-
typic expression of concomitant ACM mutations.37 Furthermore, it is unlikely that 
reported pathogenic mutations in exon 6 of the PKP2 gene are truly pathogenic, 
since the PKP2 isoform containing exon 6 is not expressed in the heart.38 Finally, 
synonymous mutations, i.e. sequence changes in the coding region of a gene that 
do not change the amino acid sequence, can be pathogenic, for instance by creating 
a cryptic splice site, eventually resulting in a change at the protein level.39
non-desmosomal genes in ACM
The identification of mutations in the five desmosomal proteins has led to the 
postulation of ACM as a ‘desmosomal disease’.20,40 However, mutations in genes 
encoding non-desmosomal proteins have also been implicated. Two families with a 
mutation in the 5’ or 3’ untranslated region of the transforming growth factor beta 
3 gene (TGFB3) were described. These mutations led to increased expression of 
TGFB3, which has a pro-fibrotic activity.41 Since then however, no other mutations in 
TGFB3 have been identified in ACM families.
Missense mutations in the gene encoding the cardiac ryanodine receptor (RYR2), 
a calcium release channel in the sarcoplasmic reticulum, have been described in 
Italian families with a distinct form of ACM, characterised by exercise-induced 
ventricular arrhythmias and a high penetrance.42 RYR2 mutations have also been 




(CPVT),43,44 and whether RYR2 mutations should be considered as causative in ACM 
is questionable.
A founder mutation in the gene encoding the transmembrane protein 43 
(TMEM43) was identified in several families from Newfoundland, Canada. This 
form of ACM was found to be fully penetrant with prominent left ventricular (LV) 
involvement and men developing a phenotype at a younger age than women.45 The 
same mutation has also been reported in an ACM family from Denmark.46 It has 
been hypothesised that the TMEM43 mutation causes fibrofatty replacement of the 
myocardium by influencing the adipogenic transcription factor PPARγ.45
Desmin is the major intermediate filament protein of both cardiac and skeletal 
muscle and it binds to the desmosome at the intercalated disc. Mutations in the 
desmin gene (DES) can cause both isolated and combined forms of skeletal myopa-
thies, cardiomyopathies and cardiac conduction disease.47 In addition, patients with 
a mutation in the DES gene who fulfilled the diagnostic criteria for ACM have been 
described.29,48,49
 Titin, the largest human protein known, is a giant myofilament and it is 
expressed in cardiac and skeletal muscle. Titin is encoded by the TTN gene, which 
contains 363 exons. TTN mutations have previously been reported in DCM and 
HCM,50,51 but comprehensive sequence analysis in large series of patients has long 
been impractical due to the large size of the gene. In 2011, complete TTN screen-
ing identified mutations in 7 out of 38 ACM families and conduction disease was 
present in 11 out of 14 mutation carriers.52 Recently, truncating TTN mutations were 
identified in 25% of familial DCM cases and in 18% of sporadic DCM cases.53 If this 
is confirmed in other cohorts, TTN mutations would be the most common cause of 
DCM, especially since the role of non-truncating mutations in the reported cohort 
still needs to be elucidated.53 Notably, the reported ACM-associated TTN mutations 
are all non-truncating mutations.52
Mutations in the gene encoding the nuclear envelope protein lamin A/C (LMNA) 
can also cause very variable phenotypes, ranging from syndromes of premature 
aging to neuromuscular diseases. LMNA mutations causing cardiac disease typically 
result in DCM associated with atrial arrhythmia and atrioventricular block, resulting 
in progressive heart failure and sudden cardiac death. In addition, mutations were 
identified in four families with severe ACM, and associated with conduction disease 
in two probands.54
Biopsy studies and functional assays
The mere presence of a novel missense mutation is clearly insufficient to label such 
a mutation as pathogenic and the interpretation of a missense mutation in an ACM 
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patient is therefore challenging. Additional evidence from assays using patient mate-
rial and functional studies can be of great help in the interpretation of mutations. 
Decreased connexin 43 expression and abnormal co-localisation with PKP2 was 
found in immunofluorescent studies on endomyocardial-biopsy samples from four 
ACM patients with PKP2 mutations.55 Immunohistochemical analysis of biopsy 
samples from ACM patients, both with and without desmosomal gene mutations, 
showed diffusely reduced signal levels for plakoglobin at the intercalated discs.56 The 
reduced plakoglobin at intercalated discs has been identified as a sensitive marker 
for ACM, but not with complete specificity, since these reduced signals have also 
been observed in patients with sarcoidosis and giant cell myocarditis.57 These are 
highly arrhythmogenic forms of myocarditis, suggesting that, at least in part, shared 
pathophysiological processes involving the cardiac desmosome underlie these dif-
ferent diseases. It has been suggested that plakoglobin is mainly redistributed from 
the intercalated discs to other cellular pools, illustrating that abnormal localisation 
is the cardinal feature and that protein degradation plays only a secondary role.58
Functional studies using full-length human DSG2 constructs expressed in neo-
natal rat cardiomyocytes were performed for three missense mutations in DSG2.59 
These mutations did not affect the binding to plakoglobin, suggesting that the 
observed loss of plakoglobin immunoreactivity is not simply the result of a change 
in binding affinity caused by a missense mutation, but rather a more complex 
mechanism, such as post-translational modifications.59 Both nuclear localisation of 
plakoglobin and reduced canonical Wnt/beta-catenin signalling have been shown 
to be the result of suppression of desmoplakin expression. As a consequence, 
increased expression of adipogenic and fibrogenic genes leads to adipocyte devel-
opment instead of myocyte development.60 
Animal models 
Several animal models of ACM have been shown to recapitulate important aspects 
of the human disease phenotype. Most of these models were not based on spe-
cific human mutations but on knock-out mouse models or embryonic morpholino 
knockdown zebrafish models.61 In the first animal study on specific ACM related 
mutations, attempts to generate cardiac-specific transgenic mouse models with 
the DSP mutations p.Val30Met or p.Gln90Arg failed, probably due to embryonic 
lethality. However, transgenic mice with cardiac-restricted overexpression of the 
DSP mutation p.Arg2834His showed increased cardiomyocyte apoptosis, cardiac 
fibrosis, lipid accumulation, and biventricular enlargement and cardiac dysfunc-
tion.62 Transgenic mice carrying the equivalent of the human p.Asn266Ser mutation 
in DSG2 also recapitulated the clinical features of ACM. The model showed the 




dysfunction, and biventricular dilatation and aneurysms.63 In another animal study, 
mice overexpressing the truncated plakoglobin protein identified in Naxos disease,16 
demonstrated fibrofatty replacement, cardiac dysfunction, and premature death. 
Reduced membrane localisation and reduced binding to desmosome proteins DSP 
and DSG2 was also observed.64 
The understanding of the pathophysiological mechanisms underlying ACM has 
increased greatly since the identification of mutations in genes encoding des-
mosomal proteins and the subsequent in vitro and in vivo studies. However, the 
interpretation of the genetic basis of the disease, the role of environmental factors 
such as exercise, and the variable clinical picture seen in ACM patients still pose a 
challenge to researchers and to clinicians taking care of the patients and families 
affected by this disease.
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AiMs And ouTline of This Thesis
In arrhythmogenic cardiomyopathy (ACM), comprehensive screening of the five 
desmosomal genes identifies a pathogenic mutation in about half of all patients. 
In addition, mutations in several non-desmosomal genes have been identified, 
illustrating the genetic heterogeneity of ACM. In the other half of the ACM patients, 
no genetic cause can be established at the moment. The identification of a mutation 
is of great importance, since it has several consequences. It can confirm a suspected 
diagnosis in a patient whose clinical features are inconclusive, and moreover, it is 
also the starting point of cascade family screening for the specific mutation. This 
will identify the family members at risk, who should be screened at regular intervals 
to enable early detection of symptoms and/or signs attributable to the disease and 
possibly lead to initiating treatment to prevent deterioration of the disease. Family 
members who are found not to carry the identified pathogenic mutation can be 
dismissed from frequent follow-up and reassured about their own risks as well as 
the risks for their children.
From a scientific point of view, the elucidation of the genetic basis of ACM will 
provide novel insights into the disease mechanisms. These insights will help us to 
better understand the pathogenesis and the variability of the disease. Ultimately, 
this knowledge could be the foundation on which gene-specific and patient-specific 
options for treatment and management can be built. This ultimate goal will only be 
reached by collecting as much data as possible, by collaborating with cardiologists, 
geneticists, pathologists, biologists, technicians, bioinformaticians, and other clini-
cians and researchers from dedicated centres all over the world. 
This thesis presents genetic and clinical studies in patients with ACM and their 
families. Considering the importance of identifying a mutation in these patients, the 
aims of this thesis were:
1. To further clarify the genetic basis of arrhythmogenic cardiomyopathy by search-
ing for novel genes and mutations; and
2. To study the clinical picture of arrhythmogenic cardiomyopathy, especially in 
familial cases.
outline
The first part of this thesis describes genetic studies and phenotypic characterisa-
tion in ACM. Chapter 2 describes the application of the haplotype-sharing test to 
identify disease-causing mutations, possibly in novel genes. A family with ACM and 
a family with dilated cardiomyopathy (DCM) were analysed using the haplotype-




to be located in the largest shared haplotypes among affected individuals within a 
pedigree and were sequenced, leading to the identification of a mutation in both 
these genes. In Chapter 3 the clinical characteristics of the PKP2 mutation carriers 
from the previous chapter are described and molecular studies on this PKP2 splice 
mutation are presented. Chapter 4 describes the largest series of patients with the 
same founder mutation in the PKP2 gene (c.235C>T; p.Arg79X). The clinical vari-
ability and age-related penetrance, hallmarks of ACM, are well illustrated by the 
phenotypic descriptions of the mutation carriers. In Chapter 5 the genetic variants 
database for ACM (available from www.arvcdatabase.info) is described in detail. This 
freely available online database lists the genetic variants found in genes associated 
with ACM and is a digital repository for both molecular data and all publications 
containing additional information on clinical and/or genetic data of listed variants. 
Chapter 6 reports a large cohort of Dutch ACM families collected in all the university 
medical centres in the Netherlands. This chapter describes the genotype-phenotype 
relationships and highlights the impact of mutation screening for family members 
of the identified index patients.
The second part of this thesis focuses on the identification of a founder mutation 
in the phospholamban gene (PLN c.40_42delAGA; p.Arg14del) in a large number 
of Dutch patients with ACM and/or DCM. The clinical characteristics of index 
patients carrying this mutation are outlined in Chapter 7. This chapter illustrates 
the overlap between different cardiomyopathy subtypes, in casu DCM and ACM, 
underscoring the importance of a molecular diagnosis in patients with inherited 
cardiomyopathy. This founder mutation is further described in Chapter 8, which 
shows the geographical distribution of mutation carriers in the Netherlands. The 
region of origin in the Dutch population was also analysed using information on the 
birthplaces of ancestors who were proven or likely carriers of the mutation. In Chap-
ter 9 a large pedigree with ACM is studied. The originally identified mutation in PKP2 
(c.419C>T; p.Ser140Phe) was found not to co-segregate with the phenotype and 
additional studies revealed that the PLN p.Arg14del mutation was the pathogenic 
mutation in this pedigree. Meticulous phenotypic characterisation of the mutation 
carriers revealed that there was no evidence of a disease-causing contribution from 
the PKP2 variant. 
Chapter 10 comprises the summary and general discussion of this thesis and 
outlines the future perspectives and possible directions for further genetic studies 
in inherited cardiomyopathies. It also considers the recent technological advances 
and their promises and limitations.
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Identifying a mutation in a heterogeneous disease such as inherited cardiomyopa-
thy is a challenge because classical methods, like linkage analysis, can often not be 
applied since there are too few meioses between affected individuals. However, if 
affected individuals share the same causal mutation, they will also share a genomic 
region surrounding it. High-density genotyping arrays are able to identify such 
regions shared among affected individuals. We hypothesise that the longest shared 
haplotype is most likely to contain the disease-causing mutation. 
We applied this method to two pedigrees: one with arrhythmogenic right ven-
tricular cardiomyopathy (ARVC) and one with dilated cardiomyopathy (DCM), using 
high-density genome-wide SNP arrays. In the ARVC pedigree, the largest haplotype 
was located on chromosome 12 and contained a causative PKP2 mutation. In the 
DCM pedigree, a causative MYH7 mutation was present on a large shared haplotype 
on chromosome 14. We calculated that a pedigree containing at least seven meioses 
has a high chance of correctly detecting the mutation-containing haplotype as the 
largest.
Our data show that haplotype-sharing analysis can assist in identifying causative 
genes in families with low penetrance Mendelian diseases, in which standard tools 





Identifying a mutation in a heterogeneous disease is a challenge with potentially 
important clinical consequences, because it may direct treatment and facilitate 
identification of family members at risk. Cardiomyopathies are a clear example of 
such a disease. These are associated with mechanical and/or electrical dysfunc-
tion that usually exhibit inappropriate ventricular hypertrophy or dilatation and are 
frequently genetic.1 Around 30, 20 and 10 genes, respectively, have been described 
underlying dilated cardiomyopathy (DCM [MIM#115200]), hypertrophic cardiomy-
opathy (HCM [MIM#192600]), and arrhythmogenic right ventricular cardiomyopathy 
(ARVC [MIM#107970]).2-6 The importance of identifying a mutation is illustrated by 
the fact that sudden death is more common in HCM patients carrying a troponin T 
gene (TNNT2) mutation,7,8 and in DCM patients carrying a lamin A/C gene (LMNA) 
mutation.9-12 
The detection of a mutation also has important implications for family members. 
Cascade screening will identify mutation carriers, and early interventions, such as 
lifestyle modifications, use of medications, and implanting an ICD, will reduce mor-
bidity and mortality. Excluding a mutation in family members will allow them to be 
dismissed from regular cardiological follow-up.13,14 In cardiomyopathies identifying 
a mutation is challenging and time-consuming and the yield from screening is small 
for most genes.15 
In low penetrance Mendelian diseases, founder mutations are likely to occur 
and these are co-inherited with adjacent chromosomal regions which are identical-
by-descent (IBD). IBD genomic regions can be found by high–density genome-wide 
SNP arrays. However, many shared haplotypes will be found, some of which will 
be identical-by-state (IBS) while others may be IBD. Such IBS haplotypes are com-
monly present in the general population and not associated with disease. In general, 
short haplotypes are common and either represent ancient IBD stretches of DNA, or 
are IBS. Larger shared haplotypes are younger and have a high probability of being 
IBD. Haplotypes with 15 or more polymorphic markers covering about 100,000 base 
pairs already have a substantial probability of being IBD.16 Mutant genes tend to 
have a common ancestor from a geographic subpopulation and will show extended 
haplotype sharing surrounding the mutant gene. It is this expected difference in 
length between IBS and IBD haplotypes that we use to identify disease loci.
To identify disease-associated haplotypes, we designed the haplotype-sharing 
test (HST), using high-density SNP array data. As a proof-of-principle, we applied 
the HST to two pedigrees: one consisting of four putative, remotely related families 
with autosomal dominant (AD) ARVC (Figure 1A), and one with AD DCM (Figure 
1B).
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family 1              family 2               family 3              family 4 
figure 1 Pedigrees of the families with autosomal dominantly inherited ARVC (A) and of the family with 
autosomal dominantly inherited DCM (B). Circles indicate females; squares indicate males; a line through 
a symbol means deceased. Black symbols represent affected persons; dotted symbols represent obligate 
carriers, who cannot be labeled as affected because the individual has not been tested or the clinical signs 
are insufficient to fulfill the formal clinical criteria; upper quadrant blackened symbols denote individuals 
who did not fulfill the clinical criteria, but who did have abnormalities compatible with ARVC; individuals 
denoted with “n” had a normal cardiac evaluation. 







Four small families with AD ARVC were investigated (Figure 1A). Three families 
could be traced back to two ancestral founder couples. Family 4 could not be linked 
to the pedigree, but their ancestors lived in the same geographical region, suggest-
ing a possible founder mutation. DNA and clinical information was available for 
16 individuals. From a four-generation family with AD DCM (Figure 1B) DNA and 
clinical information was available for 19 family members.
The studies were approved by the ethics committees of the UMC Utrecht and 
UMC Groningen and informed consent was obtained from all participants.
Genotype data
In the ARVC pedigree, genome-wide genotyping with the GeneChip® Mapping 10K 
SNP array (Xba131; Affymetrix, Santa Clara, CA, USA) was performed according to 
manufacturer’s protocols. Data from the arrays were converted to genotypes using 
GeneChip® DNA analysis software 2.0 (Affymetrix).
In the DCM pedigree, genome-wide genotyping with the Human 610-Quad 
BeadChip® 610K SNP array (Illumina, San Diego, CA, USA) was performed accord-
ing to manufacturer’s protocols. Data from the arrays were converted to genotypes 
using GenomeStudio® data analysis software (Illumina).
haplotype-sharing analysis
Using Microsoft® Office Excel 2007 (Microsoft, Redmond, WA, USA) software, 
the HST was developed to search for shared haplotypes. An algorithm checks for 
consistency of genotypes with shared risk haplotypes, using data from affected 
individuals and obligate carriers only. The algorithm starts at the p-telomere of a 
chromosome and compares all the genotypes of the first SNP. When all affected 
individuals share an allele for the SNP, the comparison continues with the next SNP. 
A run is terminated when a real inconsistency (i.e. opposite homozygosity) in a SNP 
occurs. After a run terminates, the algorithm computes the total number of SNPs 
and the length of the haplotype in Mb and cM, based on the deCODE genetic map.17 
A new run starts with the following SNP. The algorithm scans all the SNPs on each 


















figure 2 Haplotype length distribution across the genome. (A) After haplotype sharing analysis using 
a 10K SNP array in ARVC families 1-4. The largest region of 24.1 cM or 93 SNPs, flanked on either side 
by the SNP markers rs724903 and rs408435, pointed to chromosome 12p12.1-q13.13, where PKP2 is 
localised. (B) After haplotype sharing analysis using a 610K SNP array in the DCM pedigree. The largest 
region of 20.8 cM or 2,707 SNPs, flanked on either side by the SNP markers rs11621148 and rs17101350, 






In all four families of the ARVC pedigree, the HST revealed a largest haplotype run 
of 93 SNPs on chromosome 12, spanning 24.1 cM (Figure 2A and Table 1). This 
haplotype run was substantially larger than other areas which were most likely 
shared due to hidden distant ancestry or IBS (average shared haplotype length: 4.0 
SNPs and 2.1 cM).
In the DCM pedigree, the HST revealed a largest haplotype run of 2,707 SNPs 
on chromosome 14, spanning 20.8 cM (Figure 2B). This haplotype run was also 
substantially larger than other areas (average shared haplotype length: 8.1 SNPs 
and 0.06 cM).
Gene finding
We looked for known disease-associated genes in the largest haplotypes. In the 
ARVC pedigree, the largest shared haplotype stretched over a 24.1 cM region (28.0 
Mb), containing over 200 genes. Considering ARVC, the most likely candidate gene 
was the plakophilin 2 (PKP2 [MIM#602861]) gene. This gene was identified as an 
highly prevalent ARVC-associated gene during the course of this study.18,19
The largest shared haplotype in the DCM pedigree stretched over a 20.8 cM 
region (11.5 Mb), also containing over 200 genes. Considering DCM, the most 
likely candidate gene in this region was the cardiac beta myosin heavy chain (MYH7 
[MIM#160760]) gene.20 MYH7 (missense) mutations are found in 4-10% of patients 
with idiopathic DCM.20-25
Mutation identification
PKP2 mutation screening in patients from the ARVC pedigree revealed a pathogenic 
splice-site mutation c.2489+4A>C,26 segregating with the disease. This mutation 
was identified as clinically relevant by reverse-transcription PCR (RT-PCR) in lym-
phocytes showing the absence of exon 12 in the PKP2 transcript sequence in all 
affected subjects (data not shown). The absence of exon 12 leads to a frameshift in 
the coding sequence, resulting in an aberrant protein of 848 amino acids opposed 
to 863 amino acids for wild type PKP2 isoform 2b.
MYH7 mutation screening in the proband from the DCM pedigree revealed a 
c.2710C>T missense mutation which changes a highly conserved hydrophilic and 
polar arginine residue into a hydrophobic and nonpolar cysteine residue in the 
corresponding MYH7 protein (p.Arg904Cys). All available affected family members 
also carried this mutation, whereas unaffected family members did not.
Both mutations were absent in over 150 ethnically matched controls (300 alleles). 
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Table 1 The largest shared haplotype across some affected individuals from the ARVC pedigree (in grey)
snPid Position family 1 family 2 family 3 family 3
Vi:1 Vi:2 Vi:3 Vii:3 Vi:8
Mb cM hap1 hap2 hap1 hap2 hap1 hap2 hap1 hap2 hap1 hap2
rs724903 23.2 42.8 A B A B B B B B B A
rs763853 23.2 42.8 A A A A A A A A A A
 #15 SNPs
rs951821 28.7 51.3 A A B A A A A A A A
rs1601981 29.0 51.5 A B B B A B A B A B
rs986570 29.2 51.7 B A B A A A A A A A
rs986569 29.2 51.7 B A B A A A A A A A
rs958478 29.2 51.8 B B B B B B B B B B
rs3862404 30.3 53.3 A B B B B B B B B B
rs1429630 30.3 53.4 B B B B B B B B A B
rs1320925 30.3 53.4 B B B B B B B B B B
rs2114903 30.8 53.9 B A B A B A A A B A
rs720480 31.0 54.0 B A B A A A B A A A
rs724417 31.2 54.3 B A B A B A B A B A
rs1844986 31.3 54.4 A A B A A A B A B A
c.2489+4A>C 32.8 55.4 A C A C A C A C A C
rs2133675 33.1 55.5 A A A A A A A A A A
rs955648 33.1 55.5 A B A B A B A B A B
rs1392339 33.1 55.5 A B A B A B A B A B
rs1457677 33.3 55.6 B A B A B A B A B A
rs2389173 33.3 55.6 B B B B B B B B B B
rs1386934 33.7 55.6 A B B B B A A B B B
rs1386937 33.8 55.7 B A A A B A B A A A
rs1525895 33.9 55.7 A B B B A B A B A B
rs8186671 36.5 56.1 B B B B B B B B B B
rs8186802 36.5 56.1 A A A A A A A A A A
rs4088478 36.5 56.1 A A A A A A A A A A
rs8186742 36.5 56.1 A A A A A A A A A A
 #50 SNPs
rs1316607 49.3 64.0 A B A B B B A B B B
rs1902765 50.9 66.6 A B A B A B B B B B
rs1791661 51.1 66.7 A A A A A A B A B A
rs408435 51.2 66.9 A B A B B B A B B A
The phase of heterozygous SNPs is inferred from the parental haplotypes (not listed), resulting in 






Table 2 and Table 3 show the results of step-by-step haplotype-sharing analysis in 
both pedigrees. An analysis of only five individuals in each pedigree indicated the 
mutation-containing haplotype was indeed the largest. Additional individuals nar-
rowed down the size of the shared haplotype, thereby decreasing the total number 
of genes to be considered. In the DCM pedigree, we predicted the size of the unre-
combined area surrounding the mutation by using the formula: 200 cM / number of 
meioses.27 The size of the haplotypes was comparable to the expected size.
Table 2 Step-by-step haplotype analysis of the ARVC pedigree a
Average haplotype largest haplotype rank PKP2 
haplotype
ids snPs cM snPs cM
family 1 V:2/V:4/VI:1/VI:2 13.6 5.3 349 82.0 3
+ family 2  +VI:3 7.3 3.1 217 52.9 1
+ family 3  +VI:5/VII:3 4.9 2.3 120 31.6 1
+ family 4  +V:10/VI:8 4.0 2.1 93 24.1 1
Family 1 was analysed first, with subsequent analysis of families 2–4 
a Including haplotypes >1 SNP, ranked according to their length in cM.











ids snPs cM snPs cM meioses cM
Generation ii II:5/II:6/II:8/II:11 32.3 0.21 11129 78.4 4 50.0 9
+ offspring ii:1  +III:1 17.5 0.12 3589c 27.0 6 33.3 1
+ offspring ii:5  +III:3 12.5 0.09 3089 27.0 7 28.6 1
+ offspring ii:11  +III:6/IV:2 8.1 0.06 2707 20.8 9 22.2 1
Four members of generation II were analysed first, with subsequent analysis of their offspring
a Including haplotypes >1 SNP, ranked according to their length in cM.
b Based on the formula: 200 cM/ number of meioses = size unrecombined area surrounding a mutation.27
c This haplotype is 16.5 cM
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requirement for hsT
To establish the minimal number of affecteds within a pedigree to successfully apply 
the HST, we calculated all possible combinations of different numbers of meioses in 
the DCM pedigree. The results are shown in Table 4, illustrating that 5 or 6 meioses 
revealed the MYH7 haplotype as the largest in 4/19 (21%) or 9/15 (60%) combina-
tions, respectively. With 7 meioses, the MYH7 haplotype is the largest in 8/9 (89%) 
combinations. 









5 meioses: cM 6 meioses: cM
II:5/II:6/II:8 + III:1 1 27.0 II:5/II:6/II:8 + IV:2 1 20.8
II:11 + III:1/III:3 1 35.1 II:5 + III:1 + IV:2 1 20.8
II:8 + III:1/III:6 1 47.4 II:6 + III:3 + IV:2 1 21.3
II:6/II:8 + IV:2 1 68.1 II:5/II:6/II:8/II:11 + III:1 1 27.0
III:3 + IV:2 2 31.6 II:6/II:8 + III:1/III:3 1 27.5
II:8 + III:1/III:3 2 37.5 II:8/II:11 + III:1/III:3 1 27.5
II:6/II:8/II:11 + III:1 2 46.0 II:6/II:11 + III:1/III:3 1 35.1
II:5/II:6 + IV:2 2 47.0 II:8 + III:1 + IV:2 1 47.0
II:6 + III:1/III:6 2 59.0 II:6/II:8 + III:1/III:6 1 47.4
III:1 + IV:2 2 74.1 II:8 + III:3 + IV:2 2 21.3
II:6 + III:1/III:3 2 82.4 III:1/III:3/III:6 2 21.8
II:5/II:6/II:11 + III:1 3 44.7 II:6 + III:1 + IV:2 2 52.1
II:6 + III:3/III:6 4 39.9 II:5/II:8 + III:1/III:6 3 21.2
II:5/II:8 + IV:2 4 40.8 II:6/II:8 + III:3/III:6 3 21.7
II:5/II:8/II:11 + III:1 4 43.3 II:5/II:6 + III:1/III:6 4 21.2
II:8 + III:3/III:6 5 47.7 ranked 1st; Average size 9/15 28.9
II:6/II:8/II:11 + III:3 5 56.7
II:5/II:6/II:8 + III:6 7 37.7 7 meioses:
II:5 + III:1/III:6 7 47.0 II:5/II:6 + III:1 + IV:2 1 20.8
ranked 1st; Average size 4/19 48.1 II:5/II:8 + III:1 + IV:2 1 20.8
II:6/II:8 + III:3 + IV:2 1 21.3
III:1/III:3 + IV:2 1 21.3
II:6 + III:1/III:3/III:6 1 21.7
II:8 + III:1/III:3/III:6 1 21.7
II:6/II:8/II:11 + III:1/III:3 1 27.0
II:6/II:8 + III:1 + IV:2 1 47.0
II:5/II:6/II:8 + III:1/III:6 2 24.9
ranked 1st; Average size 8/9 25.2





Rare Mendelian disorders have a mutational spectrum which is characterised by 
the presence of very few major mutations but a large number of very rare muta-
tions. It is therefore reasonable to search for the presence of common mutant genes 
in patients with the same disease phenotype. It has been shown that haplotypes 
identical over 0.1 cM have a substantial probability of originating from a common 
founder.16 Such haplotypes can easily be detected with current high-density genotyp-
ing methods. 
If two individuals have a common ancestor, they may share a haplotype that has 
been shortened by recombination but that is still of detectable size. The current 
density of whole genome screens is so high that shared haplotypes of a few hundred 
thousand base pairs will contain well over 30 SNPs. If rare Mendelian disorders are 
investigated, a common disease mutation may coalesce to a common ancestor well 
within 100 generations. Of course, for many genomic areas a random coalescence 
to recent ancestors may occur as well. Due to adverse selection, most descent lines 
with deleterious mutations will gradually be eliminated leading to shorter coales-
cence times to a common ancestor. The expectation is therefore that shared areas 
surrounding disease mutations will be larger in size than shared areas due to a 
common ancestor for a neutral genomic area. This leads to a heuristic principle: 
first investigate the largest areas shared between patients or obligate carriers for 
mutant genes. The carrier frequency of such areas in the population must be fairly 
low, making the association between a rare variant and a rare marker haplotype 
more likely under the hypothesis that the shared region harbors a mutant gene that 
has led to ascertainment of the individuals who carry them. Occasionally, however, 
recombinations will take place near the mutant position and the corresponding 
shared haplotype may become small. Fortunately the total size of shared haplotypes 
that could contain a mutant gene is often not so large, and may even be as small as 
the mapping interval used for linkage analysis with a sufficient number of meioses.
The results of our analyses confirm our hypothesis. Figure 2 shows the shared 
haplotypes identified in the pedigrees that were analysed using a 10K and a 610K 
SNP array. We identified many short IBS or perhaps IBD haplotypes with an aver-
age length of 4.0 SNPs (2.1 cM) and 8.1 SNPs (0.06 cM), respectively, and in both 
pedigrees we found one larger haplotype, of 24.1 cM (93 SNPs) and 20.8 cM (2707 
SNPs), respectively. A common gene underlying ARVC, namely PKP2, was present 
in the largest haplotype of the ARVC pedigree. Screening of the PKP2 gene revealed 
a pathogenic splice-site mutation.26 
In the DCM pedigree, the largest haplotype encompassed MYH7, a common 
gene underlying DCM. Screening revealed a missense mutation of a highly con-
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served residue (p.Arg904Cys), with large physicochemical differences between the 
amino acids and which was shown to segregate with the disease in the pedigree. 
Furthermore, missense mutations in the surrounding residues 901, 905, 906, and 
908 have been identified previously in HCM.28-31 
Based on the formula 200 cM/ number of meioses, we expected the mutation-
containing haplotype to be around 22.2 cM, which corresponds well with the 
observed haplotype of 20.8 cM. When performing classic linkage in this pedigree, 
the maximal LOD score could not exceed 2.4 ((no. of meioses-1)*log2), illustrating 
that haplotype-sharing analysis can be a valuable tool in pedigrees too small for 
linkage analysis.
Our results show that haplotype-sharing analysis is a useful tool for narrowing 
down the area in which to search for a mutated gene. This might be particularly use-
ful in genetically heterogeneous disorders. Moreover, we prove that the theoretical 
model proposed by Miyazawa et al. to use homozygosity mapping through haplo-
type analysis to identify shared segments, is indeed effective.32 More recently, others 
have described statistics-based methods that calculate the size of shared haplotypes 
to map genes in genotyped pedigrees.33-35 The advantage of these methods is that 
they extend the principle of homozygosity mapping for recessive inherited diseases 
to cases of AD diseases. 
The results of the HST for different numbers of meioses in the DCM pedigree, 
suggest that 7 meioses have a high chance of correctly detecting the mutation-
containing haplotype (Table 4). Using fewer meioses is however possible, but the 
risk of detecting a false-positive largest haplotype (i.e. not containing the mutated 
gene) is substantial. We therefore recommend to apply the HST in pedigrees with 
at least 7 meioses. 
Identifying a large shared haplotype is relatively easy, since current molecular biol-
ogy tools, such as SNP genotyping technology, easily yield hundreds of thousands 
of reliable genotypes. Subsequent mutational analysis can be done by sequencing, 
and current technology is powerful enough to investigate a few candidate regions 
and confirm the results, thereby contributing significantly to the clinical diagnosis 
of heritable diseases. 
We found genes known to be associated with ARVC and DCM in the largest 
haplotypes of the studied pedigrees. Mutations in these genes could have been 
identified by a candidate gene approach, because mutations in PKP2 and MYH7 are 
frequently identified in these diseases.18-25 When a candidate gene approach fails to 
identify a mutation, a novel disease gene could be identified by screening the largest 
haplotype. With the decline of costs for SNP arrays, the HST could prove to be more 




We recommend haplotype-sharing analysis as a tool to assist in identifying genes 
in those low penetrance Mendelian diseases in which standard tools cannot be used 
due to lack of substantial pedigree information, or in which the mutation rate is 
low enough to expect founder mutations to be shared among patients. Identifying 
the largest shared haplotype can be used as a pre-screening method to identify 
candidate genes.
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objectives Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) 
is characterised by fibrofatty replacement of cardiomyocytes. In around 50% of 
index-patients, a genetic predisposition is demonstrated. The purpose of this study 
was to examine a plakophilin 2 (PKP2) splice site mutation, c.2489+4A>C, identified 
in four separately ascertained Dutch ARVD/C families.
Methods Genealogical studies and comprehensive screening of five desmosomal 
genes were undertaken. Reverse transcriptase PCR (RT-PCR) and subsequent 
sequencing was performed. 
results An A to C change (c.2489+4A>C) near the splice-donor site of intervening 
sequence 12 of PKP2 was found in all four families. Based on pedigree data and 
haplotype sharing, a common ancestor should be situated more than seven genera-
tions ago. RT-PCR demonstrated the presence of aberrant messenger RNA. Clinical 
manifestations ranged from severe disease to non-penetrance in elderly mutation 
carriers. 
Conclusions This founder mutation in PKP2 is predicted to lead to the presence of 
a dysfunctional PKP2 protein, whereas most truncating mutations are expected to 
lead to loss of protein. Mutation carriers displayed a wide range in disease severity, 
suggesting that PKP2 mutations alone are not sufficient to cause disease, which 






Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a disorder 
characterised by progressive replacement of cardiomyocytes by fibrofatty tissue, 
primarily in the right ventricle. Life-threatening ventricular arrhythmias originating 
from the right ventricle can be an early manifestation of the disease. Clinical diag-
nosis depends on fulfillment of Task Force Criteria,1 for which modifications have 
recently been proposed.2 
An important genetic contribution is evident from the fact that in 30-50% of 
cases one or more first-degree relatives also display signs of the disease.3,4 A large 
majority of mutations in ARVD/C patients has been found in genes encoding 
different components of the cardiac desmosome, i.e. plakophilin 2 (PKP2), des-
mocollin 2 (DSC2), desmoglein 2 (DSG2), desmoplakin (DSP), and plakoglobin 
(JUP),5-12 suggesting that ARVD/C is primarily a disease of disturbed desmosomal 
function.13,14 Mutations in other genes have also been reported in ARVD/C, among 
others transmembrane protein 43 (TMEM43), desmin (DES), and titin (TTN),15-18 
indicating genetic heterogeneity. In addition, several ARVD/C cases were found to 
be caused by multiple mutations in the same gene (compound heterozygosity) or 
mutations in different genes (digenic inheritance), which could result in an earlier 
onset and increased disease severity.19-21 The precise mechanisms by which muta-
tions in these genes lead to the distinct ARVD/C phenotype remain, to a large 
extend, to be elucidated. Decreased desmosome numbers, structurally abnormal 
desmosomes, secondary effects on other intercalated disk structures, or impaired 
Wnt/beta-catenin signaling, resulting in increased expression of adipogenic and 
fibrogenic genes and fat-accumulation, may all contribute to the ARVD/C patho-
physiology.22-24 However, regardless of the gene that is mutated, translocation of 
plakoglobin from the desmosome to the cytosol may be an important common step 
in disease causation.22,24,25
It has been shown that mutations in PKP2 are frequent in ARVD/C patients in 
the North-Western part of Europe and the US.5,7,26,27 In a cohort of Dutch ARVD/C 
patients up to 90% of PKP2 mutations were found in cases of proven familial dis-
ease.21 Eight different recurrent PKP2 mutations have been found in the Dutch popu-
lation, accounting for 84% (41/49) of separately ascertained PKP2 positive ARVD/C 
families. For some of them a shared PKP2 haplotype has been demonstrated, while 
other families could be traced back to a common ancestor by genealogy, sometimes 
as far as ten generations ago.7 Therefore, it is likely that several different PKP2 
founder mutations segregate in the Netherlands, which may contribute to the high 
prevalence of PKP2 mutations in Dutch ARVD/C patients. 
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Looking at the spectrum of different mutations reported in PKP2, it is evident 
that truncating mutations (nonsense and frameshift) are most frequent.28 The clas-
sification of missense variants as pathogenic, in PKP2 as well as in other genes, 
remains challenging without solid functional evidence.29 Truncating mutations are 
predicted to lead to loss of PKP2 protein by nonsense mediated messenger-RNA 
decay (NMD), although mRNA studies done by Gerull et al. show that the identified 
splice mutations had detectable mRNA with frameshifts, resulting in premature 
termination codons, that may evade NMD.5 As a general rule, introduction of a stop 
codon more than 50-55 nucleotides upstream of the last exon-intron boundary of 
any gene will lead to the breakdown of messenger-RNA in vivo, resulting in only very 
little translation of the abnormal truncated protein.30 This is an argument for haplo-
insufficiency (insufficient amounts of normal PKP2) as the predominant mecha-
nism by which PKP2 mutations predispose to disease, as opposed to a dominant 
negative effect due to the presence of abnormal PKP2 protein. Indeed, a western 
blot from a heart biopsy from a patient with PKP2 mutation c.2076_2077delAA 
(p.Ser693CysfsX49) did not show detectable protein.5
This report discusses both the clinical characteristics of patients from four dif-
ferent families that were found to have an identical splice mutation (c.2489+4A>C) 
at the C-terminal end of the PKP2 gene, and the possible mechanism by which it 
exerts its effect. 
MeThods
Clinical evaluation
All index-patients and their relatives were evaluated at the Cardiology departments 
of the University Medical Centers in Utrecht and Amsterdam. Family members were 
evaluated following a genetic counseling procedure and after informed consent had 
been obtained. Evaluation consisted of at least physical examination, 12-lead ECG 
and echocardiography. Diagnosis was based on the recently modified ARVD/C Task 
Force Criteria (TFC).2 
Genealogy
Since 1997 genealogical studies have been performed in newly ascertained ARVD/C 
cases, in order to select patients that could contribute to the finding of new ARVD/C 
loci, using identity by descent strategies.31 Investigations were carried out using 






DNA was isolated from peripheral lymphocytes according to standard protocols. In 
index-patients the coding region of the PKP2, DSC2, DSG2, DSP, JUP, and TMEM43 
genes were analysed, using denaturing high-performance liquid chromatography 
(PKP2, DSC2, DSG2) as described previously,32 and/or direct sequencing (DSP, 
JUP, TMEM43). Direct sequencing was performed with a BigDye Terminator DNA 
sequencing kit (version 2.0) on a 3730 automated sequencer (Applied Biosystems, 
Foster City, California, USA). All sequences were analysed using SeqScape software 
(version 2.1.1, Applied Biosystems). In addition, multiplex ligation-dependent probe 
amplification analysis was performed to exclude large deletions in PKP2 (SALSA 
multiplex ligation-dependent probe amplification kit P168 ARVC-PKP2, MRC Hol-
land, Amsterdam, the Netherlands). Relatives of index-patients were only analysed 
for the presence of a previously identified mutation.
Total RNA was isolated from fresh blood samples from individual VII:6 and a 
control individual using PAXgene kit (QIAGEN Benelux, Venlo, the Netherlands) 
and subjected to random hexamer primed reverse transcriptase PCR (RT-PCR). 
The obtained cDNA products were amplified by PCR with primers specific for PKP2 
coding sequence. PKP2 cDNA fragments were separated according to size using 
2% agarose gel electrophoresis along with a 100bp DNA ladder (O’GeneRuler; Fer-
mentas, Burlington, Canada). Both normal and aberrant fragments were gel purified 
and used for direct sequencing. Primers and PCR details are available upon request.
resulTs
Genealogy
In families 2 and 3 (Figure 1) common ancestors were found, that were born around 
AD 1780. Family 1 could be linked to family 2, but a link with the common ancestors 
in families 2 and 3 could not be established. Family 4 could not be traced back to the 
same ancestors, yet all ancestors lived in the same region.
Molecular genetic analyses
Analysis of the entire coding regions of PKP2, DSC2, DSG2, DSP, JUP, and TMEM43, 
including exon-intron boundaries, in the four index-patients revealed a c.2489+4A>C 
mutation in the PKP2 gene. Besides this intervening sequence mutation, no other 
mutations, including large deletions in PKP2, were found. The PKP2 c.2489+4A>C 
mutation is within the splice donor consensus sequence. Splice prediction pro-
grams were inconclusive with respect to a predicted effect on splicing (Table 1). 
The mutation was absent in over 150 ethnically matched controls (300 alleles) and 
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not annotated in both dbSNP and the 1000genomes project databases (accessed 
October 10, 2011). In addition to the four index-patients, ten relatives were also 
found to carry the PKP2 c.2489+4A>C mutation. 
RT-PCR demonstrated the presence of an abnormal PKP2 messenger RNA (Fig-
ure 2a), indicating that the effect of the c.2489+4A>C mutation is indeed through 
aberrant splicing. The abnormal PKP2 messenger RNA lacks the entire exon 12 (190 
base pairs) (Figure 2b). In the predicted protein a frameshift occurs that leads to 
stop codon 99 residues downstream, well within the 3’untranslated region of the 
PKP2 gene. Therefore, all residues normally encoded by exons 12, 13 and 14 are 
missing from the abnormal transcript, but the predicted abnormal protein is only 15 
residues shorter than the wild type protein (Figure 3). Since the stop codon occurs 
in the 3’untranslated region, the abnormal protein cannot be subjected to NMD. 
 family 1 family 2 family 3 family 4 
figure 1 Pedigrees of families 1-4. Squares denote males, circles females. Black squares/circles denote 
individuals that satisfy the 2010 Task Force Criteria (TFC) for a clinical diagnosis of ARVD/C (≥4 points). 
Upper right quadrant blackened squares/circles denote individuals that did not fulfil the TFC, but did 
have abnormalities compatible with ARVD/C at their most recent cardiac examination. +/- indicates the 
presence or absence of the PKP2 c.2489+4A>C mutation. Individuals denoted with “n” had a normal 
cardiac evaluation. Numbers in squares/circles denote the number of individuals. * Genotype used for 





All index-patients with the PKP2 c.2489+4A>C mutation fulfilled the modified TFC 
for ARVD/C.2 Figure 1 shows the pedigree of all families and clinical data on the 
PKP2 c.2489+4A>C mutation carriers are summarised in Table 2. Index-patient 1 
(VI:1) was admitted to the hospital at age 33 years with sustained monomorphic 
ventricular tachycardia (VT) (240/min) with left bundle branch block (LBBB) mor-
phology during exercise. He experienced at least four other episodes of VT, but no 
Table 1 Results of splice prediction programs
splice prediction program Wildtype
c.2489+4A>C 
mutation notes
NetGene2 0.93 0.91 Both ‘Highly confident donor sites’
NNSPLICE 0.9 0.98 0.57 donor score cutoff = 0.40




Results of the different prediction programs for the normal exon 12 donor splice site are shown.
Splice prediction are available from the following websites:
NetGene2:  www.cbs.dtu.dk/services/NetGene2; 
NNSplice 0.9:  www.fruitfly.org/seq_tools/splice.html; 
MaxEntScan:  genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html; 
GeneSplicer:  www.cbcb.umd.edu/software/GeneSplicer; 
Alamut:  www.interactive-biosoftware.com.
figure 2 RT-PCR for the PKP2 c.2489+4A>C mutation. (a) 2% Agarose gel electrophoresis showing 
cDNA products derived from mRNA of a control sample and index-patient VII:6. The first lane shows a 
100bp ladder, followd by the control, the patient sample, and a blank with primers in exons 11 and 13. 
The expected normal cDNA product with primers in exons 11 and 13 is 335bp in length. The shorter 
transcript in the patient sample (lane 3) lacks exon 12 (190bp) as shown in Figure 2b. The bands in the 
patient sample show a ~1:1 ratio, indicating that preferred PCR of the shorter transcript, lacking exon 12, 
did not occur. This could indicate partial degradation of the mutated mRNA. (b) Sequencing of the cDNA 
derived from both the normally spliced transcript and the abnormally spliced transcript demonstrating the 
skipping of exon 12.
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syncope. Supraventricular tachycardias also occurred, caused by AV-nodal re-entry 
and provoked by premature ventricular complexes. Radiofrequency (RF) ablation 
was performed for the ventricular arrhythmias from the right ventricular outflow 
tract and for the AVNRT. He has been doing well on disopyramide medication for 
twelve years. Index-patient 2 (VI:5) has been known with frequent VT episodes with 
LBBB morphology since the age of 20, which were treated with RF-ablation. At age 
36 she had an out of hospital cardiac arrest (OHCA) due to ventricular fibrillation 
(VF) while on sotalol. Subsequently an implantable cardioverter defibrillator (ICD) 
was implanted, which has delivered appropriate anti-tachycardia pacing and shocks. 
Index-patient 3 (VII:6) experienced a syncope at age 26 during exercise. She was 
admitted with a wide QRS complex tachycardia (250/min). Treatment with dyso-
pyramide was started. An AV-nodal re-entry tachycardia (AVNRT) was diagnosed 
at electrophysiological study, which was treated with RF-ablation, after a second 
arrhythmia episode. She has been free of symptoms for fourteen years. Index-patient 
4 (VI:10) had an OHCA with VF at age 29. He received an ICD and was treated with 
metoprolol for VTs. At age 33 he experienced two episodes with electrical storms 
possibly triggered by a viral infection. Metoprolol was changed to sotalol and amio-
darone was added. The patient has been doing well for nine years.
In addition to the four index-patients, two of the mutation positive family 
members developed clinical complaints likely related to ARVD/C, resulting in 6 
exon 10 exon 11 exon 12 13 14 
exon 10 exon 11 exon 12 13 14 3’ UTR 
exon 10 exon 11 13 14 3’ UTR 
exon 10 exon 11 13 14 3’ UTR 





















figure 3 Aberrant splicing as a result of the PKP2 c.2489+4A>C mutation. A and B represent the 
C-terminus of the normal PKP2 protein and the normally spliced mRNA respectively. C depicts part of 
the genomic DNA of the PKP2 gene (exons in red, introns (IVS) in grey, 3’untranslated region (UTR) 
in yellow) with the position of the wild type splice site above the bar and the mutated splice site below 
the bar. D and E show the aberrant splice product and the predicted abnormal protein respectively. The 




Table 2 Clinical data on PKP2 c.2489+4A>C mutation carriers
















































































































V:2 F 61 0 none ++ 2 Pos none No follow-up
V:4 F 69 7 none ++ ++ ++ 6 Aff anti-coagulant therapy Paroxysmal AF; 
no progression
VI:3 F 35 7 none + ++ 3 Bor none No progression
Family 2
VI:5 F 20 20 32 VT/VF/
OHCA
++ ++ ++ ++ ++ 10 Aff RF-ablation, ICD, 
sotalol
Appropriate ICD~, good LV 
function.
VII:3 M 17 11 none ++ + ++ 5 Aff none Mild progression
VII:4 F 15 11 none ++ 2 Pos none No progression
V:7 F Not evaluated
Family 3
VII:6|| F 26 26 14 syncope + ++ + ++ ++ 8 Aff RF-ablation Concurrent AVNRT; no 
progression
VI:7 F 62 3 none ++ 2 Pos none No progression
Family 4
VI:10 M 29 29 9 VF/ OHCA ++ ++ ++ ++ 8 Aff ICD, sotalol, 
amiodarone
Appropriate ICD~, mild 
progression
V:11 F 59 9 none ++ 2 Pos none Mild progression
VI:8 F 40 33 9 near 
syncope
++ ++ 4 Aff ICD Evident progression
VI:9 M 34 32 9 near 
syncope
++ ++ 4 Aff ICD, sotalol Mild progression
* Not available, ‡ minor criteria yield 1 point and major criteria 2 points; for a definite diagnosis of 
ARVD/C a minimum of 4 points is required, 3 points indicate a borderline diagnosis and 2 points 
a possible diagnosis. § for this patient a biopsy was available; it showed fibrosis but no fat and was 
considered inconclusive, || syncope probably resulting from AVNRT; thus far no symptoms have recurred 
after RF-ablation of AVNRT. 
Abbreviations: AF = atrial fibrillation, Aff = affected, AVNRT = AV-nodal re-entry tachycardia, Bor = 
borderline, F = female, ICD = implantable cardioverter defibrillator, ICD~ = ICD discharge, LBBB = left 
bundle branch block morphology, LV = left ventricle, M = male, NA = not available, nsVT = non-sustained 
ventricular tachycardia, OHCA = out of hospital cardiac arrest, Pos = possibly, RF = radiofrequency, RV 
= right ventricle, sVT = sustained ventricular tachycardia, VF = ventricular fibrillation, VT = ventricular 
tachycardia. 
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symptomatic mutation carriers. In family 4, a 34 year old male (VI:9), who had had 
no complaints at initial evaluation, received an ICD after he suffered a near syncope 
while already taking sotalol. Non-sustained polymorphic VTs of insufficient duration 
to warrant ICD therapy were subsequently recorded. His sister (VI:8) received an 
ICD shortly after she experienced a near syncope during a stressful event. Although 
without any signs of disease at initial evaluation at age 33, she developed aneurys-
matic changes of the right ventricle in the course of nine years. 
Remarkably, seven of the thirteen mutation carriers (age range at first evaluation 
15-69 years) who were evaluated, were asymptomatic. In four of them only a major 
criterion for a positive family history was available, leading to a possible clinical 
status according to the modified taskforce criteria. In three of the asymptomatic 
carriers additional criteria were present, resulting in a borderline diagnosis in one 
and a definite diagnosis in two asymptomatic carriers.2
Left ventricular involvement was not systematically assessed in these families. 
Cardiac MRI was performed in five mutation carriers; all of them showed normal LV 
volumes and LV ejection fraction. None of them showed LV wall motion abnormali-
ties or late gadolinium late enhancement. Index-patient VI-5 experienced a VT with 
RBBB morphology, but she had a normal LV function. Finally, none of the mutation 
carriers had isolated inverted T-waves in the left precordial leads V4-V6.
disCussion
PKP2 mutations are a frequent cause of ARVD/C. The PKP2 gene was first implicated 
in ARVD/C through a candidate-gene approach.5 The fact that the PKP2 locus had 
not been previously found in linkage studies can be explained by low penetrance 
resulting in phenotype negative family members who were classified as unaffected, 
although they were in fact mutation carriers. Previously, the haplotype sharing test 
identified a shared haplotype on chromosome 12p12.1-q13.13, encompassing 
PKP2, as the largest shared haplotype in these families.33 The haplotype sharing test 
compares the genotypes from SNP-arrays, using an affected-only strategy, to search 
for large shared haplotypes within pedigrees, most likely to contain a causative 
mutation. In these families, the haplotype sharing test indicated a common founder, 
who must have lived well before the 19th century. Based on pedigree data, it was 
estimated that the most recent common ancestor should be situated over seven 
generations ago. However, these are crude estimations since only four families were 
available. The actual age of the mutation could be considerably older. Little is known 
about the age of PKP2 mutations. Our data show that mutations may have occurred 




that in some families we have been able to demonstrate common ancestors as far 
as 10 generations back by genealogy, suggests that reproductive fitness in ARVD/C 
is not significantly reduced.
The PKP2 c.2489+4A>C mutation seems to be relatively frequent in the Neth-
erlands, being detected in four independently ascertained ARVD/C families, so 
far. Another five mutations (c.235C>T, c.397C>T, c.1211-1212dupT, c.2386T>C and 
c.2489+1G>A) in PKP2 have occurred at least as frequent in the Dutch ARVD/C 
cohort. Haplotype analysis and genealogy suggest that there also may be common 
founders contributing to these mutations, explaining the high prevalence of PKP2 
mutations in Dutch ARVD/C patients.32,34 
The frequent occurrence of nonsense and frameshift mutations in PKP2 is 
indicative that the causative mechanism at the protein level is that of loss of normal 
PKP2 function, as most of these mutations are predicted to lead to NMD.28 Gerull 
et al, while performing Western blot analysis on cardiac tissue in a patient with a 
PKP2 c.2076_2077delAA mutation, demonstrated reduced wild type PKP2, but were 
unable to demonstrate the predicted abnormal protein.5 This is in keeping with 
the concept of NMD in the heart. As the PKP2 c.2489+4A>C mutation cannot be 
subjected to NMD, it is predicted to lead to a dysfunctional PKP2 protein. However, 
we cannot exclude degradation of the abnormal protein through other mechanisms, 
which could still lead to haplo-insuficiency. If a dysfunctional protein is present, 
the last two conserved armadillo repeat regions would be disrupted, completely 
altering the C-terminal tail. The exact role of the C-terminal tail is unknown, while 
the N-terminal part of the protein is most important for binding other desmosomal 
proteins and targeting PKP2 to the plasma membrane.35 The pathogenic effect of 
splice mutations may be ameliorated when the induced aberrant splicing is not 
absolute, as has been shown for the only recessive PKP2 mutation thus far.36 In 
the absence of heterozygous polymorphisms in exons 12-14 of the PKP2 gene, the 
presence of a normal transcript from the diseased allele could not be assessed. 
In total 14 patients with the PKP2 c.2489+4A>C mutation (4 males, 10 females), 
including index-patients, were identified in the four families. Despite the overrepre-
sentation of female mutation carriers in this study, two out of four index-patients 
were males. Nine out of ten family members with a mutation had a cardiac work up. 
Only two of nine evaluated mutation positive family members developed clinical 
complaints (Table 2). Five family members fulfilled the modified TFC for ARVD/C. 
Incomplete penetrance and clinical variability are characteristic for ARVD/C,4 and 
are also seen in the families with the PKP2 c.2489+4A>C mutation. Compound 
heterozygosity or digenic inheritance for mutations in the desmosomal genes or in 
TMEM43 had been excluded as an explanation for this variability, but other genetic, 
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epigenetic or non-genetic factors, such as lifestyle, could have contributed to the 
clinical differences observed in these families.
Which preventive treatment modalities are justified in asymptomatic PKP2 
mutation carriers is currently undetermined. We suggest that they be followed up 
regularly in order to assess disease progression with annual echocardiography, 
Holter monitoring and exercise testing. Besides, additional cardiac MRI at intervals 
no longer than 5 years (or before implantation of an ICD) is deemed appropriate in 
the Netherlands. 
Although we find molecular diagnosis in ARVD/C a useful tool in identifying 
persons at risk for developing ARVD/C, its value is still limited by the inability to 
accurately predict phenotype from genotype, especially when a missense variant is 
identified.29 The fact that many identified PKP2 mutation carriers will never experi-
ence life-threatening arrhythmias, emphasises the need for identifying both the truly 
pathogenic mutations as well as other genetic or environmental factors that play a 
role in disease causation. We believe that the described PKP2 c.2489+4A>C muta-
tion is pathogenic, based on its co-segregation with the ARVC/D phenotype, the 
absence of the mutation in controls as well as in the dbSNP and the 1000genomes 
project databases, the fact that the mutation is located on the largest shared 
haplotype, indicating a founder effect,33 and the RT-PCR which demonstrated the 
presence of an abnormal PKP2 messenger RNA (Figure 2a). As is the case for many 
other desmosomal mutations implicated in ARVC/D, the c.2489+4A>C mutation is 
characterised by incomplete penetrance, indicating that not all mutation carriers 
will develop the disease. The mutation is predicted to lead to the presence of a 
dysfunctional PKP2 protein, whereas most truncating mutations are expected to 
lead to loss of protein. Mutation carriers displayed a wide range in disease severity, 
suggesting that PKP2 mutations alone are not sufficient to cause disease. 
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ABsTrACT
Background Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) 
is an inherited cardiac disease with reduced penetrance and a highly variable expres-
sion. Mutations in the gene encoding plakophilin 2 (PKP2) are detected in about 
50% of patients with ARVC/D. The p.Arg79X mutation in PKP2 has been identified 
in Europe and North America and has been functionally characterised. We evaluated 
the prevalence of the p.Arg79X mutation in PKP2 in the Dutch population.
Methods Twelve index patients and 41 family members were evaluated in three 
university hospitals in the Netherlands. The diagnosis of ARVC/D was established 
according to the recently revised Task Force Criteria. Segregation of the p.Arg79X 
mutation was studied and haplotypes were reconstructed to determine whether the 
p.Arg79X mutation was a recurrent or a founder mutation.
results The p.Arg79X mutation in PKP2 was identified in 12 index patients. Haplo-
type analysis revealed a shared haplotype among Dutch p.Arg79X mutation carriers, 
indicating a common founder. Six index patients (50%) had a first- or second-degree 
relative who had died of sudden cardiac death below 40 years of age. At age 60, only 
60% of the mutation carriers actually experienced any symptoms. There was no 
significant difference in symptom-free survival and event-free survival between men 
and women.
Conclusions We identified the largest series of patients with the same desmosome 
gene mutation in ARVC/D reported to date. This p.Arg79X mutation in PKP2 is 
a founder mutation in the Dutch population. The phenotypes of PKP2 p.Arg79X 






Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is an inher-
ited cardiac disease, characterised by fibrofatty replacement of cardiomyocytes, 
primarily in the right ventricle (Figure 1A).1,2 The clinical presentation of ARVC/D 
is highly variable, ranging from asymptomatic to sudden cardiac death (SCD) and/
or heart failure, even at a relatively young age.3,4 The clinical diagnosis of ARVC/D 
is based upon criteria originally proposed by an international Task Force in 1994;5 
these have recently been modified to improve diagnostic sensitivity and maintain 
diagnostic specificity.6 The modified criteria include quantitative parameters for 
the imaging studies and tissue characterisation, revised ECG criteria, and genetic 
status. Applying the modified criteria to a Dutch cohort of patients with proven 
ARVC/D, their family members, and to patients with probable ARVC/D produced a 
major increase in the diagnostic yield of ARVC/D, especially due to the revised ECG 
criteria and the identification of pathogenic mutations.7 The estimated prevalence 
of ARVC/D ranges from 1:1000 to 1:5000, with men being more frequently affected 
than women. ARVC/D is familial in up to 50% of cases.1,8-12
Since the identification of mutations in the genes encoding desmosomal pro-
teins desmoplakin (DSP)13 and plakophilin 2 (PKP2),14-17 followed by mutations in 
desmocollin 2 (DSC2),18 desmoglein 2 (DSG2),19 and plakoglobin (JUP),20 it has 
been recognised that ARVC/D is mainly a disorder of the cardiac desmosome (Fig-
ure 2), a cell adhesion complex residing in the intercalated disk of cardiomyocytes. 
Comprehensive screening of these genes encoding the proteins of this complex 
leads to the identification of a pathogenic mutation in approximately 40-60% of 
ARVC/D patients.7,21-23 PKP2 has the highest yield from mutational screening, being 
present in up to 55% of patients in the Netherlands and the USA in groups fulfilling 
the task force criteria.7,14-17
The detection of a pathogenic mutation in a proband diagnosed with ARVC/D 
has important implications for family members. Cascade screening will identify 
previously unknown mutation carriers, enabling timely diagnosis and facilitating 
prevention of subsequent complications, thereby reducing morbidity and mortal-
ity. Excluding a pathogenic mutation in a family member justifies dismissal from 
regular cardiological follow-up.24
To date, more than 140 different pathogenic mutations have been reported in 
ARVC/D patients.25 In this series of the Netherlands Heart Journal on recurrent 
and founder mutations in the Netherlands, we describe the largest series of Dutch 
patients with the same desmosome gene mutation, the p.Arg79X mutation in 
PKP2. In addition, we discuss patients carrying this mutation by comparing them 
to patients with the same mutation described in the literature, and we illustrate 
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the clinical variability linked to this mutation. We also discuss functional analyses 
that have been performed to clarify the molecular and cellular consequences of the 
p.Arg79X mutation in PKP2.
PATienTs And MeThods
Clinical evaluation and diagnostic criteria
Twelve index patients carrying the p.Arg79X mutation were evaluated in one of the 
three university hospitals working on this study in the Netherlands. A total of 41 
additional family members were also clinically and/or genetically evaluated. A history 
was taken from all the index patients, and they were evaluated by physical examina-
tion, 12-lead ECG, 24-hour Holter monitoring, exercise testing, and 2-dimensional 
transthoracic echocardiography. In addition, MRI, nuclear scintigraphy, signal-aver-
aged ECG (SA-ECG), left and right ventricular cineangiography, electrophysiology 
study, and/or a right ventricular endomyocardial biopsy were performed in a subset 
of index patients.
The diagnosis of ARVC/D in index patients was established according to the 
modified task force criteria (TFC).6 A diagnosis of ARVC/D was considered definite 
if a patient fulfilled two major, one major and two minor, or four minor criteria. For 
each category, only one major or one minor criterion can be included. A diagnosis of 
ARVC/D was considered probable if only one major and one minor, or three minor 
criteria from different categories were present. ARVC/D was considered proven 
familial if at least one additional family member was found to fulfil the TFC. End 
points/events in follow-up were death due to a cardiac cause (including SCD) and 
an appropriate discharge of an implantable cardioverter defibrillator (ICD). These 
events, and ventricular tachycardia and syncope, were considered as symptoms for 
the Kaplan-Meier analysis.
The postal codes of all the p.Arg79X mutation carriers and of all the individuals 
who underwent PKP2 sequence analysis in the Netherlands were plotted to study 





DNA for PKP2 sequence analysis was isolated from peripheral blood samples 
according to standard protocols. PKP2 primer sequences were obtained from Gerull 
et al,14 and mutational analysis was performed in all index patients, as described 
previously.17 Sequence analysis of DSC2, DSG2, DSP, and JUP was performed in six 
index patients, and in eight of twelve families we were able to study the segregation 
of the p.Arg79X mutation.
haplotype analysis
To determine whether the p.Arg79X mutation is recurrent or has a common founder, 
we previously performed haplotype analysis in five p.Arg79X index patients, using 
five repeat markers within a region of 300,000 bp, including the entire genomic 
region of PKP2.17 For patients from the other seven families, the haplotypes were 
reconstructed using the same markers. 
statistical analysis
Kaplan-Meier analysis was used to determine the cumulative symptom-free and 
event-free survival in ARVC/D patients with the p.Arg79X mutation in PKP2. The 
log-rank test was used to compare the results for men versus women, with values 
figure 1 (A) Histology: high powered visualisation of fatty infiltration (white colour) and fibrous tissue 
(blue colour) surrounding atrophic cardiomyocytes and indicative of ARVC/D. (B) ECG of patient G1-
III:1, obtained 8 months before the occurrence of SCD at the age of 27 years. The ECG showed inverted 
T waves in leads V1 and V2 (single arrow). (C) ECG of patient G1-II:1, obtained at age 56 years. The ECG 
showed inverted T waves in leads V1-V3 (single arrow). 
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of P<0.05 being considered significant. All data were analysed with the Statistical 
Package for Social Sciences (SPSS version 16.0; SPSS Inc., Chicago, Ill).
resulTs
Clinical evaluation and diagnostic criteria
The age at initial presentation, diagnostic criteria, and follow-up of patients fulfill-
ing the ARVC/D criteria are presented in Table 1 (see also Figure 3). Eleven index 
patients were diagnosed with definite ARVC/D. In patient G1-III:1, retrospective 
analysis of the ECG after SCD at the age of 27 years, showed inverted T waves in V1 
and V2 (Figure 1B), which were also found in his mother’s ECG (G1-II:1, see Figure 
1C). One other index patient (A45-IV:8) was diagnosed with ARVC/D after SCD at 
the age of 25 years. Another index patient (A44-II:4) was diagnosed with probable 
ARVC/D.
Three of twelve index patients were women, with an average age at initial presen-
tation of 37 years (22-66; median 29). Nine of the twelve index patients presented 
figure 2 Schematic representation of the molecular organisation of cardiac desmosomes. A model of the 
relative organisation of major desmosome components is presented. The plasma membrane-bound (PM) 
desmocollin 2 (DSC2) and desmoglein 2 (DSG2) proteins interact via their extracellular domains at the 
dense midline (DM) in the extracellular space between adjacent cells. Their cytoplasmic domains interact 
with plakoglobin (PG) and plakophilin 2 (PKP2) in the outer dense plaque (ODP). Also in the ODP, PKP2 
and PG interact with the N-terminal domain of desmoplakin (DSP). The C-terminus of desmoplakin 




with ventricular tachycardia (VT), one with syncope and two were diagnosed at 
autopsy.
In six families, at least one relative of the index patient fulfilled the TFC for the 
diagnosis of ARVC/D. Six index patients (50%) had a first- or second-degree relative 
with SCD (range 15-55 years). 
Figure 4 shows the symptom-free and event-free survival for p.Arg79X mutation 
carriers; there is no statistically significant difference between men and women. 
At age 40, only 32% of the mutation carriers (37% of men, 14% of women) had 
experienced any symptoms; at age 60 this number had increased to 60% (65% of 
men, 54% of women). Notably, cascade screening identified three mutation car-
riers aged 70 or over (two males aged 70 and 80, one female aged 87), who had 
never experienced any symptoms. Heart failure was not a prominent feature in the 
p.Arg79X mutation carriers.
Immunohistochemical analysis of plakoglobin, based on the use of immunoper-
oxidase as described by Asimaki et al,26 was performed on myocardial samples of 
patient III:1 from family G39. When compared to that of a myocardial sample of a 
control heart, a strong decrease of plakoglobin expression at the desmosomes, in 
both the right and left ventricle, was detected. 
The geographical distribution of mutation carriers and the number of PKP2 
analyses performed in the Netherlands are shown in Figure 5. 
Genetic evaluation
The c.235C>T mutation in exon 2 of PKP2 was identified in all 12 index patients, 
resulting at the protein level in a premature stop codon at position 79 (p.Arg79X). 
The p.Arg79X mutation occurs in 5% of all Dutch patients fulfilling the TFC (data 
not shown). The segregation of the p.Arg79X mutation was studied in eight families 
(Figure 3); we found that all family members with definite or probable ARVC/D for 
whom DNA was available carried the mutation. So far, comprehensive analysis of all 
five desmosomal genes was performed in six index patients (G01, G06, A01, A04, 
A25, U2); no additional mutations were found in DSC2, DSG2, DSP, and JUP in 
these patients.
haplotype analysis
Haplotype analysis revealed a shared haplotype among all p.Arg79X mutation car-
riers (Table 2). These data strongly suggest that the p.Arg79X mutation originated 
from a common founder rather than being recurrent. The geographic distribution of 
the index patients carrying the p.Arg79X mutation in PKP2 suggests that the muta-
tion originated from the northern region of the Netherlands.
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Table 1 Clinical characteristics of ARVC/D probands and family members with the p.Arg79X mutation





































































































G01 iii:1 || * M 27y sCd ++ + + + ++   2/3 || SCD, 27y
II:1 * F 53y Fam.scr. 48y ++ + + ++ 2/2
II:3 * F Fam.scr. 50y ++ ++ 2/0
II:4 * F Fam.scr. 46y ++ 1/0
  III:3 * M   Fam.scr. 29y       ++   ++ 2/0  
G06 ii:2 * M 43y VT ++ ++ + ++ 3/1
II:1 † F 15y SCD SCD,15y
  II:3 * F 40y Fam.scr. 40y     ++   + ++ 2/1  
G39 i:1 † M 66y VT ++ + ++ 2/1 Death, 73y
II:3 * M 65y Fam.scr. 48y + ++ ++ 1/2 ICD, 66y
  III:1 * M 21y SCD ++ ++       ++ 3/0 SCD, 21y
G40 ii:1 * M 56y VT         ++ ++ 2/0 iCd, 57y
G41 ii:3 * M 28y VT ++ + ++ 2/1 iCd, 39y
II:2 † M 29y VT + ++ 1/1 ~ICD, 36y
  III:2 * M   Fam.scr. 06y           ++ 1/0  
A01 iii:2 * f 40y VT ++ ++ + ++ ++ 4/1
II:2‡ * F Fam.scr. 87y ++ 1/0
  II:3‡ * M   Fam.scr. 80y           ++ 1/0  
A04 iii:2 * M 29y VT ++ ++ ++ 3/0 ICD, 33y
  II:3‡ * M   Fam.scr. 70y           ++ 1/0  
A25 ii:2 * M 28y VT ++ + ++ 1/2 iCd, 28y
II:1 * F 50y Syncope ++ + ++ 2/1
II:3§ † M Unknown Death, 25y
II:4 * M Fam.scr. 54y ++ 1/0
III:1 * M Fam.scr. 31y ++ 1/0
III:2‡ * M Fam.scr. 28y ++ 1/0
III:6 * F Fam.scr. 25y ++ 1/0
  III:7 * M   Fam.scr. 19y           ++ 1/0  
A43 ii:1 * f 55y syncope ++ ++ + ++ 3/1
  III:2 * F   Fam.scr. 34y           ++ 1/0  
A44 ii:4 * M 25y VT + ++ 1/1
I:2§ * F Fam.scr. 84y ++ 1/0
  II:1 † F 29y SCD           SCD, 29y
A45 iV:8 || * f 25y sCd + ++    1/1 || SCD, 25y
II:1 † F 51y SCD SCD, 51y
II:2 † M 46y SCD SCD, 46y
III:1 † M 20y SCD SCD, 20y
III:4 * F Fam.scr. 80y ++ 1/0





We identified the p.Arg79X mutation in PKP2 in 12 index patients diagnosed with 
ARVC/D or probable ARVC/D; it is thus one of the most commonly detected PKP2 
mutations in the Netherlands. Haplotype analysis strongly suggested a common 
founder. Gerull et al. identified the same mutation in 6 out of 120 probands of Western 
European descent, but could not identify shared haplotypes among these patients.14 
In addition, Dalal et al. identified the same mutation in two female ARVC/D patients 
of North American Caucasian origin, but gave no further information regarding hap-
lotype analysis.16,23 These observations suggest that the PKP2 p.Arg79X mutation is 
recurrent and that a founder effect is present in the Dutch population. A founder 
effect was also identified for three other PKP2 mutations in the same Dutch cohort 
(p.Gln133X, p.Cys796Arg, and c.2489+1G>A).17 However, no other studies have 
Table 1 Clinical characteristics of ARVC/D probands and family members with the p.Arg79X mutation





































































































A45 III:9 * M Fam.scr. 70y + ++ 1/1
III:10 † M 55y SCD SCD, 55y
III:11 * F Fam.scr. 67y ++ ++ 2/0
IV:3 * F Fam.scr. 54y ++ 1/0
IV:5 * M Fam.scr. 45y ++ 1/0
IV:6 * M Fam.scr. 38y ++ ++ 2/0 ICD, 38y
IV:9§ * F Unknown ++ 1/0
  IV:11 * F   Fam.scr. 43y           ++ 1/0  
u02 ii:4 * M 22y VT ++ ++ ++ ++ ++ 5/0 SCD, 57y
II:1 * F 64y Fam.scr. 60y + ++ ++ + ++ 3/2 ICD, 64y
II:2 * M 48y SCD ++ 1/0 SCD, 48y
III:1 * F Fam.scr. 29y + ++ 1/1
III:2 * F Fam.scr. 26y ++ ++ 2/0
  III:4 * F   Fam.scr. 25y ++       + ++ 2/1  
* proven p.Arg79X mutation carrier; † likely p.Arg79X mutation carrier; ‡ asymptomatic, no cardiac 
examination performed; § no clinical data available; || diagnosed at autopsy; ++ indicates major criterion; 
+, minor criterion; TFC, number of major/minor criteria respectively; SCD, sudden cardiac death; Fam.
scr., family screening; VT, ventricular tachycardia; ICD, implantable cardioverter defibrillator; ~ICD, 
appropriate ICD discharge.
Index patients are in bold. Family numbers correspond with Figure 3. Only the presence of a feature is 
indicated. End points are in italics.
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reported founder mutations, although a few recurrent PKP2 mutations have been 
identified (e.g. p.Ser50fsX110, p.Val837fsX930, and c.2146-1G>C).14-17 The fact that 
other groups might have studied a more heterogeneous population may account for 
the lack of founder mutations in their cohorts.
Gerull et al. found the p.Arg79X mutation in six male index patients. All had 
a history of ventricular tachycardias, two had experienced cardiac arrest, but only 
one had a positive family history.14 The first patient from North America described 
by Dalal et al. was a female athlete who presented with syncope at age 28. Cardiac 
examination revealed mild global RV dilatation, T-wave inversions in leads V1-V3, 
late potentials on SA-ECG, a left bundle branch block type VT, and >1000 ventricular 
extrasystoles/24hrs. She had a negative family history.16 Their second patient was 
also a female but her age at onset and initial presentation were not reported.23 In 
agreement with these observations, we found that nine of our twelve index patients 
were male and that VTs were present in the majority of cases (9/12). In our cohort, 
the effect of the p.Arg79X mutation in PKP2 was characterised by a remarkably high 
clinical variability, typical of ARVC/D; 13% (7/53) of our likely or proven mutation 
carriers died of SCD before age 30, while 40% did not experience any symptoms 
at age 60. In the mutation carriers with symptoms, VTs and SCD were prominent, 
although heart failure was not.
A possible explanation for this high variability may be the co-occurrence of more 
than one mutation in the desmosomal genes, which has been recognised in up to 
8% of ARVC/D patients.22,23,27 These mutations can be present in different genes 
(digenic heterozygosity) or on different alleles of the same gene (compound het-
erozygosity). Theoretically, digenic or compound heterozygosity could explain the 
severe end of the phenotypic spectrum of the p.Arg79X mutation carriers. However, 
we found no second mutation in the six index patients we analysed comprehensively 
for the five genes encoding desmosomal proteins (in addition to PKP2, DSC2, DSG2, 
DSP, and JUP). 
Although the number of identified mutations in PKP2 and other ARVC/D-related 
genes is still rapidly increasing, data on the functional effects at the cellular and 
molecular level are scarce. For the p.Arg79X mutation in PKP2, however, the con-
sequences of the expression of the mutation have been studied, using neonatal rat 
ventricular myocytes.28 This showed that the mutant protein failed to localise to the 
cell membrane, in contrast to endogenous PKP2 and DSP. The major cardiac gap 
junction protein connexin-43 (Cx43) was also reduced in this model. This was also 
true for HSP90, a protein that interacts with Cx43 and is known to be essential for 
the survival of cardiomyocytes.29,30 Finally, the expression of p.Arg79X led to the 




figure 3 Pedigrees of the 12 families with the p.Arg79X mutation in PKP2. Squares indicate male family 
members, circles indicate female family members, slashes indicate deceased family members, and 
arrows indicate index patients. Solid black symbols indicate proven ARVC/D, solid grey symbols indicate 
probable ARVC/D, half-filled black symbols indicate SCD, half-filled grey symbols indicate mutation 
carriers identified through family screening, dotted symbols indicate obligate carriers, and open symbols 
indicate unaffected family members. Genotype results are indicated by (+) = p.Arg79X present and (–) = 
p.Arg79X absent. 
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figure 4 Kaplan-Meier survival analyses of p.Arg79X mutation carriers. (A) Symptom-free survival. (B) 
Event-free survival. Death due to a cardiac cause and an appropriate ICD-discharge are considered as 
events. These events as well as ventricular tachycardia and syncope are considered as symptoms.
figure 5A  Postal code maps of the Netherlands. Distribution of index patients carrying the p.Arg79X in 
PKP2 in the Netherlands. The number of p.Arg79X mutation carriers is shown per region (in parenthesis: 




Table 2 Haplotype (in grey) associated with the p.Arg79X mutation in the Dutch population
index patient
Position G01 G06 G39 G40 G41 A01 A04 A25 A43 A44 A45* u02
32.700k 3 5 5 5 1 5 2 5 4 5 5 5 1 5 4 5 2 5 4 5 1 5 4 5
32.830k 2 6 1 6 5 6 4 6 2 6 2 6 7 6 5 6 3 6 7 6 7 6 2 6
c.235C>T C T C T C T C T C T C T C T C T C T C T C T C T
32.940k 1 2 3 2 1 2 3 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
32.970k 1 2 5 2 4 2 3 2 3 2 4 2 4 2 4 2 4 2 4 2 4 2 1 2
33.000k 1 2 2 2 1 2 10 2 8 1 4 2 8 2 2 2 2 2 8 2 9 2 6 2
The first column shows the genomic position of the markers and the c.235C>T, p.Arg79X mutation on 
chromosome 12. For each marker, the shortest haplotype is set at 1.The white and grey columns represent 
the two inherited haplotypes, one from each parent. Note that the index patient of family G41 has a 
different allele for the 33.000k marker.
* Haplotype analysed in IV:3 (not the index patient).
figure 5B  Postal code maps of the Netherlands.  Overview of PKP2 analyses in ARVC/D patients in the 
Netherlands. The number of PKP2 analyses is shown per region (in parenthesis: the number of regions, 
90 in total). On average, each region contains 180,000 inhabitants.
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these results suggest that the p.Arg79X mutation leads to a loss of myocardial 
integrity characteristic of ARVC/D.28
Finally, Asimaki et al. showed that immunohistochemical analysis of conven-
tional endomyocardial biopsy samples appears to be both a highly sensitive and 
specific diagnostic test for ARVC/D, as was demonstrated in a group of 11 ARVC/D 
patients.26 Reduced immunoreactive signal levels of plakoglobin and Cx43 were 
found to be a consistent feature in patients with ARVC/D. Although we found 
reduced signal levels for plakoglobin in one of the p.Arg79X mutation carriers, this 
was not a consistent finding in another series of patients (data not shown) and 
further studies are required to establish the possible role of immunohistochemical 
analysis in patients with ARVC/D.
ConClusions
In the majority of cases, ARVC/D is caused by mutations in genes encoding des-
mosomal proteins, especially PKP2. The PKP2 p.Arg79X mutation is a recurrent 
mutation in Europe and North America. We identified the p.Arg79X mutation in 
12 Dutch index patients and showed that they share the same haplotype, strongly 
suggesting a founder effect in the Dutch population. The PKP2 p.Arg79X mutation 
carriers comprise the largest series of patients with the same desmosome gene 
mutation reported so far, and we illustrate that the clinical phenotype is highly vari-
able, varying from SCD to non-penetrance. 
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Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a heredi-
tary cardiac disease, characterised by fibrofatty replacement of cardiomyocytes, 
ventricular tachyarrhythmias and premature sudden cardiac death. Mutations 
in genes encoding desmosomal proteins are the major cause of ARVD/C, yet the 
pathogenicity of identified variants is not always clear. We have therefore created an 
online database (http://www.arvcdatabase.info), providing information on variants 
in ARVD/C-associated genes.
We searched the literature using ARVD/C and its underlying genes (DSC2, 
DSG2, DSP, JUP, PKP2, TGFB3, TMEM43, TP63) as keywords. From the selected 
papers and our unpublished data, we collected details on the type of mutation and 
the information provided at the genetic and protein level. Entries are linked to a 
“details page” containing clinical data and the referred publication(s). To aid the 
interpretation of the effect of missense mutations, we provide data obtained from 
in silico prediction methods.
In May 2009 the ARVD/C database contained 481 variants in 8 genes, from 57 
papers and abstracts. Of these, 144 variants are considered pathogenic, 73 are 
considered unknown/unclassified variants, and 264 have no known pathogenicity. 
Data can be added online. The database is converted into the Leiden Open Variation 
Database (LOVD) format, a tool for gene-centred collection and display of DNA 
variations.
The ARVD/C database will be useful for both researchers and clinicians. The 
database can be easily searched to determine if variants have been published and 
whether they are considered to be pathogenic. External users are invited to add 





Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a heredi-
tary cardiac disease, generally characterised by fibrofatty replacement of cardio-
myocytes, primarily in the right ventricle.1,2 The resulting disruption of normal myo-
cardial architecture in ARVD/C patients can result in ventricular tachyarrhythmias, 
presenting as palpitations or syncope and sudden cardiac death (SCD) at a relatively 
young age.2-4 The clinical diagnosis of ARVD/C is based upon criteria proposed by 
an international task force in 1994.5 ARVD/C is a heterogeneous disease, marked 
by variable expression and incomplete penetrance that is usually transmitted as 
an autosomal dominant trait, although autosomal recessive transmission has been 
described.6,7 
In 2002, the first mutation causing non-syndromal ARVD/C was reported 
by Rampazzo et al:8 a mutation in the desmoplakin gene (DSP; MIM# 125647), 
encoding a component of the desmosome. It was however only after a breakthrough 
article by Gerull et al, describing 25 mutations in the cardiac desmosomal gene 
plakophilin 2 (PKP2; MIM# 602861),9 that the desmosome complex was considered 
the major structure in the cell which, when mutated, might cause ARVD/C (for a 
schematic representation of the desmosome complex see Figure 1). Many groups 
figure 1 Schematic representation of the molecular organisation of cardiac desmosomes. A model of the 
relative organisation of major desmosome components is presented. The plasma membrane-bound (PM) 
desmocollin 2 (DSC2) and desmoglein 2 (DSG2) proteins interact via their extracellular domains at the 
dense midline (DM) in the extracellular space between adjacent cells. Their cytoplasmic domains interact 
with plakoglobin (PG) and plakophilin 2 (PKP2) in the outer dense plaque (ODP). Also in the ODP, PKP2 
and PG interact with the N-terminal domain of desmoplakin (DSP). The C-terminus of desmoplakin 
anchors intermediate filaments, mainly desmin (DES), at the inner dense plaque (IDP).20 See colour figure 
on page 18. 
102
started screening genes encoding desmosome associated proteins and as a result, 
more putative disease-causing mutations in PKP2 and DSP,10-14 as well as in the 
other desmosomal genes, desmocollin 2 (DSC2; MIM# 125645), desmoglein 2 
(DSG2; MIM# 125671) and plakoglobin (JUP; MIM# 173325), were identified in 
patients with non-syndromal ARVD/C.15-19 Although ARVD/C is now considered to 
be a disorder of the cardiac desmosome,20 some non-desmosomal genes have also 
been associated with ARVD/C. Mutations in both the 5’ and 3’ untranslated region 
(UTR) of the transforming growth factor β3 gene (TGFB3; MIM# 190230), a muta-
tion in the transmembrane protein 43 encoding gene (TMEM43; MIM# 612048), 
and a mutation in the tumour protein p63 gene (TP63; MIM# 603273) have been 
identified in families with ARVD/C.21-23 In addition, mutations in the ryanodine 
receptor 2 gene (RYR2; MIM# 180902) were described in eight families with cat-
echolaminergic polymorphic ventricular tachycardia (CPVT) and a highly penetrant 
form of ARVD/C.24,25 Whether this form of CPVT should be considered a primary 
form of ARVD/C remains the subject of debate.26,27 Furthermore, several linkage 
analyses identified loci not containing the above genes, but the causative gene has 
not been identified in the respective regions yet.28-31
At present, over 140 disease-causing ARVD/C mutations have been published, 
the vast majority in genes encoding desmosomal proteins. Frameshift and nonsense 
mutations resulting in a premature stop codon and splice site mutations leading to 
aberrant splice products, found in patients with or suspected of having ARVD/C, 
are generally considered to be pathogenic. These types of mutations are often found 
in the major gene underlying ARVD/C, namely PKP2.9,13 In addition, many of the 
reported missense mutations are classified as pathogenic, though functional stud-
ies supporting these claims are often lacking. This classification is generally based 
on several criteria, such as the differences in physical and chemical properties of the 
amino acids involved in the respective substitution, the evolutionary conservation 
across several species of the particular amino acid and/or the region surrounding it, 
the localisation within a functionally important domain or in one that is predicted to 
be important, the absence of the respective mutation in control chromosomes, and 
(when known) cosegregation of the mutation with the disease in affected families. 
Notably, non-synonymous single nucleotide polymorphisms (SNPs) have been 
identified in the coding regions of all the genes known in ARVD/C. 
Judging the putative pathogenic nature of missense mutations forms an 
important challenge for researchers worldwide. Because of clinical variability and 
age-dependent penetrance, as well as the absence of functional studies, the correct 
interpretation of the pathogenicity of such variants is difficult. However, establish-
ing a clear classification will have important implications, since it will provide the 




who can be dismissed from frequent cardiological follow-up. In addition, identify-
ing a pathogenic mutation may help to correctly classify the clinical phenotype in 
equivocal cases, which are not unusual in ARVD/C. To facilitate the interpretation 
of variants, we have built a freely accessible online database, the ARVD/C Genetic 
Variants Database (www.arvcdatabase.info), containing all published variants in 
genes known to cause ARVD/C, as well as unpublished variants identified in our 
institute or in participating centres. Our publicly accessible database will greatly aid 
in verifying whether a certain mutation has been detected and/or published before 
and how it has been classified by others. It also provides the opportunity of online 
data submission to improve the quality and quantity of the data entered.
dATABAse sTruCTure
We searched the literature in Entrez PubMed (www.ncbi.nlm.nih.gov/sites/entrez) 
using ARVD/C and its underlying genes (DSC2, DSG2, DSP, JUP, PKP2, TGFB3, 
TMEM43, TP63) as search terms. For a complete list of search terms used, see 
the website (www.arvcdatabase.info/general/searchterms.aspx). We only selected 
articles published in English and searched the listed references for additional rel-
evant papers. In addition, we searched the abstracts from the scientific sessions 
of the American Heart Association and the congresses of the European Society of 
Cardiology since 2005. If the same results were published in both an abstract and 
an article, we have only referred to the article in our database. From the selected 
papers and abstracts we gathered mutation details, information at the gene level 
(the DNA change, exon and codon number) and at the protein level (the amino 
acid change, domain (if available), the type of mutation (deletion and/or insertion 
(frame shift), intronic, missense, nonsense, splice site, synonymous, untranslated 
region) and reported classification (pathogenic, unknown/unclassified variant or no 
known pathogenicity) of each mutation), as provided by the authors. All entries are 
linked to a details page, where additional clinical and functional data (if available) 
can be found, such as whether patients fulfil the task force criteria for the diagnosis 
of ARVD/C, if compound genotypes are present, as well as the frequency of identi-
fied variants in control chromosomes. All patient data have been extracted from 
published articles or articles submitted by our own group. Mutation names used are 
according to the nomenclature proposed by the Human Genome Variation Society 
(www.hgvs.org/mutnomen).32 Mutations are numbered according to the reference 
sequences (+1 = A of ATG) as listed in GenBank (www.ncbi.nlm.nih.gov/GenBank): 
NM_024422 for DSC2, NM_001943 for DSG2, NM_004415 for DSP, NM_021991 for 
JUP, NM_004572 for PKP2, NM_003239 for TGFB3, NM_024334 for TMEM43, and 
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NM_003722 for TP63. To add known polymorphisms to the database we searched 
dbSNP (www.ncbi.nlm.nih.gov/SNP) to identify SNPs in the desmosomal genes 
and TGFB3, TMEM43 and TP63. We selected all SNPs in coding regions and those 
in non-coding regions lying within 100 bases from the exon-intron boundaries of 
coding regions.
The classification of variants in our database is documented from the information 
published and the responsibility therefore remains with the respective authors, not 
with the curators. We have also provided the results of in silico prediction methods 
for the pathogenicity of all published missense variants, i.e. the Grantham score,33 
PolyPhen,34 and SIFT.35
The data thus collected were stored first in individual fields in an offline Microsoft 
Excel (Microsoft, Redmond, WA) worksheet. Porting to an online environment and 
interface programming have been described earlier.36 A duplicate of our database is 
converted into the Leiden Open Variation Database (LOVD) format (www.lovd.nl/
arvc), a gene-centred database platform which focuses on the collection and display 
of DNA sequence variations.37
dATABAse feATures
On May 8th 2009, the database contained 481 variants from 8 different genes (41 
for DSC2, 76 for DSG2, 131 for DSP, 26 for JUP, 124 for PKP2, 23 for TGFB3, 28 
for TMEM43 and 32 for TP63). The different reported classifications per type of 
mutation are listed in Table 1.
The database can be consulted at www.arvcdatabase.info through a user-friendly 
interface. The search result can be selected per gene, reported classification, muta-
tion type and number per page. The results are automatically sorted by gene, but 
custom sorting is available. The number of clinical reports describing a specific 
variant is displayed for each variant. If a variant is only documented in dbSNP, 
the number of clinical reports is given as ‘0’. Currently, 57 articles and abstracts 
are cited, containing 289 reports of and identifying 191 different variants. All cited 
references are listed with a link to the variant(s) described, as well as a link to the 
corresponding PubMed entry. Another 107 unpublished variants are added to our 
database. Clicking the ‘Show Details’ link results in the display of a details page, as 
shown in Figure 2.
The database will be updated with data from new articles from Entrez PudMed 
search results using the search terms as listed on the website, which are automati-
cally updated and emailed to the curators. Updates to the database will be reported 




exemplified by the recent discussion on the pathogenicity of the p.Glu713Lys muta-
tion in DSG2, published online in Nat Clin Pract Cardiovasc Med (see also below in 
the discussion section).7,38 The curators can add new data to the database through 
different editing tools, while external users can use an online submission form to 
Table 1 Number of different types of variants per reported classificationa
reported Classification
Variant Pathogenic unclassified Variant no known pathogenicity Total
insertion/deletion 44 1 5 50
intronic - 1 134 135
Missense 52 44 60 156
nonsense 27 - - 27
splice site 19 - - 19
synonymous  -b 24 50 74
untranslated region 2 3 15 20
Total 144 73 264 481
a   All variants in the 8 genes (DSC2, DSG2, DSP, JUP, PKP2, TGFB3, TMEM43, TP63) entered in the 
database on May 8th  2009 are listed in the table.
b   The PKP2 mutation p.Gly828Gly, which appears to be a synonymous variant, is in fact a cryptic splice 
mutation.63 It is therefore classified as a pathogenic splice site mutation.
figure 2 The ‘details’ page for the PKP2 variant p.Ser140Phe. In addition to the search result list, the 
articles reporting this variant, with a link to their corresponding PubMed entry, information about the 
frequency of the mutation in healthy controls, whether reported patient(s) fulfil task force criteria (notably, 
LDAC = left-dominant arrhythmogenic cardiomyopathy), the number of affected relatives, and additional 
information (notes) are listed. Colour figure can be viewed in the online version.
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report findings. Submissions will be checked by the curators and completed if nec-
essary. Although most entered data originates from peer-reviewed papers or dbSNP, 
unpublished data will be added to the database. These unpublished entries are vari-
ants identified in the curators’ department and/or other participating centres, and 
are clearly labelled as such. Adding these unpublished variants to the database will 
provide users with the opportunity to check if a variant has been found in another 
laboratory. Contributors of unpublished data can be contacted via the curators of 
the database.
disCussion
We have constructed a publicly accessible database containing genotype and phe-
notype data on variants found in genes known to cause ARVD/C. For clinicians the 
database can be used to assist the counselling of families with a detected variant, 
since it provides information on whether a certain variant has been classified as 
potentially pathogenic. In addition, we have provided in silico prediction methods 
to help in judging reported missense mutations, although these methods can yield 
contradictory results and are therefore not very reliable if there is no other evidence.39 
In the absence of other arguments or functional analyses, these programs should 
not be used to decide whether a sequence variation found in a patient underlies 
the respective disease, since the consequences of an erroneous prediction may be 
disastrous from the perspective of genetic counselling.40
In principle, our database provides the reported classification of a mutation as 
indicated in the original article, however, the classification may change over time, as 
the result of information from new studies and reports. For example, recently two 
responses to a review article questioned the pathogenicity of a total of four mis-
sense mutations identified in DSG2.7,38,41-43 Following these publications we changed 
the reported classification of the p.Val158Gly, p.Glu713Lys and p.Val920Gly vari-
ants from ‘pathogenic’ to ‘no known pathogenicity’ and of the p.Val56Met variant 
from ‘pathogenic’ to ‘unknown/unclassified variant’. These changes are traceable 
in the details page, including the new references. The reverse action is exempli-
fied by the case described below. Bauce et al. reported a pathogenic mutation in 
DSP, p.Arg1775Ile, in a 37-year old woman diagnosed with ARVD/C based upon 
ECG alterations, a syncopal episode five years later with loss of consciousness (on 
sotalol therapy), and a recording of sustained ventricular tachycardia. The mutation 
was detected in three asymptomatic family members but not found in 200 control 




without population frequencies or validation data. Following the authors, our data-
base reports this mutation as ‘pathogenic’. 
The fact that ARVD/C is considered a desmosome cardiomyopathy is clearly 
reflected by the large number of desmosome gene variants in the database (397/480; 
83%).20 Moreover, from a total of 143 putative pathogenic mutations, 70 (49%) are 
reported in PKP2. These current figures are biased by the fact that, after the identi-
fication of many mutations in PKP2, we and others focussed the hunt for causative 
mutations in ARVD/C patients on desmosome or desmosome-related genes in 
particular. These figures might well need to be adjusted when novel ARVD/C-related 
but non-desmosomal genes, for example those in known ARVD/C loci, are identified 
and screened for mutations. An overview of all desmosomal gene variants and their 
distribution among the different genes is shown in Figure 3. 
Syndromal ARVD/C, caused by mutations in the desmosomal genes DSP and 
JUP, have been described as Carvajal and Naxos syndromes, respectively;44-48 both 
are considered to be inherited in an autosomal recessive fashion.49 Mutations in 
TP63 are associated with several syndromes, with ectodermal dysplasia, orofacial 
clefting and limb malformations as the key characteristics.50 However, putative 
figure 3 Distribution of desmosome variants in ARVD/C patients, sorted by reported classification.
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syndromal ARVD/C caused by a mutation in TP63 has been described once.23 In 
our database we have included only those mutations causing syndromal forms 
that include ARVD/C or dilated cardiomyopathy and those causing non-syndromal 
ARVD/C. 
Following an initial report of 24 cases of right ventricular dysplasia,1 arrhythmo-
genic cardiomyopathy was originally considered a disorder of the right ventricle. 
Post-mortem studies have shown biventricular involvement51 and currently left 
ventricular involvement is increasingly being recognised, including forms with 
predominant left ventricular involvement. This is also referred to as left dominant 
arrhythmogenic cardiomyopathy and is often due to mutations in DSP.10,52-54 These 
mutations have also been incorporated into our database.
The co-occurrence of more than one mutation in desmosomal genes has been 
recognised, with different mutations being present in the same gene (compound 
heterozygosity) as well as in different genes (digenic inheritance).13,17,18,41,55-58 These 
compound genotypes have been documented in the database on the “details page” 
of the relevant mutations.
In a large cohort from Newfoundland, Canada, a missense mutation in TMEM43 
was recently identified.22 The form of ARVD/C in this cohort is characterised by 
complete penetrance of the disease, in men at the age of 63 and in women at the 
age of 76 years. Left ventricular enlargement was often a presenting feature. The 
authors hypothesised that dysregulation of the expression of the TMEM43 gene, 
which contains a response element for PPARγ (an adipogenic transcription factor), 
may explain the fibrofatty replacement of myocardium in the ARVD/C patients in 
this cohort. So far, no other pathogenic mutations in TMEM43 have been reported.
We decided not to include the RYR2 mutations in our database because of the 
debatable and specific clinical entity, including catecholaminergic polymorphic 
ventricular tachycardia (CPVT). A database containing mutations in CPVT and other 
inherited arrhythmias can be consulted at www.fsm.it/cardmoc. 
Although over 100 pathogenic desmosomal mutations have been reported in 
ARVD/C, studies concerning the functional and structural consequences of specific 
mutations are rare. Kaplan et al. published two studies on syndromal ARVD/C 
caused by homozygous deletions in DSP and JUP, respectively.59,60 More recently, 
two studies on functional and structural effects of three frameshift, two missense 
and one nonsense PKP2 mutation were published.61,62 Functional analyses are par-
ticularly valuable when the pathogenicity of missense mutations is considered, since 
these mutations, most likely, do not result in haploinsufficiency due to nonsense-
mediated mRNA decay and/or the production of a truncated protein. When more 
functional data becomes available, we will include this in our database, providing 




Establishing the pathogenicity of a mutation is very important for the diagnosis of 
ARVD/C especially, since variable expression and non-penetrance are both hallmarks 
of the disease. The detection of a pathogenic mutation in a proband diagnosed with 
ARVD/C has important implications for the family members. Cascade screening will 
result in the identification of mutation carriers, enabling timely diagnosis and facili-
tating subsequent prevention of complications and reducing morbidity and mortal-
ity. Possible interventions are lifestyle changes, such as avoiding strenuous exercise, 
drug administration, and placing of an implantable cardioverter defibrillator (ICD). 
An extra advantage is that excluding a pathogenic mutation in other family members 
will allow them to be dismissed from regular cardiological follow-up.20 
ConClusion
We have created an online database containing all the known variants published 
in genes related to ARVD/C. Although the emphasis lies on desmosomal genes, 
mutations in non-desmosomal genes have been added to our database. Research-
ers and clinicians now have the possibility to quickly verify whether their mutation 
of interest has been published or identified elsewhere but unpublished and whether 
it is considered to be pathogenic. We would therefore encourage researchers to 
add their unpublished data to our database. The classification of a mutation and 
the sharing of these data have important clinical implications for both the proband 
and family members. These data may also lead to new insights into the molecular 
mechanisms underlying ARVD/C, thereby benefiting both clinicians and research-
ers.
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Background Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) 
is an autosomal dominant inherited disease with incomplete penetrance and vari-
able expression. Causative mutations in genes encoding five desmosomal proteins 
are found in ≈50% of ARVD/C index patients. Previous genotype-phenotype relation 
studies involved mainly overt ARVD/C index patients, so follow-up data on relatives 
are scarce. 
Methods and results One hundred forty-nine ARVD/C index patients (111 male 
patients; age, 49±13 years) according to 2010 Task Force criteria and 302 relatives 
from 93 families (282 asymptomatic; 135 male patients; age, 44±13 years) were 
clinically and genetically characterised. DNA analysis comprised sequencing of 
plakophilin 2 (PKP2), desmocollin 2, desmoglein 2, desmoplakin, and plakoglobin 
and multiplex ligation-dependent probe amplification (MLPA) to identify large 
deletions in PKP2. Pathogenic mutations were found in 87 index patients (58%), 
mainly truncating PKP2 mutations, including three cases with multiple mutations. 
MLPA revealed three PKP2 exon deletions. ARVD/C was diagnosed in 31% of ini-
tially asymptomatic mutation-carrying relatives and 5% of initially asymptomatic 
relatives of index patients without mutation. Prolonged terminal activation duration 
was observed more than negative T waves in V1 to V3, especially in mutation-carrying 
relatives <20 years of age. In 45% of screened families, ≥1 affected relatives were 
identified (90% with mutations). 
Conclusions Pathogenic desmosomal gene mutations, mainly truncating PKP2 
mutations, underlie ARVD/C in the majority (58%) of Dutch index patients and 
even 90% of familial cases. Additional MLPA analysis contributed to discovering 
pathogenic mutations underlying ARVD/C. Discovering pathogenic mutations in 
index patients enables those relatives who have a 6-fold increased risk of ARVD/C 
diagnosis to be identified. Prolonged terminal activation duration seems to be a first 





Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is histo-
pathologically characterised by progressive fibrofatty replacement of myocardium, 
primarily of the right ventricle (RV).1-3 Although familial occurrence was recognised 
in the first report, only in the last decade has the genetic substrate been identified 
in genes encoding desmosomal proteins.1,4-9 Desmosomes are protein complexes in 
the intercalated disk, among others responsible for mechanical coupling of cardiac 
myocytes. Their impairment leads to both mechanical and electric uncoupling of car-
diomyocytes, followed by cell death with fibrofatty replacement.10-13 Both uncoupling 
and altered architecture result in activation delay, which is the pivotal mechanism 
for reentry and thus ventricular tachycardia (VT).14-16
ARVD/C usually shows an autosomal dominant inheritance pattern, with 
incomplete penetrance and highly variable clinical expression.1,17-20 Classically, index 
patients present between the second and fourth decades of life with VT originating 
from the RV. However, sudden death can occur as early as adolescence, whereas 
mutation carriers may also remain without any signs and symptoms into old age. It 
has been hypothesised that genetic modifiers could be responsible for this pheno-
typic variability.4,5,7,21-24
One of the primary clinical challenges in ARVD/C is timely diagnosis of the 
concealed phase, when individuals are at risk for arrhythmias despite the absence 
of symptoms. Yet, previous studies on genotype-phenotype correlations involved 
mainly overt ARVD/C index patients.17-24 Follow-up data on their relatives are scarce. 
Hence, the proportion of relatives who develop signs of ARVD/C and/or (fatal) 
arrhythmias is unknown. 
Analysing multiple genes related to ARVD/C in all index patients is essential 
for both accurate diagnosis and appropriate family counseling and screening. 
More insight into the natural variability of the disease expression and phenotypic 
consequences of genetic findings of ARVD/C is required. We therefore sequenced 
all five desmosomal genes in 149 Dutch ARVD/C index patients. The 302 family 
members were screened for the pathogenic mutations identified in their respective 
index patients. All individuals were followed up for genotype-phenotype correlations 





In total, 169 unrelated white Dutch index patients with ARVD/C diagnosed accord-
ing to the recently modified diagnostic Task Force criteria (2010 TFC) or at autopsy 
were included.25 An index patient was the first member of the family diagnosed 
with ARVD/C in whom DNA analysis was started. The diagnostic process included 
detailed clinical and family histories, a physical examination, a 12-lead ECG, exercise 
testing, chest x-ray, and 2-dimensional transthoracic echocardiography. If no VT had 
been recorded, 24- hour Holter monitoring was performed. Additional magnetic 
resonance imaging and/or left ventricular and RV cine-angiography was performed 
in 118 patients (70%), and electrophysiological studies were done in 105 patients 
(62%). See Table I in the Data Supplement for details on follow-up frequencies. 
We also included 302 relatives of 93 index patients who underwent cardiologic 
evaluation comprising at least a detailed history, physical examination, 12-lead 
ECG, and 2-dimensional echocardiography. If performed, outcomes of exercise 
tests (in 59%), 24-hour Holter monitoring (in 66%), signal-averaged ECG (in 25%), 
and electrophysiological studies (12%), as well as additional imaging by magnetic 
resonance imaging and/or RV cine angiography (42%), were included. 
All 169 families received genetic counseling and consented to both clinical 
evaluation according to 2010 TFC and genetic screening of ARVD/C-related genes.25 
Quantitative analyses were performed at the seven participating centers. Scoring 
was performed in the core laboratory in Utrecht, the Netherlands, and patients were 
included only if there were no signs of any other cardiac disease. 
diagnostic criteria 
Routine 12-lead ECGs were done with a paper speed of 25 mm/s and low-pass filter 
at 100 Hz. Depolarisation and repolarisation abnormalities were analysed only while 
patients were off drugs. Epsilon wave was defined as a distinct deflection after the 
QRS complex had first returned to the isoelectric line.26 Terminal activation duration 
(TAD) was determined as the longest value in V1 to V3, from the nadir of the S 
wave to the end of all depolarisation deflections, and considered prolonged when 
≥55 milliseconds.27 Recordings of VT episodes, both spontaneous and induced 
by programmed electric stimulation during electrophysiological studies, were col-
lected. Ventricular tachycardia morphologies were determined only if 12-lead ECGs 
were available. Tissue characterisations from biopsies were not taken into account, 





Genomic DNA was extracted from whole blood or paraffinembedded tissues as 
described previously.23 Sufficient DNA was available in 149 patients (88%) for direct 
sequencing of PKP2, DSG2, DSC2, DSP, and JUP. In addition, multiplex ligation-
dependent probe amplification analysis (MLPA) was performed to identify large 
deletions in PKP2 (SALSA MLPA kit P168 ARVC-PKP2, MRC Holland, Amsterdam, 
the Netherlands). Primer sequences and polymerase chain reaction conditions are 
available on request. 
Nonsense, frameshift, and splice-site mutations affecting positions -2, -1, +1, 
and +2, as well as PKP2 exon deletions, were all labeled truncating and considered 
to be proven pathogenic unless identified as polymorphisms. To assess the possible 
pathogenic nature of missense mutations, we used the in silico predictive programs 
Sorting Intolerant From Tolerant (SIFT) and Polymorphism Phenotyping (PolyPhen), 
which use the following criteria: difference in physicochemical properties of amino 
acids in respective substitutions, evolutionary conservation of amino acids across 
several species, presence in an evolutionary conserved region, and localisation in 
a predicted or proven functionally important domain.28,29 Missense mutations were 
considered to be most likely pathogenic when both programs predicted the genetic 
variants to affect protein function by a tolerance index score of ≤0.05 (SIFT) and the 
classification “probably damaging” (PolyPhen).28,29 Variants suspected of pathoge-
nicity also had to be absent in 200 ethnically matched (ie, white Dutch) control sub-
jects after direct sequencing. When available, data on segregation were taken into 
account. Family members were screened only for the pathogenic mutation found 
in their respective index patient. For genotype-phenotype analyses, proven patho-
genic and most likely pathogenic variants were together labeled pathogenic, and 
comparisons of truncating and missense mutations were made. All variants present 
in the general population with a frequency of >1% were considered to be sequence 
polymorphisms. Sequence variants that did not fulfill our criteria for pathogenicity 
and were not polymorphisms were labeled unclassified variants (UVs). 
In this article, “patients with mutations” and “mutation carriers” refer to patients 
carrying pathogenic mutations as identified in this study. 
statistical analysis 
Continuous variables were compared by use of the Student t test. Categorical vari-
ables were analysed by use of contingency tables and the Pearson χ2 method. If 
the expected value was <5, the Fisher exact test was used instead. To compensate 
for possible correlation of characteristics of relatives within families, mixed models 
with hierarchical structure of members within families were applied. When it was 
impossible to fit the data in these models owing to lack of variation within families, 
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Pearson χ2 tests were applied instead on a family level (ie, on the presence/absence 
of characteristics within separate families). Descriptive statistics are reported as 
mean±SD and estimates as estimated value±SE. Values of P<0.05 were considered 




Initially, 169 ARVD/C patients fulfilled the 2010 TFC. Twenty patients were excluded 
because of incomplete DNA analyses. PKP2, DSG2, DSC2, DSP, and JUP were all 
screened in the remaining 149 patients (111 male patients; mean age at inclusion, 
49±13 years). First presentation was at a median age of 37 years (range, 12 to 77 
years), mostly with monomorphic VT (n=122, 82%). These VTs were sustained in 
119 cases, and all but two had left bundle-branch block morphology (see Table 1). 
Presenting first symptoms were similar between men and women. Cardioverter-
defibrillators were implanted in 95 patients (64%): in 57 directly after diagnosis and 
in 38 after 4±7 years of follow-up. During follow-up, four patients died of ventricular 
fibrillation (three without implantable cardioverterdefibrillators, one with electrical 
storm) and two died of progressive heart failure. Three patients were indicated for 
heart transplantation; one received a transplantation. 
dnA analyses 
All pathogenic mutations are summarised in Table 2, and UVs are summarised in 
Table II in the Data Supplement. In total, 87 index patients (58%) carried at least 
1 mutation (89 in total: 70 truncating [68 PKP2] and 19 missense [12 PKP2] muta-
tions). Single mutations were identified in 84 index patients (56%): 76 in PKP2 (64 
truncating), five in DSG2, two in DSC2, and one in DSP. In addition, three patients 
(2%) carried multiple mutations. Two had a truncating PKP2 mutation and a DSC2 or 
DSP missense mutation, and one carried a homozygous DSC2 mutation (see Table 
III in the Data Supplement for details, including phenotypic characteristics). We 
identified 51 UVs in 49 patients (35 different ones; Table II in the Data Supplement). 
In 28 patients, the UV was carried in addition to a pathogenic mutation, and two 
patients carried two UVs. Table IV in the Data Supplement shows the combinations 
of pathogenic mutations and UVs per patient. Of the 35 UVs, 28 were missense vari-
ants, six were silent variants, and one was a frameshift variant. The DSC2 frameshift 




of the gene and was found in eight patients and in 3 of 200 controls (P=0.06).24 
The DSG2 variant p.Val158Gly was predicted to be pathogenic by both SIFT and 
PolyPhen. However, we found this variant in 2 of 149 patients and 3 of 300 controls 
Table 1 Clinical characteristics of arrhythmogenic right ventricular dysplasia/ cardiomyopathy index 







n % n % n % P
Male 110 75 62 71 48 80 0.284
Age at onset, mean±sd, y 37±14 35±13 40±14 0.042
follow-up, mean±sd, y 12±9 13±10 11±7 0.191
reason for first evaluation
 VT 122 82 72 83 47 78
 Aborted sudden death 12 8 8 9 4 7
 Prolonged syncope 2 1 1 1 1 2
 sudden death of a relative 2 1 0 0 2 3
 frequent PVCs 5 3 5 6 3 5
 other 4 3 1 1 3 5
TfC
epsilon wave† 22 18 14 18 8 17 0.153
late potentials‡ 44 54 22 50 22 59 0.395
Prolonged TAd† 78 62 44 56 34 72 0.734
negative T waves
 V1–V3† 98 78 69 88 29 62 0.001
 V1–V2† 8 6 5 6 3 6 1.000
 V4–V6† 6 5 2 3 3 6 0.524
Ventricular fibrillation 12 8 8 9 4 7 0.281
VT with lBBB morphology 129 88 77 89 52 87 0.945
 with superior axis 67 46 39 45 28 47 0.943
>500 PVCs/24h 33 22 20 23 13 22 0.969
structural abnormalities
 major 86 59 55 63 31 52 0.198
 minor 25 17 15 17 10 17 0.963
VT indicates ventricular tachycardia; PVC, premature ventricular complex; TFC, Task Force criteria; TAD, 
terminal activation duration; and LBBB, left bundle-branch block. P values are the difference between 
mutation carriers and noncarriers.
*  Two patients were diagnosed after autopsy; therefore, no clinical data were available. 
†  ECGs done while the patients were off drugs were available for 125 index patients: 78 with and 47 
without mutation. 
‡  Late potentials were measured in 81 patients: 69 by signal-averaged ECG and 12 by mapping during 
electrophysiological studies.
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Table 2 Patogenic mutations






no. of family 
members 
synmptomatic, 
Yes       no
Proven pathogenic
PKP2 Deletion exon 1-4 Deletion 1 1 7
Deletion exon 1-14 Deletion 1 4
Deletion exon 8 Deletion 1
c.148_151delACAG p.Thr50SerfsX61 Frameshift 2 3
c.235C>T p.Arg79X Nonsense 9 3 15
c.258T>G p.Tyr86X Nonsense 1
c.397C>T p.Gln133X Nonsense 9 3 16
c.917_918delCC p.Pro318GlnfsX29 Frameshift 3 1 1
c.1211_1212insT p.Val406SerfsX Frameshift 11 6 15
c.1369_1372delCAAA p.Gln457X Nonsense 2 4
c.1848C>A p.Tyr616X Nonsense 4 6
c.2028G>A p.Trp676X Nonsense 1 1
c.2034G>A p.Trp678X Nonsense 1 2
c.2146-1G>C Splice site 7 2
c.2386T>C p.Cys796Arg Missense ++ (3.410) 0.03 11 1 17
c.2421C>A p.Tyr807X Nonsense 1
c.2489+1G>A Splice site 6 1 7
c.2489+4A>C Splice site 4 9
c.2509delA p.Ser837ValfsX94 Frameshift 1
c.2544G>A p.Trp848X Nonsense 1 1
DSC2 c.943-1G>A Splice site 1 1
DSG2 c.378+2T>G Splice site 1
DSP c.3337C>T p.Arg1113X Nonsense 1 1
Most likely pathogenic
PKP2 c.2062T>C p.Ser688Pro Missense + 0.04 1 1
DSC2 c.608G>A p.Arg203His Missense ++ (2.295) 0.00‡ 1 2
c.942+3A>G§ Splice site 1
c.2587G>A p.Gly863Arg Missense ++ (2.492) 0.00‡ 1
DSG2 c.137G>A p.Arg46Gln Missense ++ (2.013) 0.00‡ 2 4
c.614C>T p.Pro205Leu Missense ++ (3.054) 0.00‡ 1
c.874C>T p.Arg292Cys Missense ++ (2.759) 0.00‡ 1 2
DSP c.1982A>T p.Asn661Iie Missense ++ (2.073) 0.01‡ 1
* Polymorphism Phenotyping (PolyPhen) prediction: ++, probably damaging; +, possibly damaging; -, 
benign. PSIC indicates Position-Specific Independent Counts. † Sorting Intolerant From Tolerant (SIFT) 
prediction: Amino acids with scores <0.05 are predicted to be deleterious. For previous reports on 
pathogenicity, see van der Zwaag et al.31 ‡ This substitution may have been predicted to affect function 
just because the sequences used were not diverse enough. There is low confidence in this prediction. § 
The four splice-prediction programs used (SpliceSiteFinder, MaxEntScan, NNSPLICE, and GeneSplicer) 




(P=0.67), and it has frequently been reported in other control populations.22,23,30,31 
Therefore, we classified it as an UV. 
Genotype-phenotype correlation
First, we compared the clinical characteristics of index patients with and without 
mutations independently of the number of variants (Table 1). Both groups showed 
a male predominance (71% and 80%), and age at the time of inclusion was similar 
(51±13 and 49±13 years). 
Ventricular tachycardia and/or ventricular fibrillation was recorded in 134 of 149 
index patients, showing similar frequencies among those with and without muta-
tions. However, first arrhythmic events were documented at a significantly younger 
age in mutation carriers compared with noncarriers (median age, 35 versus 42 
years; P=0.042; Figure 1). The three patients carrying two mutations had their first 
VT at 14, 17, and 20 years of age. A comparison of criteria in mutation carriers and 
noncarriers demonstrated no significant differences except that negative T waves 



























figure 1 Ventricular tachycardia/ventricular fibrillation (VT/VF)–free survival of arrhythmogenic right 
ventricular dysplasia/ cardiomyopathy (ARVD/C) index patients with vs without mutations. Patients with 
a mutation experience their first arrhythmic event at a significantly younger age than those without a 
mutation. This age is even lower if a patient carries two mutations (see text).
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None of the criteria could be explained by the type of mutation (truncating versus 
missense) except for prolonged TAD, which was observed more often in patients 
with missense mutations (13 of 15 versus 31 of 63). 
Patients carrying a single UV did not differ from patients without mutations on 
any criterion or on age of first event. However, fewer patients with a single UV had 
negative T waves in V1 to V3 than patients with one mutation (P=0.043), but they 
were similar in every other respect. Likewise, patients carrying a UV together with a 
mutation did not differ from either patients with a single mutation or those with two 
mutations (see Table V in the Data Supplement for more details). 
family history of sudden cardiac death 
Twenty-five index patients reported 30 relatives with sudden cardiac death (SCD). In 
18 families of index patients with mutations, SCD had occurred in 19 relatives (16 
male subjects). Autopsy was performed in six cases and revealed ARVD/C in all of 
them. In seven families of index patients without mutations, SCD had occurred in 
11 relatives (eight male relatives). No autopsies had been performed. Mean ages at 
SCD were similar in families with and without mutations (28 years [range, 15 to 49 
years] versus 32 years [range, 21 to 43 years]; P=0.108). However, all seven relatives 
with SCD at <20 years of age (23%) belonged to families with PKP2 mutations (six 
truncating; Table 3). 
family members 
Both genotypic and phenotypic data were available for analysis of 302 members 
from 93 different families (58 with and 35 without mutations). 
relatives symptomatic at first presentation
Twenty relatives from 18 families presented with cardiac symptoms before family 
screening was performed (13 men; mean age, 42 years [range, 20 to 71 years]). 
In 10 relatives, monomorphic left bundle-branch block VT was the first symptom. 
In addition, four family members had ventricular fibrillation (one was successfully 
resuscitated), three had prolonged syncope, two had palpitations and one had atrial 
fibrillation. Eighteen relatives fulfilled the 2010 TFC, and 18 carried pathogenic 




Table 3 Relatives <20 years of age with sudden death or arrhythmogenic right ventricular dysplasia/
cardiomyopathy signs
Age, y sex
PKP2 mutation in 
family PKP2 mutation Autopsy TfC identified
Sudden cardiac death
15 Male c.235C>T No
16 Male c.2489+1G>A‡ No
16 Male c.2489+1G>A‡ No
17 Male c.2386T>C Yes (ARVD/C)
17 Male c.397C>T No
17 Male c.1211-1212insT Yes (ARVD/C)
18 Female c.2421C>A Yes (ARVD/C)
Family screening*
14 Male Deletion exons 1-4 Prolonged TAD
17 Male c.1211-1212insT Prolonged TAD; >500 PVCs/24h
18 Male c.2489+4A>C Prolonged TAD
18 Male c.2386T>C Prolonged TAD
19 Female c.148_151delACAG Prolonged TAD
15 Male c.1369_1372delCAAA Negative T waves in V1-V2
19 Female c.2386T>C Negative T waves in V1-V2
TFC indicates Task Force criteria; ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; 
TAD, terminal activation duration; and PVC, premature ventricular complex. *Age after follow-up. ‡From 
the same family. Mutations were found in none of the other genes. All mutations were truncating, except 
missense c.2386T>C.






















No ARVD/C signs 
67 (31) 
Mutation – 
Index with mutation 
67 (31) 
No ARVD/C signs 
96 (32) 
Mutation – 
Index no mutation 
9 (5) 




No ARVD/C signs 
figure 2 Schematic representation of relatives demonstrating the distribution of arrhythmogenic right 
ventricular dysplasia/cardiomyopathy (ARVD/C) signs and symptoms as well as mutations. Numbers in 
parentheses indicate the number of different families. In total, a diagnosis of ARVD/C was made in 60 
family members from 42 different families.
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family screening of asymptomatic relatives 
The remaining 282 asymptomatic relatives (123 male subjects, 44%) were evaluated 
in the course of family screening. Mean age at first clinical examination was 39±18 
years, and follow-up 4±4 years, which was similar for male and female subjects. In 
119 members (42%) from 56 families, pathogenic mutations were identified: in 111 
PKP2 (93%; 78% truncating), five DSG2, and three DSC2 (Table 2 and Figure 2).
 Table 4 shows the results of family screening in the 282 initially asymptomatic 
family members. Most criteria were perceived either exclusively or considerably 
more often in mutation carriers. Because of the low presence of characteristics 
and low variation in families, mixed models could not be applied to these data. To 
Table 4 Clinical characteristics of asymptomatic arrhythmogenic right ventricular dysplasia/












n % n % n % n % P*
Male 123 44 45 38 32 48 47 49 0.096
Age at first evaluation, 
mean±sd, y 39±18 39±18 40±18 38±17 0.419
follow-up, mean±sd, y 4±4 4±3 4±3 3±3 0.131
ArVd/C diagnosis 42 (27) 15 37 (23) 31 0 0 5 (4) 5 0.004
epsilon wave 4 (4) 1 4 (4) 3 0 0 0 0 0.292
late potentials† 8 (8) 10 6 (6) 21 0 0 2 (2) 2 0.047
Prolonged TAd 34 (26) 12 26 (21) 22 0 0 8 (5) 8 0.030
negative T waves
 V1–V3 20 (18) 7 19 (17) 16 0 0 1 1 0.002
 V1–V2 7 (6) 2 6 (5) 5 0 0 1 1 0.410
 V4–V6 3 (2) 1 0 0 0 0 3 (2) 3 0.130
VT with lBBB morphology
 with superior axis 2 (2) 1 2 (2) 2 0 0 0 0 0.532
 with inferior axis 9 (9) 3 9 (9) 8 0 0 0 0 0.023
>500 PVCs/24h 34 (19) 12 23 (14) 19 0 0 9 (5) 9 0.304
structural abnormalities
 major 12 (11) 4 10 (9) 8 0 0 2 (2) 2 0.315
 minor 10 (7) 4 10 (7) 8 0 0 0 0 0.045
ARVD/C indicates arrhythmogenic right ventricular dysplasia/cardiomyopathy; TAD, terminal activation 
duration; VT, ventricular tachycardia; LBBB, left bundle-branch block; PVC, premature ventricular complex. 
*Difference between families of relatives with mutation vs relatives of index patients without mutation. 
Numbers in parentheses indicate the numbers of different families.




recognise the possible dependence of relatives and their phenotypes among fami-
lies, statistical analyses were performed at the family level (ie, families were scored 
positive for separate criteria if present in ≥1 relative; Table 4). Strikingly, prolonged 
TAD was observed in more cases than negative T waves in V1 to V3. This difference 
varied with age (Figure 3). Relatives <20 years of age had no negative T waves in V1 
to V3, but prolonged TAD was already observed in five of seven young relatives with 
signs of ARVD/C (Table 3). 
VTs were recorded in nine initially asymptomatic relatives (3%) from eight fami-
lies. All carried PKP2 mutations (7 truncating; Table 4). Five women (mean age 51 
years [range, 34 to 70 years]) had hemodynamically well-tolerated nonsustained left 
bundle-branch block VT during their first exercise tests. The other four (one female) 
had VT after a mean follow-up of 4.0 years (2 to 8 years at a mean age of 43 years 
[range 34 to 56 years]. Two left bundlebranch block VTs were sustained with rates of 
220 and 240 bpm, and resulted in syncope.
Altogether, 57 family members (20%) from 35 families showed signs of ARVD/C 
because they fulfilled ≥1 criteria besides those concerning family history. This group 
comprised more women than men (39 versus 18; P=0.04), and their mean age 
after follow-up was 47±16 years. Forty-eight (84%) carried pathogenic mutations 
(all PKP2, 41 truncating), and the remaining nine belonged to families with no 
identified mutation. Fourteen relatives with an unremarkable first clinical evaluation 
developed signs of ARVD/C after a mean follow-up of 4.2 years (range, 1 to 10 
years). For family members up to 50 years of age, a higher age was associated with 
figure 3 Presence of prolonged terminal activation duration (TAD) and negative T waves in V1 to V3 per 
age group in relatives with mutation vs relatives from index patients without mutation. Prolonged TAD 
was already present in many young relatives, with similar frequencies among all age groups (P=0.269). 
On the contrary, negative T waves were present more frequently with increasing age, almost exclusively in 
mutation carriers. Numbers in parentheses indicate the numbers of relatives per age group.
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an increased prevalence of ARVD/C signs, in contrast to family members ≥50 years 
of age (Figure 4). 
Forty-two initially asymptomatic family members from 27 families were diag-
nosed with ARVD/C: at first evaluation in 34 patients and after a mean follow-up 
of 5.0 years (range, 2 to 10 years) in eight patients. This group had a mean age at 
diagnosis of 39±15 years and comprised 29 females (69%). 
familial risk of ArVd/C
In initially asymptomatic relatives, ARVD/C was diagnosed in 5% (5 of 96) when 
their index patient had no identified mutation and 20% (37 of 119+67) when their 
index patient had a mutation; all 37 also carried mutations (Figure 2). Thus, identify-
ing a mutation in an index patient implies a relative risk for ARVD/C diagnosis in 
their asymptomatic relatives of 3.8±1.6. This risk increases to as much as 6.0±2.4 
for mutation-carrying relatives compared with relatives of index patients without a 
mutation (37 of 119 versus 5 of 96). 
When the symptomatic and asymptomatic mutation-carrying relatives were 
combined, 54 of 137 (39%) had an ARVD/C diagnosis compared with 6 of 98 rela-
tives of index patients without mutations (6%). 
Of the 93 families in which ≥2 members, including the index patient, were exam-
ined, 42 had familial ARVD/C (45%; 38 with mutations, all PKP2, 33 truncating). 































Age in years  
mutation
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figure 4 Relatives showing any sign of arrhythmogenic right ventricular dysplasia/ cardiomyopathy, ie, 
meeting ≥1 criteria besides those concerning family history, divided into age groups. With increasing age, 
higher percentages of relatives showed signs of disease except in at the highest age. Numbers between 





Here, we report the results of follow-up of a large number of ARVD/C families, 
including comprehensive DNA analysis. In 87 of 149 ARVD/C index patients (58%), 
pathogenic mutations were identified, predominantly truncating PKP2. ARVD/C was 
diagnosed in 60 of 302 family members (18 symptomatic, 42 asymptomatic), of 
whom 54 (90%) carried pathogenic mutations (all PKP2, 47 truncating). Identifying 
a pathogenic mutation in an index patient predicts outcome in relatives. Compared 
with relatives of index patients without mutations, mutation-carrying relatives have 
a 6-fold risk of ARVD/C diagnosis, markedly enhanced risk of ventricular arrhyth-
mias in analysed relatives, and earlier onset of ARVD/C signs and symptoms (for 
concurrent numbers, see Table 4 and Figure 4). In young relatives <20 years of age, 
sudden death and signs of ARVD/C occurred exclusively in PKP2 mutation carriers. 
Prolonged TAD, a marker of activation delay, appeared to be an early ARVD/C sign. 
Pathogenicity of dnA variants 
The large majority of DNA variations were truncating PKP2 mutations. Notably, in 
this first study applying MLPA on a large scale in ARVD/C patients, large PKP2 dele-
tions were identified in three cases. This mutational yield of 2%, which is comparable 
to the sequencing of DSC2 or DSG2, underscores the importance of performing this 
additional analysis. Notably, because this has not been tested, we cannot exclude 
the possibility that large deletions might be present in other desmosomal genes in 
patients that are as yet without a pathogenic mutation. 
The fact that a significant proportion of genetic variants remains unclassified 
represents a gap in risk assessment for index patients, and UVs are noninformative 
for family screening. However, establishing pathogenic effects of missense variants 
is difficult and requires well-validated functional assays, which are not widely avail-
able and are highly complex to perform. Linkage and segregational studies can be 
helpful to establish pathogenicity. Yet, low frequency of variants, small family size, 
and age-dependent penetrance hamper the use of these methods. 
Previous studies on mutations in DSC2, DSG2, and DSP used different criteria 
to define the pathogenicity of DNA variants. The largest studies used criteria of 
absence in control subjects and/or occurrence in a functionally important domain, 
alteration of conserved amino acids, or cosegregation with disease in a family.21,22,30 
Thus, in contrast to our study, none of these studies used all the possible predictive 
strategies together. Consequently, the variants p.Thr335Ala and p.Val392Ile in DSG2 
and p.Gln90Arg in DSP were previously classified as pathogenic, but with our defini-
tion, they were classified as UVs.21,22
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index patients 
In this study of white Dutch patients, PKP2 was by far the most important contributor 
to mutation yield (found in 52% of patients, 90% of pathogenic mutations). Previous 
studies reported PKP2 mutations in 19% to 45% of ARVD/C patients and mutations 
in other desmosomal genes in 1% to 12%.21,22,31,32 These differences can be due to 
various causes, such as the presence of founder mutations, use of different defini-
tions for pathogenicity, regional differences in other genetic and nongenetic causes, 
and strictness in applying the TFC.6,19 New genetic techniques, such as high-density 
genotyping array with haplotype sharing or exome sequencing, might elucidate new 
genes involved in ARVD/C.33 This will improve the distinction between familial and 
sporadic ARVD/C cases and ameliorate risk stratification for relatives. 
Our study suggests that UVs as defined here do not result in a more severe 
phenotype or earlier onset of ARVD/C. However, most UVs were found only in single 
patients; therefore, comparisons on the level of individual variants were not pos-
sible. Because the pathogenic influence of UVs is unknown, relatives were not tested 
for these variants. Consequently, it cannot be ruled out that, within families, carrying 
a specific UV is a risk factor for disease development. 
Index patients were included only if they fulfilled the 2010 TFC. Consequently, 
this obviously affected population cannot be regarded as representative of the vari-
able disease expression. Therefore, analysis of asymptomatic family members was 
crucial. 
family members 
The large majority (84%) of initially asymptomatic family members showing signs of 
ARVD/C carried desmosomal gene mutations (90% truncating, all PKP2). Overall, 
we found no differences between carriers of truncating and missense mutations. In 
four families with ≥2 members diagnosed with ARVD/C and in whom no mutations 
were identified, a genetic cause is highly suspected. 
Negative T waves in V1 to V3 have always been considered the most sensitive 
ECG abnormality in ARVD/C.17-20 However, in family members, we observed the new 
criterion of prolonged TAD more often and at younger age (Figure 3). In four of 
seven family members <20 years of age with signs of ARVD/C, prolonged TAD was 
the only clinical abnormality observed. Longer periods of follow-up are needed to 
demonstrate the disease progression after prolonged TAD is found and whether it is 
a good predictive marker of arrhythmias and SCD. 
disease penetrance 
Because ARVD/C is a progressive disease with age-related penetrance, it seems 




was lower in those ≥50 years of age than in their younger counterparts. Because 
individuals ≥50 years of age are also at higher risk of coronary artery disease, those 
already seeing a cardiologist may not have been referred for family screening. 
Cohorts of ARVD/C index patients universally demonstrate a male predomi-
nance.18-21 Interestingly, among the asymptomatic family members in this study, 
women were affected more often than men. Apparently, men with ARVD/C experi-
ence arrhythmias and die suddenly at a younger age and thus are more likely to 
be the index patient. The underlying mechanism is not yet known, but strenuous 
exercise by men and the prevention of programmed cell death in cardiac myocytes 
in women due to estradiol are believed to play a role.34 
At first examination, 43 of 282 asymptomatic family members (15%) already 
showed any sign of disease, including nonsustained VT in five patients and >500 
premature ventricular complexes in 24 hours in 30 patients. Because relatives with 
these arrhythmias were asymptomatic, the age of onset is unknown. Besides, only 
four relatives (all mutation carriers) went on to develop VT during follow-up. There-
fore, it was not possible to calculate the annual risk of arrhythmias or to identify 
predictive risk factors other than carrying a pathogenic mutation. Longer periods of 
follow-up of large series of relatives who initially have no signs of disease are needed 
to provide this insight. Large multicenter studies are required to achieve this. 
Contrary to our study, all previous genotype-phenotype analyses in ARVD/C fami-
lies separately addressed mutations in different desmosomal genes and involved 
only a few families. We found that 66 of 137 mutation-carrying family members 
(48%) showed some sign of ARVD/C, with ARVD/C diagnosis made according to 
2010 TFC in 39%. No direct comparison with other studies can be made, because 
different sets of diagnostic criteria were used. However, similar numbers of affected 
relatives with PKP2 mutations were reported by Dalal et al.35 and Syrris et al.20 (49% 
and 47%, respectively). Other family studies have also reported high percentages 
of relatives diagnosed with ARVD/C: 58% in DSG2, 75% in DSC2, and 54% in DSP 
mutation carriers. However, these studies comprised only 8, 2, and 4 families, 
respectively.8,30,36
study limitations 
Sequence alterations were divided into pathogenic or UVs according to arbitrarily 
defined criteria. However, in the absence of any data on pathogenicity, conclusions 
regarding the utility of genetic testing are speculative. 
All index patients were offered family screening, regardless of their mutational 
status. However, relatives of 93 of 149 fully genotyped index patients (62%) under-
went both clinical and genetic screening. Although there is no such indication, this 
might potentially create a bias in the population of relatives studied. Not all relatives 
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underwent all the diagnostic tests, as indicated in the Methods section. All family 
members included in this study underwent at least 2-dimensional echocardiography 
to screen for RV structural abnormalities. Additional magnetic resonance imaging 
wasperformed in only a minority of cases, so minor abnormalities might have been 
missed. Late potentials were measured in 25% of relatives, but activation delay was 
measured by means of prolonged TAD in all relatives. 
Thirty-six relatives of mutation-carrying index patients were not clinically evalu-
ated because they appeared to be noncarriers; thus, they could not be included in 
this study. Consequently, of families with pathogenic mutations, more relatives with 
mutations were included than without mutations (119 versus 67). 
ConClusions 
In this large follow-up study in Dutch ARVD/C families, pathogenic desmosomal 
gene mutations were found in the majority of ARVD/C index patients (58%); these 
were mainly truncating PKP2 mutations, with multiple mutations in 2% of cases. 
Performing MLPA also is important, because its mutational yield is comparable 
to the sequencing of DSG2 or DSC2. Mutation carriers presented at a younger age 
than noncarriers; this age was even lower when multiple mutations were identified. 
In total, 20% of initially asymptomatic relatives who underwent family screening 
showed some sign of ARVD/C (84% mutation carriers), mainly ECG abnormalities. 
Mutation-carrying relatives had an earlier onset of signs and symptoms, a markedly 
increased risk of arrhythmias, and a 6-fold increased risk of ARVD/C diagnosis. 
Familial cases were identified in 45% of the families screened. Prolonged TAD 
seems to be an early marker of RV abnormalities, especially in mutation-carrying 
relatives <20 years of age. 
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Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) usually 
shows an autosomal dominant inheritance pattern, with incomplete penetrance and 
variable clinical expression. Classically, index patients present between the second 
and fourth decade of life with right ventricular tachycardia. However, sudden death 
can occur at adolescence, whereas mutation-carriers may remain without signs and 
symptoms up to high age. Previous genotype-phenotype studies mainly involved 
overt index patients. Data on, mainly asymptomatic, relatives were scarce. To gain 
insight in the full spectrum of the disease, 149 ARVD/C index patients and 302 of 
their relatives were genotypically and phenotypically characterised. DNA analysis 
comprised sequencing of desmosomal genes PKP2, DSC2, DSG2, DSP, and JUP 
and multiplex ligation-dependent probe amplification (MLPA) to identify large dele-
tions in PKP2.
Pathogenic mutations were identified in 87 of 149 (58%) ARVD/C index patients, 
mainly truncating PKP2 mutations with multiple mutations in 2% of cases. MLPA 
appeared important to perform additionally: its 2% mutational yield was compa-
rable to sequencing of DSG2 or DSC2. Identification of mutations in index patients 
had major consequences for the concurrent relatives. Of the 57 of 282 (20%) 
initially asymptomatic relatives that showed any sign of ARVD/C, 84% carried a 
mutation. These 48 mutation carriers not only had earlier onset of disease signs and 
symptoms than non-carriers, but also a markedly increased risk of arrhythmias and 
six-fold risk of ARVD/C diagnosis. Familial cases were identified in 45% of families 
screened. Prolonged TAD seemed an early marker of ARVD/C, as it was observed 
more often than negative T-waves in V1-V3, especially in mutation-carrying relatives 
younger than 20 years.
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Table i Follow-up frequencies of index patients and relatives
index Patients (n=147) relatives (n=302)
mean±sd median (range) mean±sd median (range)
intervals (years) between
Visits 0.5±0.3 0.3 (0.2-1.2) 1.1±0.6 1 (0.3-5.0)
Echocardiography 3.6±2.3 2.8 (1.0-9.0) 1.7±1.5 1 (1.0-12)
Exercise Tests 3.1±2.0 2.5 (0.8-9.0) 2.6±2.1 2 (1.0-10)
24h Holter 5.1±4.7 2.5 (0.8-16) 2.6±2.0 2 (1.0-10)
Table ii Unclassified variants
Gene dnA change Protein change Type
PolyPhen 
(PsiC)* sifT† index patients, n
unclassified Variants
PKP2 c.76G>A p.Asp26Asn Missense + (1.593) 0.15 2
c.174G>T p.Glu58Asp Missense - (1.248) 0.42 1
c.759C>T p.= Silent 1
c.1378G>A p.Asp460Asn Missense - (0.0) 0.45 1
DSC2 c.1807A>C p.Ile603Leu Missense - (1.157) 0.20 1
c.1914G>T p.Gln638His Missense + (1.710) 0.01‡ 1
c.2194T>G p.Leu732Val Missense - (0.197) 0.15 2
c.2393G>A p.Arg798Gln Missense - (0.716) 0.00‡ 1
c.2686_2687dupGA p.Ala897LysfsX4 Frameshift 8
DSG2 c.445G>T p.Val149Phe Missense + (1.747) 0.00‡ 1
c.473T>G p.Val158Gly Missense ++ (2.470) 0.00‡ 2
c.783T>A p.= Silent 1
c.889G>A p.Asp297Asn Missense + (1.951) 0.00‡ 1
c.1003A>G p.Thr335Ala Missense + (1.559) 0.00‡ 3
c.1072G>A p.Ala358Thr Missense + (1.760) 0.00‡ 1
c.1174G>A p.Val392Ile Missense - (0.813) 0.14 1
c.1303G>A p.Asp435Asn Missense - (1.459) 0.19 1
c.1480G>A p.Asp494Asn Missense + (1.790) 0.00‡ 1
c.2137G>A p.Glu713Lys Missense + (1.632) 0.09 1
c.2194T>G p.Phe732Val Missense - (0.217) 0.56 1
c.2623A>G p.Met875Val Missense - (0.682) 0.65 1
c.2759T>G p.Val920Gly Missense + (1.936) 0.21 1
DSP c.105G>A p.= Silent 1
c.269A>G p.Gln90Arg Missense - (1.432) 0.00‡ 1
c.1696G>A p.Ala566Thr Missense - (1.227) 0.00‡ 1
c.2346C>T p.= Silent 1
c.4372C>G p.Arg1458Gly Missense + (1.727) 0.03‡ 1




Table ii Unclassified variants (continued)
Gene dnA change Protein change Type
PolyPhen 
(PsiC)* sifT† index patients, n
c.5218G>A p.Glu1740Lys Missense - (1.267) 0.00‡ 2
c.5498A>T p.Glu1833Val Missense + (1.942) 0.00‡ 1
c.6449C>G p.Ala2150Gly Missense - (0.986) 0.08 1
JUP c.297G>A p.= Silent 1
c.1359G>T p.Glu453Asp Missense + (1.616) 0.00‡ 1
c.1563A>G p.= Silent 2
c.1942G>A p.Val648Ile Missense - (0.417) 1.00 1
* PolyPhen prediction: ++ probably damaging; + possibly damaging; - benign; PSIC indicates Position-
Specific Independent Counts. † Sorting Intolerant From Tolerant (SIFT) prediction: Amino acids with 
scores < 0.05 are predicted to be deleterious. For previous reports on pathogeneity: see reference 31; ‡ 
This substitution may have been predicted to affect function just because the sequences used were not 
diverse enough. There is low confidence in this prediction.









VT (years) ε lP TAd
negative T
waves V1-V3 lBBB VT
v PKP2  c.917-918delCC ++ + ++
DSC2  c.2587G>A
v PKP2  c.2489+4A>C 20 ++ + ++ ++ ++
DSP  c.1982A>T
v DSC2  c.608G>A* 17 ++ + ++ + ++
DSC2  c.608G>A*
ε = epsilon waves, LP= late potentials, TAD = prolonged terminal activation duration; LBBB VT: ventricular 
tachycardia with left bundle branch block morphology
+ minor criterion, ++ major criterion; * homozygous, parents were first degree cousins
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Table iV Combinations of pathogenic mutations and/or unclassified variants





1 Mutation + 1 uV
deletion exon 8 c.2686_2687dupGA






























UV= unclassified variant; In bold: (most likely) pathogenic mutations; In italics: missense and silent 
variants. 




Table V Clinical characteristics of ARVD/C index patients related to pathogenic mutations and unclassified 
variants
Mutations and unclassified variants (uVs)
0 uV 1 1+uV 2
n 40 20 55 29 3
% male 81 76 78 66 0
Age of onset (years±sd) 41±14 38±12 35±12 34±15 17±3
n (%) n (%) n (%) n (%) n (%)
epsilon wave † 7 (24) 1 (6) 10 (19) 2 (7) 2 (67)
late potentials ‡ 14 (47) 8 (67) 11 (31) 11 (52) 0
Prolonged TAd† 24 (83) 10 (56) 30 (57) 12 (52) 2 (67)
negative T waves V1-V3 
† 18 (62 11 (61) 45 (85) 21 (72) 3 (100)
negative T waves V1-V2 
† 1 (3) 2 (11) 4 (8) 1 (3) 0
negative T waves V4-V6 
† 1 (3) 2 (11) 1 (2) 1 (3) 0
lBBB VT superior axis 17 (43) 11 (55) 24 (44) 14 (48) 1 (33)
lBBB VT 34 (85) 18 (90) 48 (87) 26 (90) 3 (100)
>500 PVCs per 24h 9 (23) 4 (20) 14 (25) 5 (17) 1 (33)
structural major TfC 17 (43) 14 (70) 32 (58) 20 (69) 3 (100)
structural minor TfC 8 (20) 2 (10) 12 (22) 3 (10) 0
† ECGs while off drugs were available for 125 probands; ‡ In 81 patients late potentials were measured: 
69 by SAECG, 12 by mapping during EPS; TAD: terminal activation duration, LBBB VT: ventricular 
tachycardia with left bundle branch block morphology, PVCs: premature ventricular complexes, TFC: Task 
Force Criteria.

7 Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: 
Evidence supporting the concept of 
arrhythmogenic cardiomyopathy
Paul A. van der Zwaag
Ingrid A.W. van Rijsingen
Angeliki Asimaki
Jan D.H. Jongbloed
Dirk J. van Veldhuisen
Ans C.P. Wiesfeld
Moniek G.P.J. Cox
Laura. T. van Lochem
Rudolf A. de Boer
Robert M.W. Hofstra
Imke Christiaans
Karin Y. van Spaendonck-Zwarts







Maarten P. van den Berg
J. Peter van Tintelen 
 
 
Eur J Heart Fail. In Press.
146
ABsTrACT
Aims To investigate whether phospholamban gene (PLN) mutations underlie 
patients diagnosed with either arrhythmogenic right ventricular cardiomyopathy 
(ARVC) or idiopathic dilated cardiomyopathy (DCM). 
Methods and results We screened a cohort of 97 ARVC and 257 DCM unrelated 
index patients for PLN mutations and evaluated their clinical characteristics. PLN 
mutation R14del was identified in 12 (12%) ARVC patients and in 39 (15%) DCM 
patients. Haplotype analysis revealed a common founder, estimated to be between 
575 and 825 years old. A low voltage ECG was present in 46% of R14del carriers. 
Compared to R14del- DCM patients, R14del+ DCM patients more often demon-
strated appropriate ICD discharge (47% vs. 10%, P<0.001), cardiac transplantation 
(18% vs. 2%, P<0.001), and a family history of sudden cardiac death (SCD) <50 
years (36% vs. 16%, P=0.007). We observed a similar pattern in the ARVC patients 
although this was not statistically significant. The average age of 26 family mem-
bers who died of SCD was 37.7yr. Immunohistochemistry in available myocardial 
samples revealed absent/depressed plakoglobin levels at intercalated disks in five 
of seven (71%) R14del+ ARVC samples, but in only one of nine (11%) R14del+ DCM 
samples (P=0.03).
Conclusions The PLN R14del founder mutation is present in a substantial number 
of patients clinically diagnosed with DCM or ARVC. R14del+ patients diagnosed 
with DCM showed an arrhythmogenic phenotype and SCD at young age can be 






Idiopathic dilated cardiomyopathy (DCM) and arrhythmogenic right ventricular 
cardiomyopathy (ARVC) are clinically heterogeneous diseases of the myocardium, 
associated with mechanical and/or electrical dysfunction.1 Clinically, ARVC is char-
acterised by ventricular arrhythmias, predominantly from the right ventricle (RV) 
and sudden cardiac death, often preceding structural changes.2-5 DCM, on the other 
hand, is characterised by left ventricular (LV) contractile dysfunction and progres-
sive heart failure, with arrhythmias often being present but less prominent.6 The 
management strategies of ARVC and DCM therefore differ. For ARVC, the aim is to 
prevent sudden cardiac death and ventricular tachycardia, by using an implantable 
cardioverter defibrillator (ICD) or anti-arrhythmic pharmacological treatment.3 The 
management of DCM is mainly directed at treating heart failure symptoms and 
preventing disease progression and related complications.6,7 ICD implantation as 
primary prevention is recommended in patients in New York Heart Association 
(NYHA) functional class II or III, who are receiving optimal medical therapy and 
have an LV ejection fraction ≤30% (American College of Cardiology/American Heart 
Association; ACC/AHA) or ≤35% (European Society of Cardiology; ESC).7,8
Although considered separate entities by both the AHA and the ESC,1,9 DCM 
and ARVC have overlapping clinical features. Classic ARVC shows primarily RV 
involvement. However, histopathologic and functional LV involvement is present 
in 76%-84% of ARVC patients. Also left-dominant forms exist leading to the pos-
tulation that left-dominant arrhythmogenic cardiomyopathy is a separate entity.10,11 
Finally, at the molecular level (desmosomal proteins, gap junctions) both ventricles 
are affected in a similar way in ARVC.12 The principal discriminating feature of left-
dominant arrhythmogenic cardiomyopathy from DCM would be the predisposition 
to ventricular arrhythmias in early stages of the disease, disproportionate to the 
morphological abnormalities and impaired systolic function.5,11,13 Conversely, dete-
riorating RV function is a strong predictor of worse outcome in DCM.14
Comprehensive screening of desmosomal genes in ARVC patients has identified 
pathogenic mutations in 40-58% of clearly affected patients.15-17 Given the clinical 
overlap between ARVC and DCM, we focused on non-desmosomal genes known to 
lead to DCM with an arrhythmogenic phenotype and which could potentially explain 
genetically unsolved ARVC cases. So far, mutations in over 30 different genes have 
been reported to cause DCM,6,18 including the gene encoding phospholamban 
(PLN). PLN is a regulator of the sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) 
pump in cardiac muscle and thus important for maintaining Ca2+ homeostasis.19 In 
DCM, three different PLN mutations have been identified;20-23 the cardiac phenotype 
of PLN mutation carriers was characterised by the presence of malignant ventricular 
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arrhythmias and interstitial fibrosis. We therefore screened both DCM and ARVC 
patients for PLN mutations and compared their clinical and genetic characteristics.
MeThods
Patients
A cohort of index patients, referred to Departments of Clinical Genetics of three 
university hospitals (University Medical Center Groningen, Academic Medical 
Center Amsterdam, and University Medical Center Utrecht, the Netherlands), by 
the attending cardiologist (heart failure specialists or cardiac electrophysiologists), 
was evaluated. No index patient within the cohort had a known familial relationship 
with any other index patient in the cohort. Retrospectively, available data on medical 
history, physical examination, 12-lead ECG, echocardiography, Holter monitoring, 
exercise testing, signal-averaged ECG, nuclear scintigraphy, magnetic resonance 
imaging and/or RV-angiography studies were collected. Age of presentation was 
defined as the age when the first symptoms or signs most likely to be attributable 
to the disease occurred. For DCM, the diagnostic criteria by Mestroni et al. were 
used.24 For ARVC, recently modified task force criteria were used.25 Two patients 
who did not fulfil the modified criteria because histomorphometric analyses of 
myocardial tissue had not been performed, were nonetheless considered as having 
ARVC, since they were previously diagnosed with ARVC, based on original task force 
criteria. The study complied with the Declaration of Helsinki and was approved by 
the local institutional review committees and informed consent was obtained from 
all participants.
electrocardiograms
ECGs from index patients and their relatives were analysed and interpreted in a 
blinded fashion by two cardiologists (R.A.d.B and M.P.v.d.B.) Low voltage on the 
ECG was defined as QRS peak-to-peak amplitude in leads I, II, and III being less 
than 0.5mV.
Genetic analysis 
Genomic DNA was isolated from peripheral blood samples according to standard 
protocols. Bidirectional direct sequencing of the coding region of PLN was per-
formed in all index patients using a BigDye Terminator DNA sequencing kit (version 
2.0) on a 3730 Genetic Analyzer (Applied Biosystems, Foster City, CA, U.S.A.). To 




gene negative ARVC index patients were screened. A total of 473 anonymous ethni-
cally matched controls were also screened.
Nine microsatellite markers around PLN were selected for haplotype analysis. 
Primers and conditions are available upon request. The availability of DNA of rela-
tives enabled the verification of the phase and reconstruction of haplotypes. Haplo-
type analysis was also performed in previously described DCM families from Greece 
and Germany.22,23 The method described by Machado et al. was used to calculate the 
age of the haplotype.26 
Besides PLN analysis, DCM index patients were screened for mutations in the 
most frequently mutated genes in DCM: LMNA, MYH7, and TNNT2. All ARVC index 
patients were also screened for mutations in PKP2, DSC2, DSG2, DSP, and JUP. 
Primers and PCR conditions are available upon request.
immunohistochemistry and histology
Formalin-fixed, paraffin-embedded myocardium samples were available from a 
subset of the ARVC and DCM patients carrying a PLN mutation and were used for 
immunohistochemical staining. Samples were analysed and interpreted in a blinded 
fashion. Information regarding antibodies and immunohistochemical protocols has 
been described before.12 Available complete hearts from transplant procedures or 
autopsies were analysed for signs of lipofibromatosis.
statistical analysis
Mutation rates in patients versus controls, clinical characteristics and ECG param-
eters of mutation-carrying index patients versus non-carriers were compared by 
either the Student’s t-test or Fisher’s exact test. Values of P<0.05 were considered 
significant. All the data were analysed with PASW 18.0 software (SPSS, Chicago, IL, 
U.S.A.).
resulTs
Patients and genetic analysis
A total of 354 unrelated index patients were evaluated; 257 diagnosed with DCM and 
97 with ARVC. A 3bp deletion of PLN (c.40_42delAGA; p.R14del) was identified in 
39 (15%) DCM index patients and 12 (12%) ARVC index patients. R14del was found 
in one of 473 control samples (P<10-18). None of the 39 R14del+ DCM patients had 
a mutation in LMNA, MYH7, or TNNT2, and none of the 12 R14del+ ARVC patients 
had a mutation in PKP2, DSC2, DSG2, DSP, or JUP. In addition, one of 46 (2%) 
ARVC index patients from the United States also carried the PLN R14del mutation. 
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Table 1 Modified task force criteria for the diagnosis of ARVC and Mestroni criteria for the diagnosis of 
DCM in PLN R14del mutation carriers































































D01 0/0 ++ ++ ++
D02 + + 0/2 ++ ++
D03 + + + 0/3 ++ ++ ++
D04‡ + + 0/2 ++ ++ +
D05 0/0 ++ ++ ++
D06 + + 0/2 ++ ++
D07 + + 0/2 ++ ++ ++
D08‡ + 0/1 ++ ++
D09 + + + 0/3 ++ ++ ++
D10 + + 0/2 ++ ++ ++
D11 0/0 ++ ++ ++
D12 0/0 ++ ++ ++
D13 + + 0/2 ++ ++ ++
D14 + 0/1 ++ ++ ++
D15 0/0 ++ ++ ++
D16 + 0/1 ++ ++ ++
D17 + 0/1 ++ ++ ++
D18 0/0 ++ ++ ++
D19 0/0 ++ ++ ++
D20 0/0 ++ ++ ++
D21 0/0 ++ ++ ++
D22 ++ + 1/1 ++ + ++
D23 + 0/1 ++ ++
D24 + 0/1 ++ ++ ++
D25 + + 0/2 ++ ++
D26 + 0/1 ++ ++
D27 + + 0/2 ++ ++ ++
D28 + + 0/2 ++ ++
D29 + 0/1 ++ ++ ++
D30 0/0 ++ ++ ++
D31 + 0/1 ++ ++ ++
D32 + 0/1 ++ ++ ++
D33 0/0 ++ ++ ++
D34 + + + 0/3 ++ ++ ++
D35 + ++ 1/1 ++ ++
D36 + + 0/2 ++ ++ ++
D37 + 0/1 ++ ++
D38 + + 0/2 ++ ++ ++




Table 1 Modified task force criteria for the diagnosis of ARVC and Mestroni criteria for the diagnosis of 
DCM in PLN R14del mutation carriers (continued)































































A01 ++ ++ + ++ 3/1 ++
A02 ++ ++ + ++ 3/2 ++
A03 + + ++ 1/2
A04 ++ ++ + + 2/2
A05 ++ + + 1/2
A06 ++ ++ + 2/1
A07 ++ ++ + 2/1
A08 ++ ++ + 2/1 ++
A09 ++ ++ ++ 3/0 ++
A10# + + + 0/3
A11 + + ++ 1/2
A12# + + + 0/3
USA   +   + ++ 1/2      
++ Indicates major criterion; +, minor criterion; only the presence of a criterion is indicated; 
LVEDD, left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; FS, fractional 
shortening; TFC, modified task force criteria;
A definite diagnosis ARVC is fulfilled by the presence of 2 major, or 1 major plus 2 minor criteria or 4 
minor criteria from different groups.; Borderline diagnosis: 1 major and 1 minor or 3 minor criteria from 
different categories; possible diagnosis: 1 major or 2 minor criteria from different categories.25
The diagnosis of DCM is based on the presence of two major criteria: 1. LVEF <45% and/or FS <25%, and 
2. LVEDD >117% of the predicted value corrected for age and body surface area. The diagnosis of familial 
DCM is made in the presence of ≥2 affected individuals in a single family or in the presence of a first-
degree relative, with well documented unexplained sudden death at <35 years of age. Members of families 
with familial DCM are considered affected in the presence of the major criteria or LVEDD >117% +one 
minor criterion or three minor criteria.24
* Not available, since available biopsies were all taken from the interventricular septum instead of the 
RV free wall and histomorphometric analyses had not been performed. ‡ LVEDD <117%; affected familial 
DCM cases. # Fulfilled the original TFC but not the modified TFC, because histomorphometric analyses of 
myocardial tissue had not been performed.
152
Haplotype analysis was performed in 36 (71%) of the Dutch R14del+ index 
patients, the patient from the United States, and in published Greek and German 
DCM families.22,23 A shared haplotype for five markers in a 1.2 Mb region surround-
ing PLN was found, although in two patients either the size of one or more markers 
had changed or a recombination had occurred. The parental ancestry of the R14del+ 
patient from the United States was German/Norwegian. The Greek patients had a 
different haplotype (See Supplementary Table S1). Allowing 25 years per generation, 
the age of the haplotype containing the mutation is estimated to be between 575 
and 825 years old.
Clinical data
Detailed clinical data of all 52 R14del+ patients (51 Dutch, 1 American) are given 
in Supplementary Table S2. Twenty-nine (56%) were female, the mean age at pre-
sentation was 44.3 ± 12.6 year, and mean follow-up was 9.2 (range 0-26) years. The 
R14del+ index patients mainly presented with ventricular tachycardia/fibrillation 
(VT/VF) (n=18), heart failure (n=11) or syncope (n=3), or were identified after fam-
ily screening following sudden cardiac death (n=7). Notably, three of five patients 
who presented with VF were <30yr. Table 1 lists the ARVC and DCM criteria for all 
52 R14del+ index patients. When evaluating retrospectively, five R14del+ patients 
diagnosed with DCM had a borderline diagnosis of ARVC (i.e. 1 major and 1 minor 
or 3 minor criteria) and 12 had a possible diagnosis of ARVC (2 minor criteria) at 
the time of DCM diagnosis. A criterion for abnormal repolarisation was present in 
23 (59%) and a criterion for arrhythmia in 22 (56%). A description of arrhythmias 
present at baseline in R14del+ DCM patients is given in Supplementary Table S3. In 
summary, a sustained or non-sustained VT or VF was present at baseline in 18/39 
(46%). In addition, although this is not an ARVC criterion as such, 15 (38%) R14del+ 
DCM patients showed RV dilatation. At time of ARVC diagnosis, four R14del+ ARVC 
patients had impaired LV systolic function; none of them had LV dilatation. 
A clinical diagnosis of DCM was made in family members of 21 of 39 (54%) DCM 
index patients, whereas in family members of 2 of 13 (15%) ARVC index patients a 
clinical diagnosis of ARVC was made. None of the DCM index patients had a family 
member with the clinical diagnosis of ARVC; one ARVC index patient had a parent 
diagnosed with DCM. The average age of the 26 family members who died of SCD 
was 37.7yr. Details on family history are given in Supplementary Table S4.
For both the DCM and ARVC groups, R14del+ index patients did not differ 
from R14del- index patients regarding age at presentation or sex (data not shown). 
Figure 1 shows their arrhythmia-related characteristics. Compared to R14del- DCM 
patients, R14del+ DCM patients more often had a positive family history for sudden 




experienced an appropriate ICD discharge. Furthermore, R14del+ DCM patients 
more often underwent cardiac transplantation (18% vs. 2%, P<0.001).
Within the ARVC group, R14del mutation carriers had more severe arrhythmia 
characteristics yet these were not statistically significant when compared to non-
carriers. Comparing R14del+ DCM patients to R14del+ ARVC patients did not reveal 
differences in these parameters.
electrocardiograms
In 46% of PLN R14del+ index patients a low voltage ECG at baseline was found. 
Inverted T waves as listed in the modified task force criteria for ARVC,25 were present 
in 29 (57%) patients, 19 of them showed inverted T waves in the left precordial leads 
(V4-V6) (Supplementary Table S5). Holter monitoring was performed in 40 R14del+ 
index patients; >500 ventricular extrasystoles per 24 hours, another diagnostic ARVC 
criterion, were present in 26 (65%).
figure 1 Arrhythmia related characteristics for both the DCM and ARVC groups. The left panel shows 
the rates of appropriate ICD discharge in patients carrying an ICD. In the DCM cohort, 108 PLN R14del- 
patients and 30 PLN R14del+ index patients underwent ICD implantation (48% vs. 77%, P=0.003) and in 
the ARVC cohort, these numbers were 54 and 10 (64% vs. 83%, P=0.21), respectively. The difference in 
the rates of appropriate ICD discharge reached statistical significance for the DCM cohort (10% vs. 47%, 
P<0.001), but not for the ARVC cohort (24% vs. 60%, P=0.053). The right panel shows family history for 
sudden cardiac death <50 years in first- and second-degree relatives. This difference reached statistical 
significance for the DCM cohort (16% vs. 36%, P=0.007), but not for the ARVC cohort (15% vs. 33%, 
P=0.22). 
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figure 2 Immunofluorescence images of endomyocardial-biopsy samples from two patients (A01 and 
A04) diagnosed with ARVC and one with DCM (D10), all carrying the PLN R14del mutation, compared to 
a control sample. Representative images from a blinded analysis of endomyocardial-biopsy samples show 
that immunoreactive signal levels for plakoglobin in two subjects with ARVC differ from the signal levels 
in a control subject and a subject with DCM. N-cadherin serves as a tissue control marker. Numbers in 
parentheses correspond to the subject numbers in Table S2 in the Data Supplement.
Table 2 Immunohistochemical diagnoses in blinded analysis of cardiac specimens from patients with 
DCM and ARVC, carrying the PLN R14del mutation
family id Patient sample type immunofluorescent signal for Plakoglobin diagnostic Test
D01 1st degree relative RV biopsy normal negative
D03 Index RV biopsy depressed positive
D08 Index explanted heart normal negative
D09 Index RV biopsy normal negative
D10 Index RV biopsy normal negative
D11 2nd degree relative RV biopsy normal negative
D15 Index RV biopsy normal negative
D16 1st degree relative autopsy normal negative
D20 Index RV biopsy normal negative
A01 Index RV biopsy absent positive
A02 Index RV biopsy absent positive
A03 Index RV biopsy absent positive
A04 Index RV biopsy absent positive
A06 Index RV biopsy normal negative
A10 Index RV biopsy normal negative
A11 Index RV biopsy very depressed positive
Family ID corresponds with index patients. Patient denotes index patient or the degree of relationship of 




immunohistochemistry and histology 
Immunohistochemistry revealed absent or markedly reduced immunoreactive 
signal levels for the desmosomal protein plakoglobin at intercalated disks in 5 of 7 
(71%) R14del+ ARVC samples. However, only 1 of 9 (11%) R14del+ DCM samples 
showed depressed signal levels (P=0.03) (Figure 2 and Table 2). An overview of 
reported histological findings in RV biopsies from PLN R14del index patients are 
given in Supplementary Table S6.
disCussion
The distinction of DCM and ARVC as separate clinical entities, which is made by 
both the AHA and the ESC,1,9 has important implications for clinical practice, guid-
ing both diagnostics and treatment. However, the considerable overlap encountered 
between different disease subtypes is an inevitable limitation of any classification.1 
The main finding of this study is that patients clinically labelled with different 
diagnoses (i.e. DCM or ARVC) based upon accepted clinical criteria, carry an identi-
cal mutation: PLN R14del. This specific mutation has extensively been studied in 
a mouse model by Haghighi et al; transgenic mice overexpressing this mutation 
exhibited depressed cardiac function, histopathologic abnormalities (fibrosis) and 
premature death, recapitulating the phenotype of the family they described.22
As phospholamban is a Ca2+-ATPase regulator, Ca2+ homeostasis might play an 
important role in the pathogenesis in R14del+ patients. Ca2+ regulates the assembly 
and disassembly of the desmosome: it is likely that both extracellular and cytoplas-
mic Ca2+ levels are important for cell-cell junction formation.27 Superinhibition of 
SERCA2a activity by mutant PLN leads to reduced Ca2+ uptake into the sarcoplasmic 
reticulum,22 which could consequently result in desmosomal disassembly due to 
elevated cytoplasmic Ca2+ levels and/or impaired Ca2+ homeostasis. 
Phenotype of r14del mutation carriers
The R14del mutation has previously been associated with a low-voltage ECG,23 which 
was also present in 46% of the R14del+ index patients described in this study. The 
substrate for these low-voltage ECGs and the observed arrhythmogenic phenotype 
may be the presence of cardiac fibrosis, which was a frequent finding at histological 
examination and has also been found in the R14del mouse model.22 
When compared to non-carrier DCM patients, patients diagnosed with DCM 
carrying PLN R14del exhibit an arrhythmogenic phenotype. This is reflected by high 
rates of ventricular tachycardia/fibrillation as presenting symptom, appropriate ICD 
interventions and positive family history for premature sudden cardiac death. In 
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addition, more R14del+ DCM patients underwent cardiac transplantation compared 
to R14del- DCM patients, further attesting to the malignancy of this mutation. 
R14del+ patients diagnosed with ARVC showed a severe arrhythmogenic phenotype 
comparable to non-carrier ARVC patients. 
Two different diagnoses or a single entity?
In cardiological practice, the diagnostic label of either DCM or ARVC is often 
determined by the initial presentation e.g. heart failure symptoms or arrhythmias, 
and this was probably also the case in the patients presented in this study. Those 
presenting with symptomatic ventricular arrhythmias were probably analysed 
with ARVC in mind, whereas patients with asymptomatic arrhythmias could have 
progressed towards heart failure and were more likely to be diagnosed as DCM. 
Ventricular ectopy and nonsustained VT could have been asymptomatic and not all 
patients diagnosed with DCM underwent Holter monitoring to detect arrhythmias. 
Follow-up by either an electrophysiologist in case of an ARVC diagnosis or heart 
failure-oriented cardiologist in case of a DCM diagnosis, may have led to findings 
that seemed to confirm which ever diagnosis was first considered. However, in 
retrospect a clear overlap was already present at the time of diagnosis (Table 1). In 
addition to similar arrhythmia related characteristics (Figure 1), five R14del+ DCM 
patients had a borderline diagnosis of ARVC and 12 had a possible diagnosis of 
ARVC at the time of DCM diagnosis. Moreover, RV dilatation was present in 15 
(38%) R14del+ DCM patients. Conversely, four R14del+ ARVC patients had impaired 
LV systolic function. These clinical findings suggest a single yet variable disease 
entity rather than two separate diagnoses, which is in agreement with the finding of 
a single underlying mutation, i.e. PLN R14del.
Taken together, our results support the concept of ‘arrhythmogenic cardiomy-
opathy’ as an entity encompassing ARVC, including left dominant arrhythmogenic 
cardiomyopathy, and arrhythmogenic forms of DCM.5,28
immunohistochemical differences
Within this PLN R14del related arrhythmogenic cardiomyopathy spectrum on the 
immunohistochemical level, samples from PLN R14del+ patients diagnosed with 
ARVC showed reduced plakoglobin signal levels in the majority (5 of 7) of cases, 
which is compatible with previous observations in ARVC,12 whereas only one of 
nine R14del+ patients with a clinical diagnosis of DCM showed identical findings 
(P=0.03). Diminished plakoglobin signal at intercalated disks appears to track with 
the ARVC phenotype rather than genotypes. Other unknown genetic, epigenetic, 
or environmental factors, such as strenuous exercise, may either cause reduced 




diagnosis), or alternatively, these factors lead to a more arrhythmogenic phenotype 
leading to a clinical diagnosis of ARVC and secondary reduced plakoglobin levels. 
We have excluded the co-occurrence of mutations in desmosomal genes in the ARVC 
patients as a cause for the reduced plakoglobin levels. Failure of plakoglobin to 
localise correctly in ARVC suggests a final common pathway in which desmosomal 
instability, caused by mutations in genes encoding either desmosomal proteins or 
other proteins such as PLN, leads to a subcellular redistribution of plakoglobin, 
which is believed to play a pivotal role in altered signalling pathways.5,29 
implications for diagnostics and therapy 
By providing evidence for the concept of arrhythmogenic cardiomyopathy, our 
results may have important diagnostic implications. The modified task force 
criteria for ARVC diagnosis are not designed to discriminate between different 
cardiomyopathy subtypes and do not contain a criterion for LV involvement with 
the exception of inverted T waves in V4-6,25 while RV involvement is not included in 
the criteria for DCM.24. We therefore call for the formulation of criteria for the diag-
nosis of arrhythmogenic cardiomyopathy, encompassing ARVC and arrhythmogenic 
forms of DCM. Regarding the therapeutic implications, the ESC’s 2008 heart failure 
guidelines recommended ICD implantation for primary prevention in non-ischemic 
cardiomyopathy, to reduce mortality in patients with an LV ejection fraction ≤35%, 
in NYHA functional class II or III.8 In our cohort, 44% of R14del+ DCM patients 
carrying an ICD had experienced an appropriate shock. This warrants caution with 
R14del+ DCM patients with a relatively preserved LV function (>30-35%). 
study limitations
As mentioned above, in DCM patients, RV function and arrhythmias were not sys-
tematically investigated, as was the case for LV function in ARVC patients, reflecting 
everyday clinical practice. In addition, the included patients had all been referred to 
tertiary referral centers, and thus possibly reflecting the more severe end of the dis-
ease spectrum. Family members were not systematically investigated in this study. 
Global relevance 
We identified the PLN R14del founder mutation in a substantial percentage of Dutch 
ARVC and DCM patients (12% and 15%, respectively), and were able to confirm this 
in an ARVC patient from the United States. The haplotype containing this mutation 
was estimated to be over 575 years old, showing that all R14del+ mutation carriers 
are distantly related, and was also present in patients from the United States and 
Germany. In addition, emigration of Dutch mutation carriers in the 19th and early 
20th century, not only to the United States but also to Canada, South-Africa, Austra-
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lia and New-Zealand, could have resulted in R14del mutation carriers on multiple 
continents. 
ConClusion
This is the first study to describe a role for PLN in ARVC. R14del+ patients diag-
nosed with DCM showed an arrhythmogenic phenotype. These findings support the 
concept of ‘arrhythmogenic cardiomyopathy’. 
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Table s1 Shared haplotype surrounding the PLN gene in R14del index patients
    Index patient
Marker Position D01 D02 D03 D04 D05 D06 D07 D08
D6S303 116.050K 227 227 235 235 225 231 233 233 233 233 227 235 227 227 235 235
PLN-650K 118.250K 394 396 394 390 394 394 394 390 394 390 394 390 394 396 394 394
PLN-200K 118.700K 439 439 439 443 439 439 439 439 439 443 439 443 439 443 439 445
PLN-50K 118.850K 288 288 288 284 288 290 288 294 288 286 288 294 288 284 288 296
PLN-R14del 118.900K + - + - + - + - + - + - + - + -
PLN+200K 119.100K 339 337 339 351 339 339 339 355 339 353 339 355 339 357 339 341
D6S304 119.450K 237 249 237 237 237 245 237 231 237 237 237 237 237 237 237 231
D6S412 120.550K 203 205 203 203 203 203 203 209 203 203 207 209 203 205 205 209
    Index patient
Marker Position D09 D10 D11 D12 D13 D14 D15 D16
D6S303 116.050K 233 233 225 225 227 227 227 233 227 227 233 233 235 235 233 233
PLN-650K 118.250K 394 394 394 394 394 396 394 394 394 396 394 394 394 394 394 392
PLN-200K 118.700K 439 443 439 443 439 443 439 437 439 441 439 441 439 441 439 439
PLN-50K 118.850K 288 288 288 286 288 286 286 284 288 294 288 292 288 290 288 290
PLN-R14del 118.900K + - + - + - + - + - + - + - + -
PLN+200K 119.100K 339 339 339 359 339 337 347 351 339 353 339 337 339 337 339 337
D6S304 119.450K 237 237 237 241 237 237 237 247 237 237 237 249 237 237 237 231
D6S412 120.550K 203 203 205 209 203 209 203 211 203 209 203 203 203 207 205 209
    Index patient
Marker Position D17 D18 D19 D20 D21 D22 D23 D24
D6S303 116.050K 227 227 227 233 233 235 227 227 235 235 229 235 231 231 225 231
PLN-650K 118.250K 394 390 394 396 394 384 394 390 394 396 394 394 394 394 394 388
PLN-200K 118.700K 439 443 439 437 439 443 439 443 439 445 439 437 439 437 439 435
PLN-50K 118.850K 288 288 288 288 288 288 288 290 288 286 288 290 288 290 288 288
PLN-R14del 118.900K + - + - + - + - + - + - + - + -
PLN+200K 119.100K 339 359 339 357 339 351 339 359 339 339 339 339 339 337 339 337
D6S304 119.450K 237 237 237 237 237 237 237 237 237 249 237 249 237 231 237 249
D6S412 120.550K 203 203 203 209 203 205 203 203 203 203 203 209 203 205 203 203
    Index patient
Marker Position A01 A02 A03 A04 A05 A06 A07 A08
D6S303 116.050K 227 227 233 233 227 227 227 227 227 237 229 229 233 233 235 235
PLN-650K 118.250K 394 390 394 390 394 396 394 392 394 394 394 394 394 394 394 394
PLN-200K 118.700K 439 443 439 441 439 441 439 441 439 437 439 441 439 437 439 443
PLN-50K 118.850K 288 288 288 292 288 290 288 298 288 286 288 294 288 288 288 286
PLN-R14del 118.900K + - + - + - + - + - + - + - + -
PLN+200K 119.100K 339 339 339 337 339 353 339 341 339 355 339 341 339 349 339 355
D6S304 119.450K 237 249 237 249 237 249 237 249 237 235 237 249 237 249 237 249




Table s1 Shared haplotype surrounding the PLN gene in R14del index patients (continued)
    Index patient
Marker Position A09 A10 A11 A12 USA Germany Greece
D6S303 116.050K 235 235 235 235 235 235 235 235 225 231 227 227 233 233
PLN-650K 118.250K 394 394 394 394 394 388 394 394 394 394 394 396 390 396
PLN-200K 118.700K 439 441 439 441 439 443 439 441 439 445 439 441 443 437
PLN-50K 118.850K 288 290 288 288 288 292 288 276 288 290 288 290 286 288
PLN-R14del 118.900K + - + - + - + - + - + - + -
PLN+200K 119.100K 339 337 339 335 339 335 339 349 337 337 339 339 355 355
D6S304 119.450K 237 249 237 247 237 237 237 249 237 249 237 245 241 249
D6S412 120.550K 203 205 NA NA 203 205 205 209 203 207 205 195 203 209
The shared haplotype is in grey. For patient D12, it is most likely that the size of the first proximal marker 
(PLN-50K) had changed. For patients D12 and the one from the United States (USA), either the size of 
the first distal marker (PLN+200K) had changed or a recombination had occurred. The identical haplotype 
found in two patients from the German pedigree, previously published by Posch et al.23 is also shown. Two 
PLN R14del mutation carriers from the Greek pedigree, previously published by Haghighi et al.22 carried 
another haplotype, as shown in the box. The position on chromosome 6 is listed.
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Table s2 Clinical characteristics of PLN R14del index patients
index 
patient sex
Age at onset, 
yrs Presentation
Age at iCd implantation, 
yrs^
follow-up, 
yrs end point, age
dCM
D01 F 59 Arrhythmia 65 (secondary) 10 ICD~, 68; Death#, 69
D02 F 54 HF 12 Death#, 65
D03 F 45 VF 48 (secondary) 17 ICD~, 52; HTx, 53
D04 F 41 AVNRT 46 (primary) 13
D05 F 46 VT 60 (primary) 18 HTx, 62
D06 M 30 Syncope 30 (primary) 5 ICD~, 32
D07 M 51 HF 58 (primary) 8 Death#, 59
D08 F 40 Arrhythmia 56 (primary) 24 ICD~, 57; HTx, 62
D09 M 48 VT 48 (secondary) 13 ICD~, 48
D10 F 41 Syncope 41 (secondary) 7 ICD~, 43
D11 F 47 Screening† 48 (primary) 4 ICD~, 50; Death#, 51
D12 M 46 HF 7
D13 M 49 Arrhythmia 50 (primary) 9 ICD~, 54; Death#, 58
D14 F 49 Screening† 50 (primary) 5
D15 F 53 HF 3
D16 M 55 HF 55 (primary) 2
D17 M 56 Arrhythmia 58 (primary) 6
D18 F 70 HF 70 (primary) 2
D19 F 49 VT 26 HTx, 59
D20 F 47 HF 47 (primary) 2 Death#, 49
D21 M 54 Arrhythmia 17 HTx, 60
D22 F 33 Fam. scr. 50 (primary) 20
D23 F 26 VF 26 (secondary) 3 ICD~, 27
D24 F 45 Syncope 46 (primary) 3
D25 F 38 Chest pain 43 (secondary) 9 ICD~, 43
D26 F 39 Fam. scr. 19
D27 M 39 Arrhythmia 40 (primary) 3 ICD~, 40; Death#, 42
D28 F 55 HF 58 (primary) 7 Death#, 62
D29 F 28 Peripartum 18 HTx, 32
D30 M 58 HF 60 (primary) 7
D31 F 45 HF 45 (primary) 0
D32 M 55 Collapse 55 (primary) 0
D33 M 86 AV block 4 Death, 91
D34 M 20 VF 29 (secondary) 9 ICD~, 29
D35 F 29 VT 37 (primary) 9 ICD~, 37; HTx, 38
D36 F 45 Fam. scr. 11
D37 M 22 VF 32 (secondary) 1 ICD~, 33
D38 M 42 VT 63 (primary) 23 Death#, 65




Table s2 Clinical characteristics of PLN R14del index patients (continued)
index 
patient sex
Age at onset, 
yrs Presentation
Age at iCd implantation, 
yrs^ 
follow-up, 
yrs end point, age
ArVC
A01 F 39 VT 38 (secondary) 7 ICD~, 39
A02 M 58 VT 58 (secondary) 9 ICD~, 65
A03 M 49 Fam. scr. 49 (primary) 10
A04 F 22 Arrhythmia 22 (primary) 8 ICD~, 23; Death#, 30
A05 M 43 VT 43 (primary) 3
A06 M 22 VT 14
A07 F 50 Fam. scr. 50 (primary) 9 ICD~, 51
A08 M 24 VT 35 (primary) 19 HTx, 43; Death# 43
A09 M 51 VT 8 Death#, 59
A10 M 38 VT 38 (primary) 11 ICD~, 46
A11 F 29 Fam. scr. 29 (primary) 10
A12 F 41 VF 41 (secondary) 16 ICD~, 46
USA F 38 Fam. scr. 38 (primary) 4
AVNRT indicates AV nodal re-entry tachycardia; Fam. scr, family screening (following SCD); HF, heart 
failure; HTx, heart transplantation; ICD, implantable cardioverter defibrillator; ICD~, appropriate ICD 
discharge; SCD, sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia.
^ Whether an ICD was as implanted for primary or secondary prevention is stated between brackets. 
*Arrhythmia not specified in medical records; # Cause of death was terminal heart failure (D01, D07, D11, 
D13, D20, D28, D38, A04, A09), VF (D27), post-HTx (A08), or unknown (D02); † Medical screening; after 
transient ischemic attack (D11), before operative procedure (D14).
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VT’s at baseline 
24h holter eCG
no of Ves at baseline 24h 
holter eCG
D01 No NA NA
D02 NA No >1000
D03 No nsVT; polymorphic 500-1000
D04 No nsVT; polymorphic >1000
D05 NA NA NA
D06 NA No >1000
D07 No No 500-1000
D08 No nsVT; unknown morphology >1000
D09 sVT; RBBB morphology No <500
D10 No No >1000
D11 No NA NA
D12 No No NA
D13 nsVT; unknown morphology NA NA
D14 No NA NA
D15 No No >1000
D16 No nsVT; unknown morphology NA
D17 nsVT; RBBB morphology nsVT; unknown morphology 500-1000
D18 No NA NA
D19 No No <500
D20 NA NA NA
D21 No NA NA
D22 No No >1000
D23 No NA NA
D24 No No 500-1000
D25 No nsVT; unknown morphology NA
D26 No No <500
D27 No No >1000
D28 NA No 500-1000
D29 NA nsVT; unknown morphology NA
D30 No No <500
D31 NA NA NA
D32 No NA NA
D33 NA NA NA
D34 No No >1000
D35 No nsVT; unknown morphology >1000
D36 No nsVT; unknown morphology 500-1000
D37 No No >1000
D38 No nsVT; unknown morphology NA
D39 No nsVT; unknown morphology NA
nsVT indicates non-sustained ventricular tachycardia; RBBB, right bundle branch block; sVT, sustained 








relatives, n description of affected family members
Age of family members 
with sCd, yrs 
dCM
D01 1 Child DCM, died at age 32
D02
D03 3 Sib HTx for CM and VTs; Sib ventricular arrhythmia
D04 5 Sib DCM, died at age 39; Cousin DCM, died at age 35 39 (1st)
D05 2 Sib DCM; Parent HF
D06 1 Sib DCM
D07 1 Sib DCM
D08 1 Sib DCM, died at age 52
D09 1 Sib SCD at age 31 31 (1st)
D10 1 Grandparent SCD at age 56 56 (2nd)
D11 2 Cousin HTx for DCM; Cousin CPR for VF
D12 1 Grandparent SCD at age 40 40 (2nd)
D13
D14 2 Parent DCM; Sib SCD at age 37 37 (1st)
D15
D16 2 Parent DCM, died at age 77; Sib SCD at age 33 33 (1st)
D17 1 Child SCD at age 26, CM at PM 26 (1st)
D18 2 Child SCD at age 32, CM at PM; Sib DCM 32 (1st)
D19 3 Cousin’s child SCD at age 37; Cousin VF 37 (4th); 58 (3rd)
D20
D21 1 Sib HF, died at age 75
D22 2 Sib DCM, SCD at age 25, Cousin SCD at age 22 25 (1st ); 22 (4th)
D23 2 Parent DCM; Aunt HTx for DCM
D24 2 Sib DCM, died at age 45
D25
D26 5 Parent ventr. arrhythmia, died at age 59; Uncle SCD at age 35 35 (2nd)
D27 3 Parent mild DCM, SCD at age 44 44 (1st)
D28 1 Sib DCM
D29
D30 2 Child DCM, died at age 42
D31 2 Parent HTx for DCM; Uncle SCD at age 58 58 (2nd)
D32 2 Parent DCM, died at age 47; Uncle DCM, died at age 49
D33 3 Three children DCM: SCD at age 27; died at age 51; died at age 52 27 (1st)
D34 3 Parent HF, died at age 50; Sib SCD at age 38 38 (1st)
D35 3 Sib DCM, died at age 35; Parent DCM
D36 3 Sib VF/HF, died at age 56; Sib SCD at age 36; Uncle SCD at age 40 36 (1st); 40 (2nd)
D37 1
D38 1
D39 Sib HF, died at age 74; Sib HF; died at age 83
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relatives, n description of affected family members
Age of family members 
with sCd, yrs
ArVC  
A01 3 Sib HTx for ARVC; Sib ventricular arrhythmia
A02 1 Sib ventricular arrhythmia
A03 2 Child SCD at age 25, ARVC at PM 25 (1st)
A04 1 Parent ventricular arrhythmia
A05
A06 1 Parent DCM, died at age 48
A07 1 Sib SCD at age 27 27 (1st)
A08
A09 1
A10 1 Sib SCD at age 33 33 (1st)
A11 5 Sib SCD at age 34, ARVC at PM; Aunt SCD at age 40, Cousin ARVC 34 (1st), 40 (2nd)
A12
USA 3 Parent SCD at age 57, Grandparent SCD at age 50 57 (1st), 50 (2nd)
CPR indicates cardiopulmonary resuscitation; HF, heart failure; HTx, heart transplantation; ICD, 
implantable cardioverter defibrillator; PM, post-mortem examination; SCD, sudden cardiac death; VF, 




Table s5 Baseline ECG characteristics of PLN R14del index patients
n=51
Female sex 28 (55%)
Age (yrs) 46.2  ± 12.4
Sinus rhythm 45 (88%)
Atrial rhythm 3 (6%)
Atrial fibrillation 3 (6%)
Ventricular rate (/min) 70 ± 12
PR interval (ms) 176 ± 34
QRS duration (ms) 102 ± 28
QTcorrected (ms)
^ 419 ± 25
Intraventricular conduction disorders 17 (33%)
RBBB 6 (12%)
Other 11 (22%)
T wave inversion – as listed in modified task force criteria 29 (57%)
in V1-V3 or beyond; RBBB absent** 4 (8%)
in V1-V4; RBBB present* 6 (12%)
in V4-V6; RBBB absent* 19 (37%)
TAD of QRS >55 ms, in V1-V3, RBBB absent* 2 (4%)
Low voltage; QRS in I, II, III <0.5mV^ 18 (46%)
RBBB indicates right bundle branch block; TAD, terminal activation duration. For continuous variables, 
values are listed as mean ± SD.  For discrete variables, values are listed as N (%).
** Task force criteria major criterion; * Task force criteria minor criterion; ^ After exclusion of 12 index 
patients with a QRS duration > 110ms.
172




D02 Two biopsies without clear abnormalities.
D03 Interstitial fibrosis, lipomatosis and hypertrophy; differential diagnosis: cardiomyopathy/ ARVC.
D09 Minor reactive adaptations compatible with hypertrophy; insufficient indications for ARVC.
D10 Interstitial fibrosis; no indications for ARVC.
D15 Aspecific myocyte hypertrophy and limited interstitial fibrosis; lipofibromatosis in a single biopsy.
D20 Myocyte hypertrophy and limited interstitial fibrosis; compatible with cardiomyopathy.
D25 Some hypertrophic and slightly irregular arranged cardiomyocytes; extensive intersitial fibrosis.
D34 Lipomatosis and fibrosis.
D38 Hypertrofic cardiac muscle with locally interstitial fibrosis.
ArVC
A01 Myocyte hypertrophy with fibrolipomatosis, compatible with ARVC.
A02 Histology fairly typical for ARVC.
A03 Focal interstitial fibrosis, no evident increase of adipocytes.
A04 Fibrosis, some adipocytes, compatible with ARVC.
A05 Small areas with lipofibromatosis, compatible with ARVC.
A06 Histology compatible with ARVC.
A10 In one of two 2 biopsies a small focus of adipocytes, interstitial fibrosis, compatible with ARVC.
A11 Remarkable increase of fat and connective tissue, compatible with ARVC.
The RV biopsies were not systematically studied. The original reported conclusions from pathologists 
from different centers are listed in this table. 
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Background Recently, we showed that the c.40_42delAGA (p.Arg14del) mutation in 
the phospholamban (PLN) gene can be identified in 10-15% of Dutch patients with 
dilated cardiomyopathy or arrhythmogenic cardiomyopathy. The arrhythmogenic 
burden of the p.Arg14del mutation was illustrated by the high rate of appropriate 
ICD discharges and a positive family history for sudden cardiac death. 
Methods Our goal was to evaluate the geographical distribution and the origin of 
this specific mutation in the Netherlands and to get an estimation of the prevalence 
in a Dutch population cohort. Therefore, we investigated the postal codes of the 
places of residence of PLN p.Arg14del mutation carriers and places of birth of their 
ancestors. In addition, a large population-based cohort (PREVEND) was screened 
for the presence of this mutation.
results By April 2012, we had identified 101 probands carrying the PLN p.Arg14del 
mutation. A total of 358 family members were also found to carry this mutation, 
resulting in a total of 459 mutation carriers. The majority of mutation carriers live 
in the northern part of the Netherlands and analysing their grandparents’ places of 
birth indicated that the mutation likely originated in the eastern part of the province 
of Friesland. In the PREVEND cohort we identified six heterozygous PLN p.Arg14del 
mutation carriers out of 8,267 subjects (0.07%).
Conclusion The p.Arg14del mutation in the PLN gene is the most frequently identi-
fied mutation in Dutch cardiomyopathy patients. The mutation that arose 575-825 
years ago is likely to have originated from the northeastern part of the province of 






Inherited cardiomyopathies are genetically heterogeneous disorders of the heart 
which often develop during adolescence or early adult life.1 Cardiomyopathies are 
grouped into different categories, based on their functional and morphological 
properties and subdivisions can be made according to the genetic basis.2,3 Genetic 
overlap between cardiomyopathies is well-recognised. Hypertrophic cardiomyopa-
thy (HCM) is characterised by a thickened wall of the left ventricle,4 and mutations 
in any of nine genes encoding sarcomeric proteins can be found in 30-65% of HCM 
patients worldwide.5-7 However, mutations in these genes can also be identified in 
18% of patients with dilated cardiomyopathy (DCM),8 which is characterised by left 
ventricular dilatation and contractile dysfunction. Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) is another cardiomyopathy subtype, characterised by fibro-
fatty replacement of cardiomyocytes, primarily in the right ventricle.9 In addition to 
this classic right ventricular subtype, biventricular involvement and left ventricular 
predominance have been described.10 ARVC is considered to be mainly a “disease 
of the desmosome”, a cell-cell adhesion complex.11 Screening of desmosomal genes 
has identified mutations in 40-58% of patients diagnosed with ARVC, but also in 5% 
of patients in a DCM cohort from the United Kingdom.12-15 The observed clinical and 
genetic overlap between ARVC and DCM has led to the postulation of arrhythmo-
genic cardiomyopathy as the encompassing entity.16
Of the cardiomyopathies, DCM is genetically the most heterogeneous; in addi-
tion to the sarcomere genes, more than 30 genes have been identified in DCM 
families.17 One of the genes implicated in DCM encodes phospholamban (PLN), 
a calcium handling protein in the sarcoplasmic reticulum of cardiac muscle.18 A 
number of mutations have been identified, leading to a highly variable phenotype, 
ranging from cardiac death in early adulthood to middle-aged asymptomatic muta-
tion carriers.19,20 
The yield from screening cardiomyopathy populations for PLN mutations is gen-
erally very low, ranging from 0.08% to 0.38% in selected cohorts.21-25 Surprisingly, we 
identified the PLN p.Arg14del mutation not only in 13% (31/240) of Dutch patients 
diagnosed with DCM, but also in 12% (12/97) of Dutch patients diagnosed with 
ARVC.26 The arrhythmogenic burden of the p.Arg14del mutation was illustrated by 
the high rate of appropriate ICD discharges and a positive family history for sudden 
cardiac death. Furthermore, p.Arg14del mutation carriers more frequently under-
went cardiac transplantation, compared to patients with familial DCM.26 Cascade 
screening has identified dozens of family members carrying the same mutation. 
Both variable expression and age-dependent penetrance, which are hallmarks of all 
inherited cardiomyopathies, are characteristic of the p.Arg14del mutation. 
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Recurrent and founder mutations in the Netherlands causing cardiac disease 
have been described in a series of the Netherlands Heart Journal.7,27-30 Here, we 
report our analysis of the origin of the p.Arg14del mutation, both by geographic 
region using postal code maps, and by age using haplotype analysis. Furthermore, 
we screened a large population-based cohort for the presence of the p.Arg14del 




Sequencing analysis and haplotype analysis for the PLN p.Arg14del mutation 
has been described elsewhere.26 To estimate the age of the haplotype, the linkage 
disequilibrium between the mutation and recombinant microsatellite markers was 
calculated and the recombination fraction from the distances between the mutation 
and microsatellite markers was determined, enabling estimation of the number of 
generations since a mutation had occurred.31
Postal code analysis
The postal codes of the places of residence of all PLN p.Arg14del mutation carriers 
were plotted to study their geographical distribution. To study the region where the 
mutation likely originated, we used a scoring system based on the birthplaces of 
the grandparents of the proband carrying the PLN p.Arg14del mutation. Without 
any additional genetic results, each grandparent had a chance of 1 in 4 of being a 
carrier of the mutation and therefore a score of ¼ was applied to the postal code 
of each grandparent’s place of birth. If it was known whether the mutation was 
inherited either paternally or maternally, that pair of grandparents had a chance of 
1 in 2 of being a carrier of the mutation and a score of ½ was applied to the postal 
codes of their places of birth. If it was proven which grandparent was the carrier of 
the mutation, a score of 1 was applied to the postal code for their place of birth. The 
sum of all the scores per postal code area was plotted. These analyses were based 
on the PC2 code (the first two numbers of the postal code) of the mutation carriers 






A large population-based cohort from the city of Groningen, in the north of the 
Netherlands, the Prevention of Renal and Vascular ENd-stage Disease (PREVEND) 
cohort (N = 8,267), was screened for the presence of the PLN p.Arg14del muta-
tion. The PREVEND study was designed to prospectively investigate the association 
between urinary albumin excretion and renal and cardiovascular outcome in the 
general population. The study protocol is described in elsewhere.32,33 In the period 
1997-1998, 8,592 participants were enrolled in the study and DNA samples were 
available for 8,267 participants. The PREVEND study was approved by the local 
medical ethics committee and conducted in accordance with the Declaration of 
Helsinki. 
Mutation detection
The prevalence of the PLN p.Arg14del mutation in the PREVEND cohort was evalu-
ated using KASPar® PCR SNP genotyping system (KBiosciences, Herts, UK). All the 
8,267 available DNA samples were screened for the mutation.
resulTs
Genetic evaluation
By April 2012, we had identified 101 unique probands carrying the PLN p.Arg14del 
mutation. A total of 358 family members were found to carry the same mutation, 
resulting in a total of 459 mutation carriers and an average of 4.5 (range 1-17) muta-
tion carriers per family. 
Haplotype analysis was performed in 49 of the 101 Dutch PLN p.Arg14del fami-
lies and in three families from the United States, Germany and Greece.26 A shared 
haplotype for five markers in a 1.2 Mb region surrounding PLN was found, although 
patients from the Greek family with the p.Arg14del mutation carried another hap-
lotype (Table 1). Allowing 25 years per generation, the age of the ‘Dutch’ haplotype 
containing the mutation is estimated to be between 575 and 825 years old.26 
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Table 1 Shared haplotype surrounding the PLN gene for the p.Arg14del mutation carriers from the 
Netherlands, Germany and the US
dCM index patients
Marker Position d02 d04 d06 d08 d10 d12
D6S303 116.050K 235 235 233 233 227 235 235 235 233 233 227 233
PLN-650K 118.250K 394 396 394 390 394 390 394 394 394 394 394 394
PLN-200K 118.700K 439 439 439 439 439 443 439 445 439 443 439 437
PLN-50K 118.850K 288 288 288 294 288 294 288 296 288 286 286 284
PLN-R14del 118.900K + - + - + - + - + - + -
PLN+200K 119.100K 339 337 339 355 339 355 339 341 339 339 351 347
D6S304 119.450K 237 249 237 231 237 237 237 231 237 241 237 247
D6S412 120.550K 203 205 203 209 203 203 205 209 205 209 203 211
ArVC index patients
Marker Position A01 A03 A05 A07 A09 A11
D6S303 116.050K 227 227 227 227 227 237 233 233 235 235 235 235
PLN-650K 118.250K 394 390 394 396 394 394 394 394 394 394 394 388
PLN-200K 118.700K 439 443 439 441 439 437 439 437 439 441 439 443
PLN-50K 118.850K 288 288 288 290 288 286 288 288 288 290 288 292
PLN-R14del 118.900K + - + - + - + - + - + -
PLN+200K 119.100K 339 339 339 353 339 355 339 349 339 337 339 335
D6S304 119.450K 237 249 237 249 237 235 237 249 237 249 237 237
D6S412 120.550K 203 203 203 205 203 203 203 195 203 205 203 205
non-dutch index patients
Marker Position us Germany Greece
D6S303 116.050K 225 231 227 227 233 233
PLN-650K 118.250K 394 394 394 396 390 396
PLN-200K 118.700K 439 445 439 441 443 437
PLN-50K 118.850K 288 290 288 290 286 288
PLN-R14del 118.900K + - + - + -
PLN+200K 119.100K 337 337 339 339 355 355
D6S304 119.450K 237 249 237 245 241 249
D6S412 120.550K 203 207 205 195 203 209
The shared haplotype in a selection of PLN p.Arg14del probands is marked in grey. 
For patient D12, the size of the first proximal marker (PLN-50K) had most likely changed. For patients 
D12 and the one from the United States (US), either the size of the first distal marker (PLN+200K) had 
changed or a recombination had occurred. The identical haplotype, found in two patients from the 
German pedigree published by Posch et al.,34 is also shown. Two PLN p.Arg14del mutation carriers from 
the Greek pedigree published by Haghighi et al.21 carried another haplotype, as shown in the box. The 






The geographic distribution of the place of residence of the mutation carriers is 
plotted in Figure 1, which shows that the majority of the identified carriers live in the 
northern part of the Netherlands and in the province of Noord-Holland, and that the 
numbers decrease gradually towards the south.
To determine the origin of the Dutch founder haplotype containing the PLN 
p.Arg14del mutation, we analysed the place of birth of the proband’s grandparents 
and scored the corresponding postal codes according to their chance of being the 
grandparent carrying the mutation. Data on these places of birth were available for 
60 of the 101 probands and the results are shown in Figure 2. We found that the 
majority of ancestors came from the eastern part of the province Friesland.
The phenotypes of PLN p.Arg14del mutation carriers vary greatly, not only 
between families, but also within the same family, as illustrated by the family shown 
in Figure 3A and Table 2. The proband III:1 was diagnosed with ARVC at age 21. She 
sought medical attention after experiencing palpitations. She presented with a low-
voltage ECG with ventricular bigeminy and monomorphic ventricular extrasystoles 
form the right ventricular ourflow tract (Figure 3B). During the course of 9 years 
follow-up, she developed progressive heart failure and experienced several appro-
priate ICD discharges because of ventricular tachyarrhythmias. She was placed on 
the waiting list for a cardiac transplantation, but died at age 30. Her mother, who 
also carried the PLN p.Arg14del mutation, had recordings of non-sustained VTs on 
24h Holter ECG monitoring, but her evaluation was otherwise unremarkable. The 
grandfather, also a mutation carrier, died at age 75 without ever seeking medical 
attention because of possible cardiac problems. The proband’s two sisters (age 30 
and 27 when last evaluated) were found to be carriers of the PLN p.Arg14del muta-
tion and are being monitored frequently, but have not experienced any symptoms, 
although the oldest sister demonstrated 1,100 premature ventricular complexes on 
24h Holter monitoring (Table 2).
Cohort study
In the PREVEND cohort we identified six heterozygous PLN p.Arg14del mutation car-
riers out of 8,267 subjects (0.07%). These PLN p.Arg14del mutation carriers (age at 
baseline 48±16 years; 4 males) did not have a clinically manifested cardiomyopathy 
at baseline. Three mutation carriers were diagnosed with hypertension at baseline, 
and three were diagnosed with diabetes mellitus. One subject (male, age at baseline 
69 years) developed heart failure during the 10-year follow-up period; the others had 
not experienced heart failure at a mean age of 53.4 years. None of the six mutation 
carriers were diagnosed with atrial fibrillation or left ventricular hypertrophy on the 
ECG. The set-up of the database provided no additional cardiological data.
182 figure 3 (A) Pedigree of a family carrying the PLN p.Arg14del mutation, illustrating the variability of the 
phenotype. Squares indicate male family members, circles indicate female family members, slashes 
indicate deceased, and the arrow points to the index patient. The solid black symbol indicates proven 
ARVC, while open symbols indicate clinically unaffected family members. Genotype results are shown 
by the p.Arg14del mutation present (+) or absent (–). (B) Baseline ECG of patient III:1, diagnosed with 
ARVC. The ECG shows signs of both DCM and ARVC: low voltage, ventricular bigeminy with left branch, 
left axis morphology (suggesting right ventricular outflow tract origin) and negative T-waves in the 
precordial leads.
figure 1 Postal code map showing the distribution of PLN p.Arg14del mutation carriers in the 
Netherlands. The number of PLN p.Arg14del mutation carriers per region is shown (in parenthesis: the 




figure 2 Postal code map illustrating the likely origin of the founder haplotype containing the PLN 
p.Arg14del mutation. The number of points based on the grandparents’ birthplaces is shown (in 
parenthesis: the number of postal code regions, 90 in total). On average, each region contains 180,000 
inhabitants. The province of Friesland is enclosed by the bold border.
Table 2 Clinical characteristics of the family members shown in Figure 3
id sex
Age at 1st 
evaluation results at 1st evaluation follow-up notes
I:1 M NA NA NA †75 yrs
I:2 F 77 yrs 24h ECG showed PVCs; echocardiography normal NA
II:1 F 43 yrs 24h-ECG showed non-sustained VT; 
echocardiography normal
11 yrs No progression
II:2 F NA NA NA  
III:1 F 21 yrs Low voltage ECG; abnormal SA-ECG;  
15,000 PVCs on 24h ECG; sustained VT on EPS; fibrofatty 
replacement on cardiac biopsy; diagnosed with ARVC; ICD 
implanted
9 yrs †30 yrs; died of heart failure 
while on waiting list for HTx
III:2 F 20 yrs Family screening; no abnormalities 10 yrs 1,100 PVCs on 24h ECG
III:3 F 17y Family screening; no abnormalities 10 yrs Delivered a healthy boy at 
28 yrs
IV:1 M NA NA NA  
EPS indicates electrophysiology study; HTx cardiac transplantation; ICD implantable cardioverter 




The p.Arg14del mutation in the PLN gene is the most frequently identified mutation 
in cardiomyopathy patients in the Netherlands. Mutation carriers showed high rates 
of appropriate ICD discharges, cardiac transplantation and a positive family history 
for sudden cardiac death.26 This mutation has also been identified in cohorts in other 
countries, such as Germany, Spain, Greece, Canada, and the United States.21,22,34,35 
(and personal communications M. Gollob & R. Hamilton). The German family and 
an ARVC patient from the United States carried the same haplotype surrounding 
the PLN gene as the patients from the Netherlands. The Greek patients carried 
another haplotype, illustrating that the PLN p.Arg14del mutation is recurrent, with 
at least two different haplotypes identified. All the Dutch patients carried the same 
haplotype and we estimated this haplotype to be between 575 and 825 years old. 
Although we have identified the founder effect of the PLN p.Arg14del mutation in 
the Netherlands, we cannot exclude that its origin is foreign, due to immigration 
from Germany, Belgium, France or Spain for example, especially considering the age 
of the mutation.36 The emigration in the 19th and early 20th century of PLN p.Arg14del 
mutation carriers from the Netherlands or from other Northern European countries 
to the United States and Canada has likely resulted in the presence of this muta-
tion in North America. Dutch mutation carriers could also have emigrated to South 
Africa, Australia and New Zealand. The presence of the p.Arg14del mutation needs 
to be confirmed in genetic studies in these countries.
To estimate the geographical origin of the p.Arg14del mutation, we used a scor-
ing method based on the places of birth of the probands’ grandparents. This scoring 
system revealed the eastern part of the province Friesland as the most likely area 
of origin of the p.Arg14del mutation in the Netherlands (Figure 2). Most current 
mutation carriers live in the northern part of the Netherlands including the province 
of Noord-Holland, i.e. close to the origin of the mutation, and a gradual decline 
towards the southern part of the Netherlands can be seen in Figure 1. As has been 
shown for other founder mutations in the Netherlands, including some described in 
the NHJ series,7,27-30 the migration of much of the Dutch population, and therefore 
mutation carriers, has been fairly limited and the distribution of current mutation 
carriers already gives a clear indication of its origin.
Following the identification of the p.Arg14del mutation in cardiomyopathy 
patients, we sought to identify whether the mutation was also present in a large 
population-based cohort from the northern Netherlands that had not been selected 
for the presence of cardiomyopathy or other cardiac diseases. Six of 8,267 subjects 
(0.07%) were identified as mutation carriers, suggesting that the mutation could be 




Postal code analysis suggested a lower frequency towards the south. By April 2012, 
the population of the three northern provinces of Groningen, Friesland and Drenthe 
was 1.7 million.37 Given these numbers, approximately 1,250 PLN p.Arg14del muta-
tion carriers are suspected to live in these provinces. The prevalence of the mutation 
in other provinces is expected to be lower, but since they have larger populations 
(e.g. 2.7 million in the province of North Holland), the total number of Dutch PLN 
p.Arg14del carriers is likely to be more than 2,000. Cascade family screening is 
ongoing and will probably identify several hundred more carriers.
The age at inclusion (48±16 years) of these carriers illustrates the age-dependent 
penetrance and variable expression of the p.Arg14del mutation. Since the onset of 
mutation-related symptoms (mean age 44.4 years) is well after the start of their 
reproductive age,26 many mutation carriers had already had children, explaining the 
continued high prevalence of the mutation. This mean age is likely to be biased, 
since the index patients usually mark the severe end of the disease spectrum. Some 
index patients had had a child who had died of sudden cardiac death at a much 
younger age than their age of onset.
Following the arrhythmogenic profile of the PLN p.Arg14del mutation, primary 
prevention by implanting an ICD could be beneficial for mutation carriers. We aim 
to determine the risk factors which will identify individuals at high risk for life-
threatening ventricular arrhythmias. Identification of independent risk factors would 
enable the selection of PLN p.Arg14del mutation carriers who are most likely to 
benefit from an ICD, while the absence of such risk factors in other carriers would 
justify alternative treatment options. We have setup the PHOspholamban RElated 
CArdiomyopathy STudy (PHORECAST, www.phorecast.nl) to evaluate the possible 
risk factors for life-threatening ventricular arrhythmias. This study will be of great 
importance for all p.Arg14del mutation carriers as well as their cardiologists, who 
are faced with a great variability of symptoms and large clinical differences, both 
between and within affected families.
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introduction Arrhythmogenic cardiomyopathy (ACM) is considered a predominantly 
right ventricular (RV) desmosomal disease. However, left-dominant forms due to 
desmosomal gene mutations, including PKP2 variant c.419C>T (p.Ser140Phe), 
have been described. Recently, a non-desmosomal phospholamban (PLN) mutation 
(c.40_42delAGA; p.Arg14del) has been identified causing dilated cardiomyopathy 
and arrhythmias. By cosegregation analysis of PKP2 variant p.Ser140Phe versus 
PLN mutation p.Arg14del we aimed to gain more insight into pathogenicity. 
Methods and results A Dutch family (13 family members, median age 49, range 
34-71 years) with ventricular tachycardia underwent meticulous phenotypic charac-
terisation and screening of five desmosomal genes (PKP2, DSC2, DSG2, DSP, JUP) 
and PLN. Six family members fulfilled 2010 ACM Task Force Criteria. Seven had 
signs of left ventricular (LV) involvement (inverted T waves in V4-V6, LV wall motion 
abnormalities and late enhancement, reduced LV ejection fraction), including six 
family members with proven ACM. PKP2 p.Ser140Phe was found as a single variant 
in three, combined with PLN p.Arg14del in three others. PLN mutation p.Arg14del 
was found in nine family members, including the six with ACM and all seven with 
LV involvement. PLN p.Arg14del was found as single mutation in six, and combined 
with PKP2 p.Ser140Phe in three others. A low voltage ECG was seen in four of nine 
PLN mutation-carriers. None of the PKP2 single variant carriers showed any sign of 
RV or LV involvement.
Conclusion In this family, PLN mutation p.Arg14del cosegregates with ACM and 
with electrocardiographic and structural LV abnormalities. There was no evidence of 





In the classical description, arrhythmogenic right ventricular dysplasia/cardiomyo-
pathy (ARVD/C) was characterised by ventricular arrhythmias of right ventricular 
origin with fibrofatty replacement of cardiomyocytes, predominantly in the right 
ventricle (RV).1-4 More recently, patients and families with ventricular arrhythmia 
and similar ARVD/C histopathologic changes in the left ventricle (LV) have been 
recognised and described as left-dominant arrhythmogenic cardiomyopathy 
(LDAC).5 Mutations in desmosomal genes cause both ARVD/C and LDAC and at the 
molecular level both ventricles and the interventricular septum are similarly affected 
by down-regulation and altered distribution of intercalated disk proteins.6-8 The des-
ignation “arrhythmogenic cardiomyopathy” is now the preferred terminology when 
the clinical presentation of a cardiomyopathy is predominantly with arrhythmia 
rather than heart failure.9
Arrhythmogenic cardiomyopathy (ACM) is considered a hereditary disease 
primarily due to mutations in genes encoding cardiac desmosomal proteins. 
Desmosomes are protein complexes located in the intercalated disk which are 
important for mechanical integrity.10 Desmosomal dysfunction with loss of mechani-
cal cell-cell adhesion leads to down-regulation of other intercalated disk proteins, 
i.e. gap junction proteins (connexin43) and sodium channels (Nav1.5).7,11 These 
alterations give rise to electrical cell-cell uncoupling and slow conduction respec-
tively, thereby providing a substrate for early activation delay and thus re-entrant 
ventricular tachyarrhythmia.7,8,10,12-20 Presumably, at a later stage myocyte loss and 
fibrofatty replacement will have a major impact on tissue architecture, giving rise to 
zig-zag conduction pathways and load mismatch, further contributing to enhanced 
activation delay.8,12-14
Pathogenic mutations in five known desmosomal genes are related to right, left, 
and biventricular forms of ACM: plakophilin 2 (PKP2), desmoplakin (DSP), plako-
globin (JUP), desmoglein 2 (DSG2), and desmocollin 2 (DSC2).15,21-27 In approxi-
mately 60% of Dutch ACM patients a pathogenic desmosomal mutation is found, 
predominantly in the PKP2 gene.20,22
The PKP2 variant c.419C>T (p.Ser140Phe) is a missense variant which alters 
one amino acid. It has been reported to be associated with both classical right-
sided ACM, and with a left-dominant form.5,21,28 This variant has been identified in 
individual patients who, according to the Task Force Criteria (TFC), have ACM.5,21,28-34 
PKP2 p.Ser140Phe has also been identified in 5 families with ACM.21,28,30,32
However, the pathogenicity of this variant is not supported by in silico prediction 
algorithms Sorting Intolerant from Tolerant (SIFT) and Polymorphism Phenotyp-
ing-2 (PolyPhen-2).35,36 SIFT and PolyPhen-2 predict a tolerated (0.17) and benign 
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(0.001) effect of the missense variant on PKP2 protein function. No functional tests 
to assess pathogenicity have been performed thus far. 
This report presents a family with monomorphic ventricular tachycardia (VT) with 
two potentially causative mutations, the desmosomal PKP2 variant p.Ser140Phe and 
a recently identified mutation c.40_42delAGA (p.Arg14del) in the non-desmosomal 
phospholamban (PLN) gene. PLN is involved in calcium homeostasis and muta-
tion carriers are phenotypically characterised by low voltage electrocardiograms, 
ventricular arrhythmias, and contractile dysfunction.37-40
The aim of the study was to gain insight into the pathogenicity of the PKP2 vari-
ant p.Ser140Phe by cosegregation analysis of the PKP2 variant p.Ser140Phe versus 
the PLN mutation p.Arg14del.
MeThods
study population
A Dutch family of four generations and 30 family members, 13 of whom were avail-
able for screening (median age 46, range 34-71 years, four men), with VT underwent 
meticulous phenotypic characterisation and mutation analysis. 
Clinical evaluation
Standard patient evaluation included detailed assessment of clinical and family 
history, physical examination, and 12-lead ECG (while off drugs). In the presence 
of cardiac symptoms and/or an abnormal ECG, analysis was extended with 48-hour 
ambulatory ECG monitoring (11/13), maximal treadmill exercise testing (7/13), 
chest X-ray (5/11), 2D-transthoracic echocardiography (11/13), magnetic resonance 
imaging (MRI; 8/13) including delayed enhancement (DE; 6/13) analysis, and in a 
minority, LV/RV cine-angiography (3/13), electrophysiologic study (EPS; 3/13), and 
endomyocardial biopsy (2/13). Diagnosis of ACM was according to the revised 2010 
TFC.41 Family members were further analysed for LV abnormalities. LV involvement 
was considered positive in the presence of at least one of the following: negative 
T waves in left precordial leads V4-V6, LV wall motion abnormalities (akinesia or 
dyskinesia) and/or DE in the LV on imaging studies, and left ventricular ejection 
fraction (LVEF) < 50%. 
Molecular analysis
Genomic DNA was extracted from peripheral blood as described before.20 Direct 
sequence analysis of all coding regions and intron/exon boundaries of the five 




performed in the index patient. The remaining 12 family members available for 
screening were analysed for the PKP2 variant and the PLN mutation found in the 
index patient. Primer sequences and PCR conditions are available on request. 
resulTs
family
At age 51, the index patient (III:8, see pedigree in Figure 1) presented with a poorly 
tolerated monomorphic VT with right bundle branch block (RBBB) morphology, 
right axis deviation, and cycle length 230 ms. Clinical analysis showed low volt-
age ECG (voltages <0.5mV in standard leads), and a structurally normal heart on 
cine-angiography and echocardiography with LVEF 62%. At age 63, she presented 
again with a hemodynamically poorly tolerated VT with the same morphology and 
axis, but remarkably longer cycle length (while off drugs) of 350 ms (Figure 2). By 
then, the LVEF had deteriorated to 32%. The ECG repeatedly showed markedly low 
voltages in the standard leads (Figure 3). Left and right ventricular cine-angiogram 
revealed dyskinesia at the LV apex, and akinesia inferiorly of the tricuspid valve with 
poor RV function. Coronary angiogram (CAG) was unremarkable. The clinical VT 
was inducible with programmed electrical stimulation (PES) in the RV apex (cycle 
figure 1 Pedigree of the Dutch family with PKP2 variant c.419C>T (p.Ser140Phe) and PLN mutation 
c.40_42delAGA (p.Arg14del). No other desmosomal mutations identified in the index patient (arrow). 
In addition, 12 family members screened for PKP2 variant and PLN mutation carriership. Phenotypic 
characterisation with regard to arrhythmogenic cardiomyopathy (ACM) diagnosis with left ventricular 
(LV) and right ventricular (RV) involvement, and presence of low voltages (voltages <0.5mV in standard 
leads). Square: male, circle: female, +: mutation carrier, -: non-carrier, ?: PKP2 not screened, diagonal line: 
deceased. 
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length 600 ms and two extrastimuli). In addition, two other RBBB VT morphologies 
were inducible during PES. All VT episodes could be terminated by burst pacing. 
Management included implantation of a cardioverter defibrillator (ICD). Heart 
failure became more prominent at age 64, with a clinical decline in condition when 
she developed atrial fibrillation. 
Family screening was initiated after the index patient’s second presentation. 
There were no sudden cardiac deaths in the family. Family members of the first and 
figure 2 ECG of the index patient (III:8) at second presentation. 12-lead ECG recording (while off drugs) 
of monomorphic ventricular tachycardia with right bundle branch block morphology, right axis deviation 
and cycle length 350 ms at second presentation of index patient at age 63. 
figure 3 ECG of the index patient (III:8) while off drugs. Outstanding are the low voltages (voltages 




second generation reached old age. Findings in the family are summarised in Table 
1.
Her sister (III:9) had an abnormal ECG and atypical chest pain since age 58 
(CAG normal). The ECG showed negative T waves in leads V1-V6 (Figure 4). 24-Hour 






























PLN + + + + + + + + +
PKP2 + + + + + +
eCG
Low Volt + + + +
V1-V3 +
V4-V6 + + + + + +
Prol. TAD
Arrhythmias
LBBB VT + + +
RBBB VT +
>500 VES + + + + + na na
imaging
WMA RV + + + na
WMA LV + + na
DE RV na + na na na na na
DE LV na + na + na na na na
RVEF(%) 33 na 47 32 na 54 na 47 56 na na na na
LVEF(%) 50 na 50 51 58 60 32 60 68 na na na na
diagnosis
ACM + + + + + +
RV inv. + + + +
LV inv. + + + + + + +
Only the presence of a feature is indicated, by a ‘+’ sign. Family members are sorted based on their 
genetic results and numbered according to pedigree (Figure 1) with age (years) noted below family 
number. 
PLN: phospholamban. PKP2: plakophilin 2. Low Volt: low voltages on ECG, voltages <0.5mV in standard 
leads. V1-V3: negative T waves in leads V1-V3. V4-V6: negative T waves in leads V4-V6. Prol. TAD: prolonged 
terminal activation duration (≥55 ms). LBBB VT: VT with left bundle branch block morphology. RBBB VT: 
VT with right bundle branch block morphology. 500 VES: fulfilment of Task Force criterion >500 ventricular 
extrasystoles/24hour. WMA: wall motion abnormalities (akinesia/dyskinesia). DE: delayed enhancement. 
RV: right ventricle. LV: left ventricle. RVEF: right ventricular ejection fraction. LVEF: left ventricular ejection 
fraction. ACM: arrhythmogenic cardiomyopathy. RV/LV inv.: RV/LV involvement. na: not applicable. 
198
ECG showed ventricular ectopy (238/24hour) with left bundle branch block (LBBB) 
morphology. MRI demonstrated a dyskinetic area in the RV and delayed enhance-
ment in the lateral wall of the LV, with LVEF 60%. At age 65, ventricular ectopy 
increased to 493/24hour and non-sustained VT (NSVT) episodes were recorded. 
During PES no arrhythmias were inducible, late potentials were found in outflow 
tract, basal-anterior, and inferior-apical region of the RV, and voltage mapping 
revealed multiple sites with endocardial low voltages (voltages ≤1.5mV in bipolar 
recordings). Endomyocardial biopsy showed normal endomyocardium. Analysis 
was followed by ICD implantation. 
Another sister (III:10) had negative T waves in V2-V6, frequent ventricular ectopy 
(3379/24hour), and reduced RV function (RVEF 33%), with LVEF 50%. A brother of 
the index patient (III:11), aged 62 years, had a normal ECG and structurally normal 
heart on echocardiography and MRI.
The eldest daughter of the index patient (IV:5) had palpitations. She had negative 
T waves in V2-V6, frequent ventricular ectopy (2431/24hour), NSVT episodes, and DE 
in the inferior and lateral region of the LV apex. No arrhythmias were inducible with 
PES, voltage mapping demonstrated low endocardial voltages in anterior outflow 
tract, and inferior free-wall region of the RV. Endomyocardial biopsy showed normal 
myocardium. An ICD was implanted. The son of the index patient (IV:6) did not 
have any cardiac complaints, his ECG however, showed negative T waves in V3-V6, 
MRI analysis showed a wider RV (47mm) than LV (45mm) but no other signs of 
ACM. His sister (IV:7) was asymptomatic with a normal ECG and echocardiogram.
The eldest son (IV:8) of the sister (III:9) of the index patient was asymptom-
atic with normal ECG. His brother (IV:9) had a history of palpitations but without 
figure 4 ECG of the sister (III:9) of the index patient while off drugs. Remarkable are the negative T waves 




documented episodes of tachycardia. His ECG showed low voltages but no inverted 
T waves. Exercise testing and MRI analysis revealed no abnormalities with good sys-
tolic function of both ventricles. Their sister (IV:10) was asymptomatic with normal 
ECG and echocardiogram. The youngest of these siblings (IV:11) was asymptomatic, 
and the ECG was normal. 
Both cousins of the index patient, monozygotic twins (IV:3 and IV:4) were evalu-
ated. At age 43, patient IV:3 showed a low voltage ECG with inverted T waves in 
V4-V6, frequent ventricular ectopy (1042/24hour), and normal ventricular function 
with RVEF 47% and LVEF 50%. Her sister (IV:4) had low voltages and negative T 
waves in V4-V6, RV wall motion abnormalities and DE, a reduced RV function with 
RVEF 32%, and LVEF 51%. 
diagnosis of arrhythmogenic cardiomyopathy and lV involvement
According to revised 2010 TFC, ACM was diagnosed in 6 family members (III:8, 
III:9, III:10, IV:3, IV:4, IV:5; median age 55, range 46-71 years; all women), as shown 
in Table 1 (see also Figure 1). Diagnosis in this family was based on major and 
minor criteria for family history, depolarisation and repolarisation abnormalities, 
ventricular arrhythmias, and either global or regional dysfunction and structural 
alterations of the RV.
LV involvement was identified in seven family members (III:8, III:9, III:10, 
IV:3, IV:4, IV:5, IV:6; median age 46, range 44-71 years; see Table 1). Those seven 
included the six family members with ACM diagnosis. One family member (IV:6) 
with LV abnormalities and prominent ventricular ectopy (407/24 hour) had only one 
major and one minor criterion, based on family history and inverted T waves in left 
precordial leads, and therefore did not meet the diagnosis of ACM. 
dnA analyses
In DNA of the index patient, sequence analysis of all five desmosomal genes and 
of the non-desmosomal gene PLN resulted in the identification of the PKP2 variant 
p.Ser140Phe and the PLN mutation p.Arg14del. No other mutation was identified 
in the index patient.
PKP2 p.Ser140Phe was identified as single variant in three family members (IV:7, 
IV:8, IV:10; median age 42, range 37-42 years). PLN mutation p.Arg14del was identi-
fied in nine family members, as single mutation in 6 family members (III:10, III:11, 
IV:3, IV:4, IV:5, IV:9, median age 46, range 40-64 years), and combined with the 
PKP2 variant in three others (III:8, III:9, IV:6; median age 66, range 44-71 years). 
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Genotype-phenotype correlation
All six family members with ACM diagnosis carried the PLN mutation p.Arg14del, 
four of them as single mutation (III:10, IV:3, IV:4, IV:5; see pedigree Figure 1). More-
over, all seven patients with LV involvement were PLN p.Arg14del positive. PLN 
mutation carriers often had a low voltage ECG (voltages <0.5 mV in standard leads; 
4/9 mutation carriers; see Table 1), and frequently had inverted T waves in V4-V6 (6/9 
mutation carriers). In contrast, none of the PKP2 single variant carriers (IV:7, IV:8, 
IV:10, aged 42, 42, and 37) showed any sign of RV or LV involvement. 
disCussion
Pln cosegregation and mutation carrier characteristics
Cosegregation analysis of PKP2 variant p.Ser140Phe versus PLN mutation 
p.Arg14del demonstrated that the PLN mutation cosegregates with ACM diagnosis 
and electrocardiographic and structural LV abnormalities. In this family, mutation 
carriers were often identified by the presence of low voltage ECGs. In addition, PLN 
mutation carriers with ACM had RV and LV involvement, negative T waves in V4-V6, 
and wall motion abnormalities and/or DE in the LV. 
It is remarkable that none of the PLN mutation carriers in this family showed 
prolonged terminal activation duration (TAD), or epsilon waves in V1-V3, primarily 
representing activation delay in the RV outflow tract, whereas prolonged TAD was 
identified previously in 71% of patients with classical ACM, i.e. ARVD/C.19 These 
observations suggest that PLN mutation carriers form a specific subgroup of ACM 
patients.
The p.Arg14del mutation results in the deletion of a highly conserved residue and 
is not found in large control populations.38,39 PLN gene mutations have previously 
been associated with low voltages on ECG recordings, with ventricular tachyarrhyth-
mias, and contractile dysfunction in dilated cardiomyopathy (DCM) patients.37,38,40 
The attenuated amplitudes on ECG recordings were found irrespective of structural 
abnormalities on imaging studies.38,40 In our study, patient IV:9 had low voltages 
without any MRI abnormalities, including DE analysis. Similar patients in whom 
the electrocardiographic and arrhythmic abnormalities were the earliest disease 
manifestation have been reported, as have patients in whom arrhythmia and MRI 
late enhancement preceded ECG or structural imaging abnormalities.6 Therefore 
a mutation specific process leading to fibrosis and ultimately arrhythmias or heart 
failure has been hypothesised. Low voltages in the absence of fibrosis could indicate 
electrical changes due to chronic increased intracellular calcium levels.40 The exact 




forms of ACM, modifying factors are important in the clinical presentation of PLN 
mutation carriers. The monozygotic twins IV:3 and IV:4 are clinically different, with 
markedly reduced RV function in patient IV:4 and preserved RV function in patient 
IV:3. In addition, family member III:11, aged 62 years, did not show any sign of RV 
or LV disease. At this stage, the potential role of environmental factors and genetic 
modifiers is still obscure. 
PKP2 cosegregation
Initial molecular genetic screening of the five known desmosomal genes identi-
fied the missense variant p.Ser140Phe in the PKP2 gene. The literature on PKP2 
p.Ser140Phe (Table 2), presents conflicting data. The variant is found in healthy 
controls, in individual ACM or DCM patients, and in families with ACM. Identifica-
tion in controls appears infrequent, and the overrepresentation in ACM patients and 
families has been considered suggestive of a disease-modifying or even pathoge-
netic role of the variant.21,28,30
The findings in this study challenge this suggested classification. In our Dutch 
family the PKP2 variant was the only variant identified after genetic screening of 
the five desmosomal genes. Nevertheless, the daughter of the index patient had 
ventricular arrhythmias and structural changes in the LV but did not carry the vari-
ant. Furthermore, three family members already aged 37, 42, and 42 years, with 
PKP2 p.Ser140Phe as the sole variant did not display any sign of RV or LV involve-
ment. Since the single PKP2 variant carriers were all from the youngest generation, 
a selection bias due to age-related penetrance is possible, but unlikely since these 
individuals were aged around 40 years. However, in individuals with a PLN mutation 
a modifier effect of the additional PKP2 variant, suggested by the overrepresentation 
of the variant in patients in the literature, can not be excluded. Nonetheless, there is 
no evidence of an individual disease causing contribution of the single PKP2 variant 
p.Ser140Phe in this family.
Several arguments support the non-pathogenicity of the single PKP2 variant. 
In silico prediction algorithms do not support pathogenic classification of the 
p.Ser140Phe variant. The variant affects a mildly conserved residue and the resulting 
phenylalanine at position 140 is found at that position in other species.15,30 Second, 
in a study by Christensen et al. this variant is found in 3 out of 55 ACM patients 
but also in 5 out of 650 healthy controls.30,31 Moreover, the individual ACM patient 
first described in the study by Dalal et al. carrying the variant, was also carrying a 
second, pathogenic mutation in PKP2 (c.2146-1G>C), and an unclassified variant 
in DSG2 (c.166G>A p. Val56Met).29,32,42 In addition, the cosegregation of the PKP2 
p.Ser140Phe variant has been studied in five families with ACM: Syrris et al. and 
later Sen-Chowdry et al. described a family of three generations with sudden cardiac 
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death, VT, and structural alterations in the RV and LV, with affected patients carrying 
PKP2 p.Ser140Phe.21,28 Nonetheless, a first degree relative had structural abnormali-
ties in the RV and NSVT but did not carry the variant. Similar are the results of a 
study of Christensen et al. and a study by Xu et al., who described the variant in ACM 
patients but established that there is incomplete cosegregation in three distinct 
families.30,32 










Garcia-Pavia et al. 2011.43 DCM PKP2, DSC2, 
DSG2, DSP, 
JUP
0/200 1/89 No cosegregation Mutation
Christensen et al. 2010.30,31 1994 PKP2, DSC2, 
DSG2, DSP, 
JUP,TGFB3





Elliott et al. 2010.44 DCM PKP2, DSC2, 
DSG2, DSP,
JUP
0/200 3/100* No analysis Mutation
Fressart et al. 2010.34 1994 PKP2, DSC2, 
DSG2, DSP, 
JUP
0/300 1/135 No analysis Variant of 
unknown 
significance
Xu et al. 2010.32 1994 PKP2, DSC2, 
DSG2, DSP, 
JUP, DES
0/700 1/198** Incomplete 
cosegregation
Variant Dalal et al.
2006 
Sen-Chowdry et al. 2007.28 # PKP2, DSC2, 
DSG2, DSP, 
JUP
0/0 2/200 Incomplete 
cosegregation in one 
family
Mutation Syrris et al.
2006
Koopmann et al. 2007.45 BrS PKP2, JUP† 1/75 1/38 No analysis Polymorphism
Dalal et al. 2006.29 1994 PKP2 0/200 1/58 No analysis Mutation
Syrris et al. 2006.21 1994 PKP2‡ 0/200 1/100 Incomplete 
cosegregation
Mutation
Gerull et al. 2004.15 1994 PKP2 0/250 1/120 No analysis Mutation
TFC: Task Force Criteria for ACM diagnosis, 1994: original criteria, 2010: new revised criteria, DCM: 
criteria for dilated cardiomyopathy, BrS: Criteria for diagnosis of Brugada syndrome. Genes: PKP2: 
plakophilin 2, DSP: desmoplakin, JUP: plakoglobin, DSG2: desmoglein 2, DSC2: desmocollin 2, TGFB3: 
tumor growth factor beta3, DES: desmine, SCN5A: sodium channel5a. 
# used Task Force guidelines from Corrado et al.46 and modified criteria for familial ACM diagnosis from 
Hamid et al.47 †: When SCN5A was negative, PKP2 and JUP were tested, ‡: When DSP and JUP were 
negative, PKP2 was tested, *: 1 patient also carried DSP c.8134G>A; p.Ala2712Thr, **: proband is digenic 





desmosomal disease in this family? 
The non-desmosomal PLN mutation p.Arg14del cosegregates with ACM diagnosis 
and LV abnormalities whereas the desmosomal PKP2 variant p.Ser140Phe does 
not. ACM is usually associated with desmosomal gene mutations. There is limited 
knowledge on the pathogenic mechanism of non-desmosomal PLN mutations in 
ACM patients. Down-regulation of the desmosomal protein plakoglobin has been 
hypothesised as a final common pathway for the ACM phenotype.8,20 The PLN muta-
tion may have indirect effects on cardiac desmosomes, thus explaining the ACM 
phenotype. 
limitations
Only one family with 13 family members was available for cosegregation analysis of 
PKP2 p.Ser140Phe versus PLN p.Arg14del. This study should be extended in other 
families. Moreover, functional analysis should be performed to assess the apparent 
non-pathogenicity of PKP2 variant p.Ser140Phe demonstrated in this study. How-
ever, cosegregation analysis demonstrated cosegregation of the PLN mutation with 
the diagnosis of ACM and LV involvement. Available evidence did not reveal other 
mutations as causal for the familial ACM in this family. 
ConClusion
A PLN mutation cosegregates with the diagnosis of ACM and with electrocardio-
graphic and structural LV abnormalities. Mutation carriers are phenotypically char-
acterised by low voltages and inverted T waves in left precordial leads on the ECG. 
In this family, there is no evidence of individual disease causing contribution of the 
single p.Ser140Phe variant in PKP2. 
Acknowledgements
The authors are grateful to the family members for their effort, interest, and coop-
eration. This study was supported by the Netherlands Heart Foundation (grants 
2007B132 and 2007B139), Interuniversity Cardiology Institute of the Netherlands 
(project 06901), and the Heart Lung Foundation Utrecht. WJM acknowledges a 




1. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, Grosgogeat Y. Right 
ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65:384-98. 
2. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden 
death in young people. N Engl J Med. 1988;318:129-33. 
3. Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular 
cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation. 1996;94:983-91. 
4. Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, Fontaliran F, Nava A, Silvestri F, Blomstrom-
Lundqvist C, Wlodarska EK, Fontaine G, Camerini F. Spectrum of clinicopathologic manifestations of 
arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 
1997;30:1512-20. 
5. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, Pennell DJ, McKenna WJ. 
Left-dominant arrhythmogenic cardiomyopathy an under-recognized clinical entity. J Am Coll Car-
diol. 2008;52:2175-87. 
6. Norman M, Simpson M, Mogensen J, Shaw A, Hughes S, Syrris P, Sen-Chowdhry S, Rowland E, 
Crosby A, McKenna WJ. Novel mutation in desmoplakin causes arrhythmogenic left ventricular 
cardiomyopathy. Circulation. 2005;112:636-42. 
7. Oxford EM, Musa H, Maass K, Coombs W, Taffet SM, Delmar M. Connexin43 remodeling caused by 
inhibition of plakophilin-2 expression in cardiac cells. Circ Res. 2007;101:703-11. 
8. Asimaki A, Tandri H, Huang H, Halushka MK, Gautam S, Basso C, Thiene G, Tsatsopoulou A, 
Protonotarios N, McKenna WJ, Calkins H, Saffitz JE. A new diagnostic test for arrhythmogenic right 
ventricular cardiomyopathy. N Engl J Med. 2009;360:1075-84. 
9. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, 
Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, 
Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP, Heart Rhythm Society (HRS), European Heart 
Rhythm Association (EHRA). HRS/EHRA expert consensus statement on the state of genetic test-
ing for the channelopathies and cardiomyopathies: this document was developed as a partnership 
between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). 
Europace. 2011;13:1077-109. 
10. Kaplan SR, Gard JJ, Carvajal-Huerta L, Ruiz-Cabezas JC, Thiene G, Saffitz JE. Structural and molecu-
lar pathology of the heart in Carvajal syndrome. Cardiovasc Pathol. 2004;13:26-32. 
11. Sato PY, Musa H, Coombs W, Guerrero-Serna G, Patino GA, Taffet SM, Isom LL, Delmar M. Loss 
of plakophilin-2 expression leads to decreased sodium current and slower conduction velocity in 
cultured cardiac myocytes. Circ Res. 2009;105:523-6. 
12. De Bakker JM, van Capelle FJ, Janse MJ, Tasseron S, Vermeulen JT, de Jonge N, Lahpor JR. Slow 
conduction in the infarcted human heart. ‘Zigzag’ course of activation. Circulation. 1993;88:915-26. 
13. Cabo C, Pertsov AM, Baxter WT, Davidenko JM, Gray RA, Jalife J. Wave-front curvature as a cause of 
slow conduction and block in isolated cardiac muscle. Circ Res. 1994;75:1014-28. 
14. Fast VG and Kleber AG. Role of wavefront curvature in propagation of cardiac impulse. Cardiovasc 
Res. 1997;33:258-71. 
15. Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, Lerman BB, Markowitz SM, 
Ellinor PT, MacRae CA, Peters S, Grossmann KS, Drenckhahn J, Michely B, Sasse-Klaassen S, 
Birchmeier W, Dietz R, Breithardt G, Schulze-Bahr E, Thierfelder L. Mutations in the desmosomal 





16. Saffitz JE. Dependence of electrical coupling on mechanical coupling in cardiac myocytes: insights 
gained from cardiomyopathies caused by defects in cell-cell connections. Ann N Y Acad Sci. 
2005;1047:336-44. 
17. Basso C, Czarnowska E, Della Barbera M, Bauce B, Beffagna G, Wlodarska EK, Pilichou K, Ramondo 
A, Lorenzon A, Wozniek O, Corrado D, Daliento L, Danieli GA, Valente M, Nava A, Thiene G, 
Rampazzo A. Ultrastructural evidence of intercalated disc remodelling in arrhythmogenic right 
ventricular cardiomyopathy: an electron microscopy investigation on endomyocardial biopsies. Eur 
Heart J. 2006;27:1847-54. 
18. Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury DS, Marian AJ. Sup-
pression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of 
arrhythmogenic right ventricular cardiomyopathy. J Clin Invest. 2006;116:2012-21. 
19. Cox MG, Nelen MR, Wilde AA, Wiesfeld AC, van der Smagt JJ, Loh P, Cramer MJ, Doevendans PA, 
van Tintelen JP, de Bakker JM, Hauer RN. Activation delay and VT parameters in arrhythmogenic 
right ventricular dysplasia/cardiomyopathy: toward improvement of diagnostic ECG criteria. J 
Cardiovasc Electrophysiol. 2008;19:775-81. 
20. Cox MG, van der Zwaag PA, van der Werf C, van der Smagt JJ, Noorman M, Bhuiyan ZA, Wiesfeld AC, 
Volders PG, van Langen IM, Atsma DE, Dooijes D, van den Wijngaard A, Houweling AC, Jongbloed 
JD, Jordaens L, Cramer MJ, Doevendans PA, de Bakker JM, Wilde AA, van Tintelen JP, Hauer RN. 
Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in 
index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dyspla-
sia/cardiomyopathy genotype-phenotype follow-up study. Circulation. 2011;123:2690-700. 
21. Syrris P, Ward D, Asimaki A, Sen-Chowdhry S, Ebrahim HY, Evans A, Hitomi N, Norman M, Pantazis 
A, Shaw AL, Elliott PM, McKenna WJ. Clinical expression of plakophilin-2 mutations in familial 
arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006;113:356-64. 
22. Van Tintelen JP, Entius MM, Bhuiyan ZA, Jongbloed R, Wiesfeld AC, Wilde AA, van der Smagt J, 
Boven LG, Mannens MM, van Langen IM, Hofstra RM, Otterspoor LC, Doevendans PA, Rodriguez 
LM, van Gelder IC, Hauer RN. Plakophilin-2 mutations are the major determinant of familial arrhyth-
mogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2006;113:1650-8. 
23. Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, Zimbello R, Simionati B, Basso C, 
Thiene G, Towbin JA, Danieli GA. Mutation in human desmoplakin domain binding to plakoglobin 
causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 
2002;71:1200-6. 
24. McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, Norman M, 
Baboonian C, Jeffery S, McKenna WJ. Identification of a deletion in plakoglobin in arrhythmogenic 
right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). 
Lancet. 2000;355:2119-24. 
25. Asimaki A, Syrris P, Wichter T, Matthias P, Saffitz JE, McKenna WJ. A novel dominant mutation in 
plakoglobin causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2007;81:964-
73. 
26. Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, Frigo G, Vettori A, Valente M, 
Towbin J, Thiene G, Danieli GA, Rampazzo A. Mutations in desmoglein-2 gene are associated with 
arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006;113:1171-9. 
27. Syrris P, Ward D, Evans A, Asimaki A, Gandjbakhch E, Sen-Chowdhry S, McKenna WJ. Arrhythmo-
genic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal 
gene desmocollin-2. Am J Hum Genet. 2006;79:978-84. 
206
28. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and genetic char-
acterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides 
novel insights into patterns of disease expression. Circulation. 2007;115:1710-20. 
29. Dalal D, Molin LH, Piccini J, Tichnell C, James C, Bomma C, Prakasa K, Towbin JA, Marcus FI, Spevak 
PJ, Bluemke DA, Abraham T, Russell SD, Calkins H, Judge DP. Clinical features of arrhythmogenic 
right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 
2006;113:1641-9. 
30. Christensen AH, Benn M, Tybjaerg-Hansen A, Haunso S, Svendsen JH. Missense variants in 
plakophilin-2 in arrhythmogenic right ventricular cardiomyopathy patients--disease-causing or 
innocent bystanders? Cardiology. 2010;115:148-54. 
31. Christensen AH, Benn M, Bundgaard H, Tybjaerg-Hansen A, Haunso S, Svendsen JH. Wide spec-
trum of desmosomal mutations in Danish patients with arrhythmogenic right ventricular cardiomy-
opathy. J Med Genet. 2010;47:736-44. 
32. Xu T, Yang Z, Vatta M, Rampazzo A, Beffagna G, Pilichou K, Scherer SE, Saffitz J, Kravitz J, Zareba W, 
Danieli GA, Lorenzon A, Nava A, Bauce B, Thiene G, Basso C, Calkins H, Gear K, Marcus F, Towbin 
JA, Multidisciplinary Study of Right Ventricular Dysplasia Investigators. Compound and digenic 
heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 
2010;55:587-97. 
33. Tan BY, Jain R, den Haan AD, Chen Y, Dalal D, Tandri H, Amat-Alarcon N, Daly A, Tichnell C, James 
C, Calkins H, Judge DP. Shared desmosome gene findings in early and late onset arrhythmogenic 
right ventricular dysplasia/cardiomyopathy. J Cardiovasc Transl Res. 2010;3:663-73. 
34. Fressart V, Duthoit G, Donal E, Probst V, Deharo JC, Chevalier P, Klug D, Dubourg O, Delacretaz 
E, Cosnay P, Scanu P, Extramiana F, Keller D, Hidden-Lucet F, Simon F, Bessirard V, Roux-Buisson 
N, Hebert JL, Azarine A, Casset-Senon D, Rouzet F, Lecarpentier Y, Fontaine G, Coirault C, Frank R, 
Hainque B, Charron P. Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/
cardiomyopathy: spectrum of mutations and clinical impact in practice. Europace. 2010;12:861-8. 
35. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev 
SR. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248-9. 
36. Ng PC and Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11:863-
74. 
37. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn 
HS, Adamopoulos S, Liggett SB, Dorn GW, MacLennan DH, Kremastinos DT, Kranias EG. Human 
phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between 
mouse and human. J Clin Invest. 2003;111:869-76. 
38. Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D, 
Parekh RR, Dorn GW,2nd, MacLennan DH, Kremastinos DT, Kranias EG. A mutation in the human 
phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl 
Acad Sci U S A. 2006;103:1388-93. 
39. DeWitt MM, MacLeod HM, Soliven B, McNally EM. Phospholamban R14 deletion results in late-
onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1396-8. 
40. Posch MG, Perrot A, Geier C, Boldt LH, Schmidt G, Lehmkuhl HB, Hetzer R, Dietz R, Gutberlet 
M, Haverkamp W, Ozcelik C. Genetic deletion of arginine 14 in phospholamban causes dilated 
cardiomyopathy with attenuated electrocardiographic R amplitudes. Heart Rhythm. 2009;6:480-6. 
41. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, 
Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn 




arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force 
criteria. Circulation. 2010;121:1533-41. 
42. Den Haan AD, Tan BY, Zikusoka MN, Llado LI, Jain R, Daly A, Tichnell C, James C, Amat-Alarcon N, 
Abraham T, Russell SD, Bluemke DA, Calkins H, Dalal D, Judge DP. Comprehensive desmosome 
mutation analysis in North Americans with arrhythmogenic right ventricular dysplasia/cardiomy-
opathy. Circ Cardiovasc Genet. 2009;2:428-35. 
43. Garcia-Pavia P, Syrris P, Salas C, Evans A, Mirelis JG, Cobo-Marcos M, Vilches C, Bornstein B, 
Segovia J, Alonso-Pulpon L, Elliott PM. Desmosomal protein gene mutations in patients with 
idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study. 
Heart. 2011;97:1744-52. 
44. Elliott P, O’Mahony C, Syrris P, Evans A, Rivera SC, Sheppard MN, Carr-White G, Pantazis A, 
McKenna WJ. Prevalence of desmosomal protein gene mutations in patients with dilated cardiomy-
opathy. Circ Cardiovasc Genet. 2010;3:314-22. 
45. Koopmann TT, Beekman L, Alders M, Meregalli PG, Mannens MM, Moorman AF, Wilde AA, Bezzina 
CR. Exclusion of multiple candidate genes and large genomic rearrangements in SCN5A in a Dutch 
Brugada syndrome cohort. Heart Rhythm. 2007;4:752-5. 
46. Corrado D, Fontaine G, Marcus FI, McKenna WJ, Nava A, Thiene G, Wichter T. Arrhythmogenic 
right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on 
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial 
and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific 
Council on Cardiomyopathies of the World Heart Federation. Circulation. 2000;101:E101-6. 
47. Hamid MS, Norman M, Quraishi A, Firoozi S, Thaman R, Gimeno JR, Sachdev B, Rowland E, 
Elliott PM, McKenna WJ. Prospective evaluation of relatives for familial arrhythmogenic right ven-
tricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol. 
2002;40:1445-50. 







Arrhythmogenic cardiomyopathy is a progressive, heritable myocardial disorder 
resulting in ventricular arrhythmias and sudden cardiac death, but also in end-stage 
heart failure.1 Initially, it was believed that the disease resulted from abnormal devel-
opment of the right ventricle, resulting in the term “right ventricular dysplasia”.2 
Early publications described involvement of the right ventricle, which was con-
sidered the classic subtype of the disease. More recently however, involvement of 
both ventricles and left ventricular predominance have been described.3-5 The terms 
“right ventricular” and “dysplasia” seem to be outdated and the preferred term for 
this type of inherited cardiomyopathy is now “arrhythmogenic cardiomyopathy” 
(ACM). The disease usually presents in young adolescence or early adulthood, but 
a diagnosis in children under the age of 10 years is rare.6,7 Genetic causes, mainly 
mutations in genes encoding for desmosomal proteins, can be identified in about 
50% of cases. 
 The first part of this thesis describes genetic studies and phenotypic charac-
terisation in ACM. Chapter 2 describes the application of the haplotype-sharing 
test to identify disease-causing mutations. Many families affected with a subtype 
of cardiomyopathy are too small to perform classical linkage analysis. We therefore 
performed the haplotype-sharing test to search for large shared segments in the 
individuals’ genomes that are most likely to contain the causative mutation in a 
family. Affected individuals will have inherited the haplotype with this mutation from 
a common ancestor. The common ancestor could be from several generations ago, 
so that the affected individuals might be unaware of the fact that they are related to 
each other. DNA from proven affected family members was genotyped using single 
nucleotide polymorphism (SNP) arrays and the data from these analyses were com-
bined to search for shared haplotypes. Both a family with ACM and a family with 
dilated cardiomyopathy (DCM) were analysed using the haplotype-sharing test. In 
both pedigrees, we searched for mutations in the genes located in the largest shared 
haplotypes and we were able to identify mutations in PKP2 and MYH7, respectively. 
Furthermore, we calculated that with a pedigree containing at least seven meioses, 
the chances are high that the largest shared haplotype will be the one to contain 
the causative mutation. This proof-of-principle study showed that the haplotype-
sharing test can assist in identifying causative genes in families with low penetrance 
Mendelian diseases, in which standard tools cannot be used because of insufficient 
pedigree information. The haplotype-sharing test can also be used if a common 
ancestor is suspected based on the place of birth of the individuals, even if they are 
not known to be related.
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Chapter 3 describes molecular studies on the PKP2 mutation identified in 
chapter 2, together with the clinical data of the mutation carriers. The identified 
PKP2 splice site mutation (c.2489+4A>C) is predicted to lead to the expression of 
a dysfunctional PKP2 protein, rather than a loss-of-function protein. The clinical 
manifestations in mutation carriers ranged from severe disease to non-penetrance 
in elderly mutation carriers. This study suggests that this PKP2 mutation alone is 
not sufficient to cause disease and that other genetic and/or environmental factors 
also contribute to the development of the disease. This exemplifies the variable 
expression and incomplete penetrance characteristic of ACM.
Founder mutations are frequently identified in Dutch patients with inherited 
cardiac diseases. Chapter 4 describes the largest series of patients with the same 
founder mutation in the PKP2 gene (p.Arg79X). Twelve index patients and 41 family 
members were evaluated. Haplotype analysis revealed a shared haplotype among 
all mutation carriers, indicating a common founder. Sudden cardiac death (SCD) 
in individuals younger than 40 years of age had occurred in 50% of these families, 
while only 60% of the mutation carriers had experienced any symptoms by age 60, 
again illustrating the clinical variability and reduced penetrance in ACM. 
The pathogenicity of identified genetic variants in ACM patients is not always 
clear. In Chapter 5, the genetic variants database for ACM (available from www.
arvcdatabase.info) is described in detail. This freely available, online database lists 
the genetic variants in genes associated with ACM and is a digital repository for both 
molecular data and all the publications containing additional information on clinical 
and/or genetic data of identified variants. In June 2012, the database contained 
856 variants and data from 111 publications. The database has been proven to be 
useful: since its launch in October 2008, it has been visited 125,000 times by 11,500 
returning visitors from more than 50 countries.
Chapter 6 reports a large cohort of Dutch ACM families, collected in all the 
university medical centres in the Netherlands. To gain more insight into the natu-
ral variability of the disease expression and phenotypic consequences of genetic 
findings in ACM, all five desmosomal genes were sequenced in 149 Dutch ACM 
index patients. In total, 302 family members were screened for carriership of the 
identified pathogenic mutations in their family. Pathogenic mutations were found in 
58% of index patients; these were mainly truncating PKP2 mutations but included 
three cases with PKP2 exon deletions. A PKP2 mutation could be identified in 90% 
of families with more than one affected individual. The discovery of a pathogenic 
mutation in index patients enabled the identification of those relatives who have 





The second part of this thesis focuses on the identification of a founder mutation 
in the phospholamban gene (PLN p.Arg14del) in a substantial number of Dutch 
patients with ACM and/or DCM. The clinical characteristics of index patients car-
rying this mutation are outlined in Chapter 7. A cohort of 97 unrelated ACM index 
patients and 257 unrelated DCM index patients was screened for PLN mutations. 
The p.Arg14del mutation was identified in 12% of ACM patients and in 15% of 
DCM patients in the Netherlands. This is the highest single mutation yield reported 
in Dutch cardiomyopathy patients. Patients carrying the PLN p.Arg14del mutation 
presented with a low voltage ECG in 46% of cases and demonstrated an arrhythmo-
genic phenotype, with high rates of appropriate implantable cardioverter defibrilla-
tor (ICD) discharges, cardiac transplantation, and a family history of sudden cardiac 
death. The average age of 26 family members who died of SCD was 37.7 years. 
Surprisingly, immunohistochemical analysis in myocardial samples, considered a 
diagnostic test for ACM, revealed absent or depressed plakoglobin levels at interca-
lated disks in five of seven (71%) p.Arg14del ACM samples, but in only one of nine 
(11%) p.Arg14del DCM samples. This chapter illustrates how one mutation can 
result in different clinical diagnoses, in this case both ACM and DCM, and that there 
is an overlap between these inherited cardiomyopathy subtypes.
The geographical distribution of carriers of this PLN founder mutation in the 
Netherlands is described in Chapter 8. Haplotype analysis revealed a common 
founder, estimated to be between 575 and 825 years old. Over 450 carriers have 
been identified and the majority live in the northern part of the Netherlands, includ-
ing the province of Noord-Holland. Analysis of their grandparents’ places of birth 
indicated that the mutation likely originated in the eastern part of the province 
Friesland. Screening of a large population-based cohort (PREVEND) for the pres-
ence of this mutation identified six PLN p.Arg14del mutation carriers out of 8,267 
subjects (0.07%). These findings illustrated that the PLN p.Arg14del mutation is 
highly prevalent in the general population in the northern part of the Netherlands 
and that this mutation is also one of the most prevalent cardiomyopathy related 
genes in other parts of the Netherlands.
In Chapter 9, a large pedigree with ACM was studied. A previously identified 
mutation in PKP2 (p.Ser140Phe) was found not to co-segregate with the disease in 
this family. After meticulous phenotypic characterisation, we could find no evidence 
that the PKP2 variant contributed to the disease. However, the PLN p.Arg14del 
mutation was present in all family members with ACM and all of them had left 
ventricular involvement. Out of nine identified mutation carriers, four also had a 
low voltage ECG.
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In patients with inherited cardiomyopathy the identification of a pathogenic muta-
tion can confirm the diagnosis and subsequently asymptomatic relatives can be 
identified after cascade family screening. Clinical geneticists are at the heart of 
multidisciplinary teams consisting of genetic counsellors, molecular geneticists, 
cardiologists, pathologists, neurologists, and researchers, who together care 
for cardiomyopathy patients and their families. Following the recent advances in 
genetic research, as addressed in the General discussion, many novel mutations 
will be identified and counselling these families will become increasingly difficult. A 
challenging future lies ahead for clinical geneticists and their colleagues, but their 






In the last two decades, genetic research in families with cardiomyopathy has 
rapidly shifted from basic science towards routine clinical application, thereby 
changing the clinical practice. For instance, it has resulted in the fact that nowadays 
genetic counselling is recommended for all patients and their relatives with cardio-
myopathy.8 The yield of genetic testing for cardiomyopathies ranges from <20% for 
restrictive cardiomyopathy to around 60% for hypertrophic cardiomyopathy.8 This 
means that currently no mutation can be identified in 40-80% of index patients with 
a suspected inherited form of cardiomyopathy. It is important to realise that not all 
forms of idiopathic cardiomyopathy are genetic. Unknown environmental factors 
could cause isolated or even familial cases of cardiomyopathy in the absence of 
a pathogenic mutation, so a yield of 100% is highly unlikely. Another factor that 
hampers genetic analyses in cardiomyopathy patients is the genetic heterogeneity. 
This is especially the case in dilated cardiomyopathy (DCM) where nearly 50 genes 
have now been identified, but most of these genes are found to hold mutations in 
only a small percentage of cases or even in single families. The recent identification 
of truncating titin gene (TTN) mutations in 25% of familial DCM cases is the excep-
tion to this rule.9 Due to the high costs and laborious tests, many cardiomyopathy 
patients will usually be screened for mutations in only a few genes. As a result, only 
the genes that supposedly account for the highest percentage of cases are being 
analysed. Sequence analysis of the remaining genes is hardly ever performed, and 
a definite diagnosis cannot be made in many cases.10 In general, it is rare that we 
have any clinical clues to guide the genetic screening in inherited cardiomyopathies. 
Examples of phenotypical information that could guide specific genetic testing are 
the presence of cardiac conduction disorders in ACM or DCM, which are frequently 
observed in patients with mutations in the LMNA, DES, and SCN5A genes,11-13 or 
relatively less hypertrophy in patients with HCM caused by mutations in the TNNT2 
gene.14 Moreover, mutations can be present in more than one gene and the number 
of mutations can sometimes be related to the clinical impact; the involvement of 
two or three genes is usually associated with a more severe clinical picture.15-19 
The identification of multiple mutations that can be associated with the pheno-
type poses a great challenge for clinical and molecular geneticists. Cardiomyopa-
thies have previously been considered to be monogenic disorders, but the presence 
of multiple mutations indicates a more complex genetic background. A pathogenic 
mutation could be potentiated by other variants present in the same gene, in other 
genes, or even in the intergenic region. On the other hand, additional mutations 
could also reduce the strength of a pathogenic mutation. The presence of such 
additional mutations could explain the large clinical variability seen in patients and 
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within families with inherited cardiomyopathies. At the same time, this illustrates the 
importance of correctly interpreting the identified variants. Although in silico predic-
tion programs and co-segregation analysis can assist, a lack of functional data and 
animal models hampers our interpretation of the mutations identified. Frequency 
data on identified mutations can be helpful, but large series of well-characterised 
patients are needed to establish enhancing or reducing effects between mutations. 
The gathering of genetic data is rapidly becoming easier but, as a result, the clas-
sification and interpretation is becoming more and more challenging. To establish 
the effects of variants of unknown significance, we need to perform large-scale func-
tional studies, but these are expensive and laborious. Gehmlich et al. studied DSC2 
mutations identified in ACM patients by expressing mutant proteins in multiple 
cellular systems.20 A Western blot of the p.Thr275Met mutant protein, expressed in 
COS-1 cells, showed an impaired maturation process from the uncleaved precursor 
form to the cleaved mature form. The p.Arg203Cys protein was only detected in the 
precursor form. Localisation studies of the DSC2 mutants in the cardiac cell line 
HL-1 showed that the p.Thr275Met protein was able to localise in the desmosomes, 
but a shift towards vesicular and Golgi apparatus localisation was observed. The 
p.Arg203Cys protein failed to localise at the cell borders and was absent from des-
mosomal structures.20 These results show how functional assays could aid in the 
interpretation of (missense) mutations. 
The study of mutations in zebrafish (Danio rerio) could be another approach 
for systematic mutation screens. Zebrafish that carried human Nexilin (NEXN) 
mutations, introduced by PCR mutagenesis, showed a similar cardiac pathology as 
human NEXN mutation carriers, including induced Z-disk damage and heart failure, 
confirming the disease-causing nature of these mutations.21 
These approaches are not yet available for large-scale use, due to the needed 
time and resources. A model that classifies identified mutations without the need of 
additional experiments would be very helpful in this era of rapid emerging genetic 
data. A classification system combining in silico prediction methods and a structural 
model with phenotypic and segregation data to predict CHD7 missense variants 
in CHARGE syndrome has been published.22 The model led to a more confident 
prediction of pathogenicity. Such a model could also be useful for the classification 
of missense variants in cardiomyopathy related genes. The incorporation of seg-
regation studies, however, is difficult in inherited cardiomyopathies, since carriers 
of pathogenic mutations associated with cardiomyopathy could be mildly affected 
or even unaffected, given the variable expression and incomplete penetrance. The 
confirmation of model-based predictions by functional assays would be a powerful 




Given the challenges in the inpterpretation of variants, counselling patients and 
their families will also become increasingly difficult. Multiple variants are being 
identified in cardiomopathy patients and the effects of these variants, both private 
and in combination with others, are often not yet understood. However, the identi-
fication of a pathogenic mutation can be of great clinical significance for the index 
patient under evaluation, because some genes are associated with important phe-
notypes such as early onset and/or sudden cardiac death, which could be prevented 
by placing an implantable cardioverter defibrillator.23,24 Much effort and resources 
are needed to correctly interpret identified variants. When a variant is classified as 
disease-causing or disease–contributing, cascade genetic screening of family mem-
bers can be initiated. Those family members who are found not to be a carrier of the 
identified mutation(s) can be dismissed from frequent follow-up, further illustrating 
the importance of genetic testing in patients with cardiomyopathy.25 
The study of induced pluripotent stem cells (iPSCs), derived from patients with 
inherited cardiomyopathy, offers an opportunity for creating disease-specific cellular 
models to investigate underlying mechanisms. Generated cardiomyocytes from 
iPSCs derived from DCM patients carrying a mutation (p.Arg173Trp) in the TNNT2 
gene recapitulated the morphological and functional phenotypes of DCM to some 
extent.26 Compared to controls, these cardiomyocytes exhibited altered calcium reg-
ulation and decreased contractility. Treatment with β-adrenergic blockers improved 
the function of iPSC-derived cardiomyocytes from DCM patients, illustrating that 
these cells may serve as a useful platform for exploring the effects of identified 
mutations and disease mechanisms.26 In another study, generated cardiomyocytes 
from iPSCs from a patient with ACM, carrying a p.Leu614Pro mutation in the PKP2 
gene, showed reduced cell surface localisation of desmosomal proteins and a more 
adipogenic phenotype.27 These patient-specific cells may therefore be a useful tool 
to study these cardiomyopathies and although iPSC-studies cannot discriminate 
between multiple mutations identified in one patient, these studies could prove to 
be usefull in selecting specific therapeutic options.
Mutation detection arrays
After years of serial testing of one or a few genes at a time, several customised 
resequencing arrays have recently been developed to sequence large numbers of 
genes in parallel, in a cost-efficient manner. Analysis of all coding exons, splice site 
junctions and 5’ untranslated regions of 12 genes in 38 unrelated HCM patients led 
to the identification of a pathogenic mutation in 60% of familial cases and in 10% 
of sporadic cases.28 A similar approach was applied in 73 previously tested DCM 
patients, who were screened for mutations in 19 genes using the ‘DCM CardioChip’. 
Combined with previously published data, the authors calculated a clinical sensitiv-
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ity for this chip of 26-29% (notably, the chip did not include the TTN gene).29 Since 
not many clear genotype-phenotype relationships have been identified that can 
guide the genetic screening in inherited cardiomyopathies, sequencing of multiple 
genes in the same experiment is a reasonable approach to adopt and several arrays/
chips are now commercially available. 
next-generation sequencing
Rapid technological advances have led to the application of novel platforms which 
supersede the array/chip techniques. The introduction of so-called next-generation 
sequencing (NGS) has led to spectacular developments in genetic research. Sanger 
sequencing is currently being replaced by different sequencing technologies able 
to rapidly sequence millions of nucleotides in multiple samples in parallel. Next-
generation techniques are based on library preparation: Genomic DNA is randomly 
broken into small fragments. These fragments are hybridised using a library con-
taining the sequences of the genes of interest. In the next step, these fragments are 
amplified and sequenced. Imaging techniques and bioinformatics tools enable the 
generation of large volumes of sequence data and the identification of mutations 
in the patient’s DNA. The risk of false-positive results (i.e. erroneously reported 
mutations which are not actually present) due to technical and bioinformatical limi-
tations of these methods means the reported mutations must be confirmed, which 
is still done by Sanger sequencing.30 These targeted platforms can generate a large 
coverage (the number of reads covering a specific DNA sequence), thereby lowering 
the risk of false-positives. In our first series of 96 cardio myopathy patients, we found 
no false-positives after confirming 40 identified variants. In addition, we identified 
all the 91 variants previously detected using Sanger sequencing (unpublished data).
Targeted enrichment of DNA fragments encoding known (or suspected) disease 
genes is a promising application of NGS in the field of inherited cardiomyopathies.10 
A proof-of-principle study analysed 47 cardiomyopathy-related genes in five HCM 
and five DCM patients. The targeted approach was applied to increase the coverage 
of the genomic regions of interest, i.e. the 47 genes, which was increased more than 
2,000-fold compared to the whole genome. A pathogenic mutation was identified in 
six of these ten patients.31 The authors stated that the results can be made available 
within two weeks and the testing costs less than $1,800 (€1,500). In our laboratory, 
using a targeted approach containing 50 cardiomyopathy genes, the results can 
be available within three weeks and cost around €400 for the enrichment kit and 
sequencing chemicals, but excluding salaries and overhead. 
Sequencing of dozens of genes in a single experiment will lead to the identifi-
cation of several previously unknown variants, of which only one or a few will be 




in our series of 96 cardio myopathy patients (unpublished data). Multiple affected 
family members could be studied to gain more insight in the pathogenicity of the 
identified variants. A variant present in all affected individuals but absent in healthy 
family members and controls is more likely to be pathogenic, but variants that are 
only identified in some or even only one of the affected family members could still 
contribute to the disease in that individual. The interpretation of identified variants 
is, as mentioned above, a major challenge and will likely be the bottleneck in genetic 
studies of inherited cardio myopathies. Much more data will become available with 
the increased speed and lower costs of next-generation sequencing, but the inter-
pretation of many novel variants requires expertise, time and additional studies, 
which are often not readily available. 
A drawback of any custom-made approach is that they will unavoidably miss 
the genes that are identified after the panel has been designed. In 2011 three novel 
cardiomyopathy genes were discovered (Figure 1 in Chapter 1),32-35 illustrating the 
rapid developments being made in inherited cardiomyopathies. 
exome sequencing
The disadvantage of the non-incorporated genes in custom panels can be overcome 
by targeting the entire protein-coding sequence of the genome, called the ‘exome’. 
The exome encompasses ~1% of the genome and includes 180,000 exons from 
more than 20,000 genes. After enrichment of the exome, similar NGS techniques 
can be applied as described above. Since all coding regions are targeted in exome 
sequencing, a large number of variants are identified for each sample. Typically, 
each exome contains between 20,000 and 50,000 variants.36 Multiple bioinformati-
cal filtering steps have to be applied to limit the number of potential disease-causing 
variants. Quality control steps will exclude those variants that have insufficient cov-
erage, i.e. only a few sequence reads are aligned at a certain position, or are of low 
confidence, e.g. because only a low percentage of the reads contain a supposedly 
heterozygous variant. Non-coding variants and synonymous variants are usually 
filtered out, although non-coding variants in the promoter or untranslated region of 
a gene could be pathogenic and synonymous variants could influence mRNA splic-
ing. Together with the exclusion of known variants from databases such as dbSNP, 
the 1000 Genomes Project, the Genome of the Netherlands project and/or in-house 
databases, the initial number of variants will be reduced by ~99%. However, filtering 
merely based on the presence in a database carries the risk that truly pathogenic 
variants may be excluded, since these pathogenic variants can be listed in the data-
bases (known for dbSNP) and because recessive variants with relatively large carrier 
frequencies could also be listed. After these filtering steps, the remaining 150-500 
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private and potentially pathogenic variants will need further (in silico) analysis to 
single out the causative mutation or mutations.36
Exome sequencing has been shown to be a very powerful tool in identifying 
disease-causing genes in a variety of Mendelian disorders.37 In particular, mutations 
in autosomal recessive diseases and de novo mutations in autosomal dominant 
diseases have been identified using this approach in recent years. In cases of reces-
sively inherited disorders and suspected consanguinity, the pathogenic mutations 
are most likely homozygous. When there is no evidence of consanguinity, the 
pathogenic variants could be compound heterozygous, i.e. two different mutations 
in both alleles of the same gene. Notably, homozygous mutations can also be identi-
fied in the absence of consanguinity. Prioritising for genes with two mutations can 
reduce the number of candidate genes to as few as seven or less, using a sample 
from only a single patient.38-41
As with recessive disorders, the identification of de novo mutations has been 
shown to be feasible with exome sequencing, using a trio design with sequencing of 
the parents and the affected offspring. Sporadic diseases with a reduced reproduc-
tive capacity could be recessive, but could also be caused by de novo autosomal 
dominant mutations. These mutations can be selected by filtering out all variants 
that are present in the parents’ exomes. This strategy has been used to identify 
mutations in mental retardation, autism, and schizophrenia.42-44 The reported rates 
of de novo coding mutations ranged from 0.75 to 0.90 per trio in these studies, 
which is in agreement with the calculation that, on average, a newborn has 50 to 
100 de novo mutations in his or her genome, resulting in approximately 0.86 de novo 
amino acid-altering mutations.45
The identification of a mutation in an autosomal dominant pedigree is more 
difficult, since all shared heterozygous variants could be disease-causing. However, 
succesfull cases in which the causative mutation was found have recently been 
reported: In a family with autosomal dominantly inherited amyotrophic lateral 
sclerosis, exome sequencing was combined with linkage analysis to identify the 
causative mutation.46 In a large family with Charcot-Marie-Tooth disease, exome 
sequencing in three affected individuals, separated by eight meioses, identified only 
one variant shared by each individual.47  
exome sequencing for cardiomyopathies
Unfortunately, the powerful strategies mentioned in the previous section are not 
very suitable for the genetically heterogeneous inherited cardiomyopathies, since 
they are mostly autosomal dominantly inherited and the affected families are often 
small. De novo mutations have been described in cases of cardiomyopathy,48-52 but 




restricted cardiomyopathy.53,54 However, assuming a de novo mutation in a cardio-
myopathy patient is dangerous, since incomplete penetrance could well explain the 
absence of a phenotype in a parent who is a carrier of the causative mutation.
To apply exome sequencing in families with autosomal dominant diseases such 
as inherited cardiomyopathies, additional steps need to be taken. Combining exome 
sequencing with linkage strategies is a possible solution to this problem. In a fam-
ily with recessively inherited cardiomyopathy, linkage analysis and homozygosity 
mapping identified the disease locus on chromosome 7q21. Exome sequencing of 
two affected sisters revealed a single shared homozygous missense mutation in the 
GATAD1 gene, located on the 7q21 locus.34 We have shown that a haplotype-sharing 
test (HST) using SNP-arrays can help in identifying shared loci which are most likely 
to contain the causative mutation. In the reported families, cardiomyopathy associ-
ated genes were located in these regions and mutations in PKP2 and MYH7 were 
identified.55 In another family with dilated cardiomyopathy, by applying the HST 
and exome sequencing, we identified a TTN mutation located in the second-largest 
shared haplotype.56 A similar approach identified a TTN mutation in four patients 
with hereditary myopathy with early respiratory failure, who were later found to share 
a haplotype containing the TTN gene, indicating a common ancestor.57 
Since classic linkage analysis is often not feasible in cardiomyopathy families, 
due to the small family sizes and the incomplete penetrance, a combined approach 
of the HST and exome sequencing, preferably with sequencing of at least two 
affected family members, could be successful. Even in small families, the HST could 
be useful, since each informative meiosis excludes 50% of the genome. Although 
the studies mentioned above used SNP arrays for the haplotyping or linkage studies, 
it is possible to infer haplotypes from the available exome data from multiple family 
members. This has been shown for the autosomal recessive hyperphosphatasia-
mental retardation syndrome.58
Exome data could also be used for a targeted approach. In this case there is no 
targeted capturing of genes associated with cardiomyopathy, but a targeted bioin-
formatics filtering for variants in any of these cardiomyopathy-related genes. At the 
moment, this may be more expensive and laborious, and more important, current 
exome enrichment strategies still result in incomplete representation and coverage 
of exons of interest, which would result in clinically relevant mutations being missed 
(see also below). However, when these strategies are improved, an advantage of 
exome sequencing will be that newly reported disease genes can be studied using 
the already available data without the need to perform new experiments. With falling 
costs, exome sequencing will eventually be replaced by whole-genome sequencing, 
enabling the study of the non-coding part of the genome, in addition to the exome.
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drawbacks of exome sequencing
Although exome sequencing will be successfully applied in many more Mendelian 
diseases in the coming years, there are a number of drawbacks that need to be 
recognised. The definition of the exome is not a strict or universal one. Different 
commercial exome platforms target different exonic segments; the comparison of 
Nimblegen, Agilent, and Illumina platforms showed that the targeted regions ranged 
from 44 Mb to 62 Mb and from 188,000 exons to 300,000 exons.59,60 So depending 
on the selected platform, the gene(s) and/or exon(s) containing the disease-causing 
mutation(s) could not be targeted at all and therefore these mutations will not be 
identified using that platform. When taking a 10-fold coverage as a minimum, the 
overall targeting efficiency for each platform (at 80 million reads), ranged from 
96.8% for Nimblegen, to 90.0% for Illumina, and 89.6% for Agilent.60 This shows 
that up to 10% of the exome would not pass the quality control filters if set at ≥10 
fold coverage for a large (80 million reads) dataset, so in one out of ten cases, the 
causative mutation might be missed due to a lack of coverage. To overcome this 
issue, more reads could be sequenced but this will mean higher costs. 
The filtering steps used could also filter out the mutation due to bioinformatic 
problems, e.g. the presence of the mutation in a control cohort such as dbSNP. If 
the mutation is a synonymous variant which results in cryptic RNA splicing, this 
variant is also likely to be excluded during filtering. Large insertions or deletions 
might also be missed, although these can be detected by using array-comparative 
genomic hybridisation (array-CGH) or might be detetcted by still to be developed 
bioinformatical tools that will be able to deduce copy number information from 
exome data. In addition, when the cause of the disease is located outside the 
exome, i.e. in the non-coding region of the genome, this will not be targeted with an 
exome platform. To search for variants outside the coding regions, whole-genome 
sequencing could be performed. As for exome sequencing, performing whole-
genome sequencing will result in very large amounts of data that cannot be easily 
interpreted at the moment, although whole-genome sequencing will become more 
informative in the future and could also be applied for genome-wide association 
studies and linkage analysis. With falling costs, a transition from exome sequencing 
to whole-genome sequencing can be anticipated. The non-targeted whole-genome 
sequencing approach will result in a more proportionate distribution of sequence 
reads and therefore in higher coverage.
Genetic strategy for cardiomyopathies
A scheme for the genetic analysis of patients diagnosed with cardiomyopathy is 
shown in Figure 1. Depending on the phenotype and the costs, one or a few can-
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Genetic analysis in a cardiomyopathy patient 
Consider: 
• Performing HST/linkage analysis 
• Whole-genome sequencing 
• Array CGH 
• Missed mutation  




Sanger sequencing of candidate gene(s) 
Mutation identified? 
YES NO 
Interpretation and classification  
of identified variants 
figure 1 Schematic overview for the genetic analysis in inherited cardiomyopathies. Sanger sequencing of 
one or a few candidate genes should be considered first. If not performed or no mutations are identified, 
different next-generation sequencing strategies could be used, depending on the available resources. 
Targeted analaysis could be performed using targeted enrichment or after targeted filtering of exome 
or whole-genome data. If no mutation is identified, several options could be considered, e.g. missing 
a mutation due to erroneous filtering. The interpretation and classification of the identified variants 
is the ultimate and most challenging step in the identification of pathogenic mutations in inherited 
cardiomyopathies.
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patients with ACM, this would mean that sequencing of the PKP2 gene, and the 
PLN gene in the case of Dutch ancestors, should be performed first, especially in 
familial Dutch cases, which are in 90% of cases caused by PKP2 mutations,61 and 
the remaining 10% is almost completely caused by PLN mutations (unpublished 
data). If no causative mutation can be identified or multiple mutations are expected, 
as is the case in about 6% of ACM patients (see Introduction; Table 3), or as could 
be indicated by the severity of the disease, a targeted analysis could be performed. A 
targeted approach as a first step is justified for DCM patients, since so many genes 
are associated with the disease. It depends on the available resources whether 
this could be done by targeted enrichment of the known cardiomyopathy genes or 
by exome sequencing with targeted filtering. Although we have not identified any 
false-positive variants using our targeted approach, Sanger sequencing could be 
used to confirm true-positive calls and can subsequently be used for co-segregation 
analysis and cascade screening in family members. If no mutation is identified, 
the haplotype-sharing test or another type of linkage analysis should preferably be 
combined with exome sequencing. This requires sampling of additional affected 
family members. If no mutation can be identified using thess strategies, several 
other options can be considered. First, the option that the disease is not genetic, 
which should of course be considered from the start, but it becomes more likely 
after extensive genetic research has not pinpointed a genetic cause. Second, the 
genetic cause could have been missed due to one of the reasons mentioned in the 
previous section and alternative techniques like array-CGH should be considered. 
Third, future developments could help identify a mutation in a patient. These could 
be: (a) genetic findings, e.g. non-coding variants identified using whole-genome 
sequencing and/or epigenetic changes (i.e. heritable changes in gene expression 
without changes in their coding sequence). Examples of such changes are histone 
modification and DNA methylation.62 (b) clinical developments in the family of a 
patient could also provide new insight; if more family members go on to develop 
the disease the likely success of haplotype sharing and filtering for shared variants 
will increase. So, after a certain period, a family could be re-evaluated, using new 
information. 
risk stratification and personalised medicine
The implementation of exome or whole-genome sequencing will have a large impact 
on patient care. The identification of a genetic cause for the disease is only the start-
ing point of the influence of genetic information. It can aid in making a more accu-
rate diagnosis and prognosis, in choosing treatment options, and further enables 
other family members at risk for the disease to be identified. Genetic information 




study on risk factors for malignant ventricular arrhythmias in carriers of mutations 
in the LMNA gene, the presence of a truncating or splice mutation was found to 
be an independent risk factor, when compared to missense mutations.63 Another 
example is the long QT syndrome type 1 (LQTS1), a disease characterised by a 
prolonged QT interval and life-threatening arrhythmias, caused by mutations in the 
KCNQ1 gene. SNPs in the 3’ untranslated region of the KCNQ1 gene were found 
to greatly modify disease severity in LQTS1 patients.64 Compared with LQTS type 2 
and type 3, beta-blocker therapy is more efficient in patients with LQTS1, illustrating 
a genotype-specific response and the importance of knowing the mutated gene.65 
Although these are illustrative examples, risk-stratification and treatment strategies 
based on the genetic background will remain unavailable for the majority of patients 
with inherited cardiomyopathies until large-scale collaborative studies have been 
performed. Given the genetic heterogeneity of the cardiomyopathies, this will be a 
great challenge.
In pharmacogenomics, genetic variation is being used to tailor drug therapies. 
These variations could modulate the pharmacokinetics of a drug, e.g. by slowing 
down its metabolism, resulting in increased availability of the compound and thus 
requiring a lower maintenance dose. A well-known cardiovascular example is the 
anti-coagulant drug warfarin: polymorphisms in three genes have been identified 
as influencing the appropriate dose of warfarin and dosage regimens based on the 
genotype data have been shown to reduce the risk of hospitalisation.66,67 Over 2,000 
genes have been suggested to be involved in drug response, but the pharmacoge-
nomics of cardiovascular disease is not yet established in clinical practice.68 With 
the increasing emergence of genetic information, the use of pharmacogenomics 
will progress, but we should be cautious about being too optimistic, because it 
may prove to be like gene-therapy, which seemed very promising at first, but turned 
out to be much more difficult than anticipated. For instance, in pharmacogenomics 
we cannot exclude that proven effects of certain polymorphisms are enhanced or 
undone by other genetic variants that remain to be elucidated. 
A nice example on the incorporation of whole-genome sequencing in risk assess-
ment was published recently.69 The authors reported the presence of 69 pharma-
cogenomic variants, of which 63 had previously been reported and six were novel 
but located in genes related to drug response. Furthermore, they used the genotype 
status for SNPs that have been associated in numerous genome-wide association 
studies to estimate disease probabilities for 55 diseases. For 15 of these diseases, 
the genetic risk was increased or decreased, defined by a likelihood ratio of >2 or 
<0.5, based on the genotype data.69
Several companies are nowadays offering SNP genotyping arrays to calculate 
personalised genetic risks directly to consumers. With the decreasing costs, such 
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companies will be offering exome or whole-genome sequencing in the near future. 
Patients will bring their own genetic data to their appointment with a clinical geneti-
cist or other medical doctor, who will be expected to be able to judge these data 
in an appropriate way. Even though the significance of many variants will remain 
unknown for a long time, well-known pathogenic mutations will also be revealed 
and these will need appropriate interpretation and management. Clinical geneti-
cists and genetic counsellors are trained to counsel patients and families about 
their genetic risks. Ideally, individuals are being counselled about their risks and 
the consequences of test results before genetic testing is started. With increasing 
uptake of commercially available genetic tests, however, more and more individuals 
will not seek genetic counselling until after genetic testing. These companies could 
hire geneticists to deal with questions from their consumers, but clinical geneticists 
and other health care professionals need to be aware that the impact of genetic 
information will rapidly increase. A boom could be expected, but even likely this 
is followed by decreased enthousiasm of consumers when they realise that at the 
moment much of their genetic data is non-informative or not interpretable with the 
current knowledge.
Taken together, the rapid progress in genetics in recent years will revolutionise 
the field of medicine, offering great opportunities to improve the care of patients 
but at the same time introducing many challenges. The available exome or whole-
genome data of patients will contain many variants of unknown significance. Correct 
interpretation of these variants will need reliable prediction models and preferably 
large-scale functional assays, which will form the new bottleneck in the genetic 
assessment of patients. In the case of arrhythmogenic cardiomyopathy, in the five 
desmosomal genes alone, multiple variants are expected to be present in 6% of 
patients. In theory, these additional variants could explain the clinical variability 
seen between patients and within families, but in practice the weight of each vari-
ant and their possible interactions are very hard to determine. The presence of a 
pathogenic mutation in a patient with arrhythmogenic cardiomyopathy indicates a 
risk for a malignant course of the disease, but genotype-specific treatment is, as yet, 
unavailable.
It is important to note is that non-targeted approaches such as exome and 
whole-genome sequencing could identify mutations in genes not related (or not 
yet known to be related) to the disease, but which could be clinically relevant. An 
example of such an accidental finding would be the identification of a mutation 
in the BRCA1 gene, which conveys an increased risk of breast cancer and ovarian 
cancer. Genetic counselling is therefore of the utmost importance. Not all patients 




for, even if surveillance and treatment options are available, illustrating the need 
for proper counselling and informed consent. Whether or not there is a duty for the 
physician to recontact the patient on discovering something which may, or certainly, 
impact their (later) health is part of an unresolved legal and ethical discussion.70 
In theory, insurance companies could use genetic data to assess the risks of 
individuals and increase their premium, or even exclude individuals at higher risk. 
To protect individuals from discrimination by life or health insurance companies on 
the basis of their genetic information, genetic non-discrimination legislation has 
now been introduced in most European countries, beginning in 1990 in Belgium. 
Since 2008, the United States has a federal law called the Genetic Information 
Non-discrimination Act to protect against genetic discrimination for employment 
and health insurance.71 In the Netherlands, insurance companies are also restricted 
in the use of genetic information of their clients. A survey among hypertrophic 
cardiomyopathy (HCM) mutation carriers showed that they frequently encounter 
problems when applying for insurances, often in the case of manifest disease, but 
the risk assessment of insurance companies is largely justified. However, 5% of 
mutations carriers encountered potentially unjustified problems, indicating the 
necessity to monitor the application of the existing laws and regulations by insur-
ance companies.72 Furthermore, updates of current legislation could be needed to 
accommodate emerging genetic data.
To keep up with the pace of genetic progress, we need to further combine clinical 
care with genomic and basic research in order to unravel new molecular pathways 
underlying diseases and new treatment options. The functional characterisation of 
novel variants is laborious work but it is proving indispensable. A challenging future 
lies ahead for clinical geneticists and genetic counsellors who will be confronted with 
increasing amounts of genetic data, often lacking a well-argumented interpretation. 
We need to be aware of the risks of genetic discrimination and the challenges posed 
by accidental findings. With these challenges in mind, the sharing of data in large, 
freely accessible databases or biobanks and large-scale international collaborations 
are essential. These steps will prevent that the ongoing progress in genetic research 
remains limited to the scientific community and should guarantee that patients will 
also benefit from our shared efforts.
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ACM  arrhythmogenic cardiomyopathy
AD  autosomal dominant 
AF   atrial fibrillation 
AHA  American Heart Association
ARVD/C arrhythmogenic right ventricular dysplasia/cardiomyopathy
AVNRT  AV-nodal re-entry tachycardia 
CAG  coronary angiogram
cM  centiMorgan
CPVT  catecholaminergic polymorphic ventricular tachycardia
Cx43  connexin 43
DCM  dilated cardiomyopathy
DES  desmin 
DSC2  desmocollin 2 
DSG2  desmoglein 2 
DSP  desmoplakin 
ECG   electrocardiogram
EPS  electrophysiology study 
ESC  European Society of Cardiology
HCM  hypertrophic cardiomyopathy
HF  heart failure
HST  haplotype sharing test
HTx  heart transplantation
IBD  identical-by-descent
IBS  identical-by-state
ICD  implantable cardioverter defibrillator
JUP  plakoglobin
LBBB  left bundle branch block
LD   linkage disequilibrium
LDAC  left-dominant arrhythmogenic cardiomyopathy 
LMNA  lamin A/C
LV  left ventricle/ventricular
LVEDD  left ventricular end-diastolic diameter
LVEF  left ventricular ejection fraction
Mb  megabase
MLPA  multiplex ligation-dependent probe amplification
MRI  magnetic resonance imaging
MYH7  beta myosin heavy chain
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NCCM  non-compaction cardiomyopathy
NMD  nonsense mediated decay 
nsVT   non-sustained ventricular tachycardia 
NYHA  New York Heart Association
OHCA  out of hospital cardiac arrest
PHORECAST  PHOspholamban RElated CArdiomyopathy STudy 
PKP2  plakophilin 2
PLN  phospholamban
PolyPhen  Polymorphism Phenotyping
PVC  premature ventricular complex 
RBBB  right bundle branch block
RCM  restrictive cardiomyopathy
RT-PCR  reverse-transcription polymerase chain reaction
RV  right ventricle/ventricular
RVEF   right ventricular ejection fraction
SA-ECG  signal-averaged ECG 
SCD   sudden cardiac death
SERCA2a  sarcoplasmic reticulum Ca2+-ATPase
SIFT  Sorting Intolerant From Tolerant
SNP  single nucleotide polymorphism
sVT   sustained ventricular tachycardia 
TAD  terminal activation duration
TFC  task force criteria
TMEM43 transmembrane protein 43
TTN  titin
UTR  untranslated region
UV  unclassified variant
VES  ventricular extrasystole
VF  ventricular fibrillation
VT  ventricular tachycardia
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nederlAndse sAMenVATTinG
Genetische en klinische karakterisering van aritmogene cardiomyopathie
Aritmogene cardiomyopathie is een progressieve, erfelijke hartspierziekte die 
kan leiden tot ventriculaire ritmestoornissen en plotse hartdood, maar ook tot 
eindstadium hartfalen.1 Aanvankelijk dacht men dat de ziekte het gevolg was van 
“rechter ventrikel dysplasie”, een abnormale ontwikkeling van de rechter ventrikel.2 
De eerste publicaties beschreven de betrokkenheid van de rechter ventrikel en dit 
werd beschouwd als het klassieke type van deze ziekte. Recenter zijn echter ook 
publicaties verschenen waarin betrokkenheid van beide ventrikels of vooral de linker 
ventrikel is beschreven.3-5 De termen “rechter ventrikel” en “dysplasie” lijken dus 
achterhaald en de naam “aritmogene cardiomyopathie” (ACM) heeft nu de voor-
keur voor deze vorm van een erfelijke hartspierziekte. ACM openbaart zich meestal 
tijdens de adolescentie of bij jonge volwassenen en een diagnose bij kinderen onder 
de 10 jaar is zeldzaam.6,7 De prevalentie in de algemene bevolking wordt geschat op 
1:1.000 – 1:5.000.2 Een erfelijke oorzaak, meestal een mutatie in een gen coderend 
voor een eiwit dat onderdeel uitmaakt van het desmosoom, kan worden aangetoond 
in ca. 50% van de gevallen.
Het eerste deel van dit proefschrift bestaat uit genetische studies en beschrijvingen 
van het klinisch beeld van ACM. Hoofdstuk 2 beschrijft de toepassing van de haplo-
type-sharing test om ziekteverwekkende mutaties op te sporen. Veel families met 
een erfelijke hartspierziekte zijn te klein voor klassieke linkage analyse, een vorm 
van genetisch koppelingsonderzoek. Daarom hebben we de haplotype-sharing test 
ontwikkeld om in families te zoeken naar grote gedeelde stukken van het genoom, 
die het meest waarschijnlijk de ziekteverwekkende mutatie bevatten. Aangedane 
familieleden hebben een haplotype (een combinatie van allelen op een chromo-
soom) met deze mutatie geërfd van een gezamenlijke voorouder. Deze voorouder 
kan vele generaties terug geleefd hebben, met als gevolg dat aangedane personen 
niet altijd weten dat zij verwant zijn aan elkaar. Het DNA van bewezen aangedane 
familieleden is gegenotypeerd met behulp van single nucleotide polymorphism 
(SNP) arrays en de resultaten zijn gecombineerd om te zoeken naar gedeelde 
haplotypes. Zowel een familie met ACM als een familie met dilaterende cardiomyo-
pathie (DCM) is geanalyseerd met de haplotype-sharing test. In beide stambomen 
hebben we gezocht naar gemuteerde genen in het grootste gedeelde haplotype en 
hebben we mutaties kunnen aantonen in respectievelijk het PKP2 gen en het MYH7 
gen. Bovendien hebben we uitgerekend dat een stamboom met minimaal zeven 
meioses een goede kans biedt om een mutatie te vinden in het grootste gedeelde 
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haplotype. Deze ‘proof-of-principle’ studie toonde aan dat de haplotype-sharing test 
kan bijdragen aan het identificeren van de ziekteverwekkende mutatie in families 
met laag penetrante Mendeliaanse aandoeningen, waar standaard methoden tekort 
schieten vanwege te kleine stambomen. De haplotype-sharing test kan ook worden 
toegepast als een gedeelde voorouder niet bekend is, maar wel wordt verondersteld, 
bijvoorbeeld als patiënten uit dezelfde regio afkomstig zijn.
Hoofdstuk 3 beschrijft moleculaire studies naar de PKP2 mutatie die is gevon-
den in hoofdstuk 2 en de klinische gegevens van de dragers van deze mutatie. De 
aangetoonde PKP2 splice site mutatie (c.2489+4A>C) leidt naar verwachting tot de 
expressie van een PKP2 eiwit met een gestoorde functie en niet tot een eiwit met een 
verminderde functie. Het klinisch beeld van mutatiedragers varieerde van ernstig 
aangedaan tot non-penetrantie (de ziekte komt niet tot uiting) op hoge leeftijd. 
Dit onderzoek suggereert dat alleen een PKP2 mutatie onvoldoende is om ACM te 
veroorzaken en dat andere genetische en/of omgevingsfactoren ook bijdragen aan 
het ontwikkelen van deze ziekte. Deze studie is een goed voorbeeld van de variabele 
expressie en de onvolledige penetrantie die beide kenmerkend zijn voor ACM.
Een founder mutatie, eenzelfde mutatie die afkomstig is van een verre voorouder, 
is regelmatig aangetoond bij Nederlandse patiënten met een erfelijke hartziekte. 
Hoofdstuk 4 beschrijft de grootste serie ACM patiënten met dezelfde founder muta-
tie in het PKP2 gen (p.Arg79X). Twaalf indexpatiënten en 41 familieleden zijn geëva-
lueerd en haplotype analyse toonde een gedeeld haplotype bij alle mutatiedragers, 
suggestief voor een founder mutatie. In 50% van deze families was plotse hartdood 
onder de leeftijd van 40 jaar opgetreden, terwijl slechts 60% van de mutatiedragers 
symptomatisch was op de leeftijd van 60 jaar. Ook deze studie is dus illustratief voor 
de variabele expressie en de verminderde penetrantie van ACM.
Of een aangetoonde mutatie daadwerkelijk ziekteverwekkend is, is niet altijd 
duidelijk. In Hoofdstuk 5 is de database met genetische variaties bij ACM (www.
arvcdatabase.info) in detail beschreven. In deze vrij toegankelijke, online database 
zijn alle genetische varianten in met ACM geassocieerde genen opgenomen. Deze 
database is een digitale opslagplaats voor moleculaire data en alle publicaties met 
aanvullende klinische en genetische gegevens. In juni 2012 bevatte de database 
856 genetische varianten en gegevens van 111 publicaties. De database heeft zijn 
waarde bewezen: sinds de lancering in oktober 2008 is de database ruim 125.000 
keer bezocht door 11.500 terugkerende bezoekers uit meer dan 50 landen.
Hoofdstuk 6 beschrijft een groot cohort van Nederlandse ACM families, verza-
meld in alle universitaire medische centra in Nederland. Om meer inzicht te krijgen 
in het natuurlijke beloop van de ziekte en de consequenties van een aangetoonde 
mutatie, werden alle vijf desmosomale genen geanalyseerd in 149 indexpatiënten. 
In totaal werden 302 familieleden onderzocht op dragerschap van de in hun familie 
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aangetoonde mutatie. Ziekteverwekkende mutaties werden aangetoond in 58% van 
de indexpatiënten. Dit waren met name PKP2 mutaties, inclusief drie patiënten 
met grote deleties in PKP2. In 90% van de families met meer dan één aangedaan 
familielid werd een PKP2 mutatie vastgesteld. Familieleden met een ziekteverwek-
kende mutatie hebben een zesmaal verhoogd risico op het ontwikkelen van ACM 
ten opzichte van familieleden uit een familie waar geen mutatie is vastgesteld. Dit 
rechtvaardigt frequente controles om beginnende symptomen op tijd op te sporen.
Het tweede deel van dit proefschrift betreft de identificatie van een founder mutatie 
in het phospholamban gen (PLN p.Arg14del) in een substantieel aantal Nederlandse 
patiënten met ACM of DCM. De klinische kenmerken van indexpatiënten met deze 
mutatie zijn beschreven in Hoofdstuk 7. Een cohort van 97 ACM indexpatiënten en 
257 DCM indexpatiënten werd gescreend op PLN mutaties. De p.Arg14del mutatie 
is aangetoond in 12% van de ACM patiënten en in 15% van de DCM patiënten. 
In Nederland is dit het grootste aantal patiënten met een hartspierziekte dat door 
dezelfde mutatie wordt veroorzaakt. Patiënten met de PLN p.Arg14del mutatie 
presenteerden zich in 46% van de gevallen met een laag voltage ECG en toonden 
een aritmogeen fenotype: een hoge mate van ontladingen van een implanteerbare 
cardioverter-defibrillator (ICD), harttransplantaties en een positieve familieanam-
nese voor plotse hartdood. De gemiddelde leeftijd van de 26 familieleden die over-
leden aan een plotse hartdood was 37,7 jaar. Immunohistochemische analyse van 
hartbiopten, beschouwd als een diagnostische test voor ACM, toonde afwezige of 
verminderde expressie van plakoglobine in de intercalaire schijven (die hartspiercel-
len aan elkaar koppelen), in vijf van zeven (71%) ACM samples en in slechts één van 
negen (11%) DCM samples. Dit hoofdstuk illustreert hoe een mutatie kan leiden tot 
verschillende klinische diagnoses, in dit geval ACM en DCM, en dat er een overlap 
is tussen deze twee hartspierziekten.
De geografische spreiding van dragers van de PLN p.Arg14del founder mutatie 
is beschreven in Hoofdstuk 8. Haplotype analyse onthulde een gemeenschappelijke 
voorouder die 575 tot 825 jaar geleden leefde. Meer dan 450 mutatiedragers zijn 
inmiddels geïdentificeerd en de meerderheid leeft in het noorden van Nederland, 
inclusief Noord-Holland. Een analyse van de geboorteplaatsen van de grootouders 
van de mutatiedragers toonde aan dat de oorspong van de mutatie waarschijnlijk 
in het oosten van de provincie Friesland ligt. Screening van een groot bevolkings-
cohort (PREVEND) identificeerde zes PLN p.Arg14del mutatiedragers in een groep 
van 8.267 personen (0.07%). Deze resultaten toonden aan dat de PLN p.Arg14del 
mutatie frequent voorkomt in de algemene bevolking van de noordelijke delen van 
Nederland en dat deze mutatie ook in andere delen van Nederland een van de meest 
voorkomende oorzaken van een erfelijke hartspierziekte is.
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In hoofdstuk 9 is een grote familie met ACM onderzocht. Een eerder aange-
toonde mutatie in het PKP2 gen (p.Ser140Phe) bleek niet bij alle aangedane per-
sonen in deze familie aanwezig te zijn. Nadat de familieleden uitgebreid in kaart 
waren gebracht, konden we geen bewijs vinden dat de PKP2 variant daadwerkelijk 
bijdraagt aan de ziekte. De PLN p.Arg14del mutatie was echter wel aanwezig bij alle 
familieleden met ACM en bij allen was de linker ventrikel ook aangedaan. Van de 
negen PLN p.Arg14del mutatiedragers hadden vier een laag voltage ECG.
Bij patiënten met een erfelijke hartspierziekte kan de identificatie van een ziekte-
verwekkende mutatie de diagnose bevestigen en vervolgens kunnen (asymptoma-
tische) familieleden worden opgespoord door familieonderzoek. Klinisch genetici 
vormen het hart van multidisciplinaire teams, bestaande uit genetisch consulenten, 
moleculair genetici, cardiologen, pathologen, neurologen en onderzoekers, die 
gezamenlijk zorg dragen voor patiënten met een hartspierziekte en hun familiele-
den. In de ‘General discussion’ wordt ingegaan op de recente ontwikkelingen in het 
genetisch onderzoek. Deze zullen leiden tot het opsporen van vele nieuwe mutaties 
en dat maakt het counselen van deze families steeds ingewikkelder. Voor klinisch 
genetici en hun collega’s belooft het een uitdagende toekomst te worden. Patiënten 
en hun families zullen baat hebben bij de vooruitgang die zal worden geboekt door 
deze uitdagingen aan te gaan.
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bijzonder Hennie Bikker, Dennis Dooijes, Roselie Jongbloed, Ronald Lekanne dit 
Deprez en Arthur van den Wijngaard wil ik hier danken voor hun bijdrage aan dit 
proefschrift.
De betrokken klinisch genetici wil ik bedanken voor het counselen van de patiën-
ten en het verzamelen van de data, met name Imke Christiaans, Eline Nannenberg, 
Laura van Lochem, Arjan Houweling, Jasper van der Smagt en Jan Post. Jasper, 
hoofdstuk 3 is een beloning voor jouw doorzettingsvermogen.
Alle cardiologen die een rol hebben gespeeld bij het tot stand komen van dit 
proefschrift wil ik hartelijk danken voor het verwijzen van de patiënten en hun 
betrokkenheid. In het bijzonder Rudolf de Boer, Isabelle van Gelder, Dirk Jan van 
Veldhuisen en Ans Wiesfeld wil ik danken voor hun bijdrage. Rudolf, jouw humor en 
enthousiasme heb ik zeer gewaardeerd. Dirk Jan, ik heb geleerd dat het schrappen 
van grote stukken tekst makkelijker kan zijn dan het lijkt, waarvoor dank.
Prof. Suurmeijer. Hartelijk dank voor het beschikbaar stellen van de afbeeldingen 
van de biopten en het geduld om deze samen met mij te beoordelen.
Prof. Hauer. Uw enthousiasme voor dit onderwerp is van grote waarde geweest 
voor mij en dit proefschrift. U bent zeer hartelijk en staat altijd open voor discussie. 
Dank voor de zeer plezierige samenwerking.
Peter en Evert, mijn paranimfen. Heel erg bedankt voor jullie hulp met de laatste 
loodjes. Dankzij jullie kan ik met minder zorgen toewerken naar de grote dag en ik 
ben blij dat jullie dan naast mij zullen staan. 
Dit promotieonderzoek heeft me veel nieuwe contacten en mooie reizen opgeleverd, 
maar belangrijker is dat mijn familie en vrienden er waren voor de nodige afleiding 
en relativering. 
Arjan, Bart, Benjamin, Bert, Ernst, Evert, Frank, Geert, Gerrit Jan, Jaap B, Jaap U, 
Jan Willem B, Jan Willem V, Johan, Kai, Lars, Maarten, Mark L, Mark vd W, Martijn 
van N, Martijn vd P, Merijn, Micha, Pieter, Rieuwerd, Rogier, Sander en Stephan; 
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sommigen van jullie ken ik al van jongs af aan en anderen pas enkele jaren. Dankzij 
jullie kan ik schitteren op de trainingen, helaas komt dat er tijdens de wedstrij-
den maar weinig uit. Ook aan de vrijdagmiddagborrels, de vele fietstochten en de 
teamuitjes bewaar ik zeer goede herinneringen. Rieuwerd, heel erg bedankt voor het 
ontwerpen van de omslag van dit proefschrift. 
Antonie, Jan-Arnout, Jisva en Frank J. We zien elkaar niet vaak, maar dat is geen 
belemmering voor een echte vriendschap. Ieder gaat zijn eigen weg, maar het con-
tact blijft en daar ben ik oprecht blij om.
Lieve familie en schoonfamilie, bedankt voor jullie belangstelling en adviezen. 
Jaap, tijdens het koffie drinken in de Euroborg konden we snel even bijpraten over 
mijn onderzoek, over Ruth, over voetbal en over andere belangrijke zaken. Gelukkig 
waren er ook voldoende momenten die langer dan een kwartier duurden. Emmie en 
Luppo, bedankt voor jullie betrokkenheid. Het is heerlijk om bij jullie langs te gaan 
en verder niets te hoeven.
Lieve Esther, hoewel je nu je dromen achterna gaat in Amsterdam, twijfel ik er 
niet aan dat we je nog regelmatig over de vloer zullen krijgen. Dat moet je vooral 
blijven doen, je bent altijd welkom.
Lieve Nynke, mijn grote kleine zusje, na wat omzwervingen ben je in de journalis-
tiek terecht gekomen en daar ben je helemaal op je plaats. Je culinaire inspanningen 
zijn aan mij altijd goed besteed. Ik vind het erg leuk om van je te horen hoe je aan je 
carrière werkt en ik ben trots op je. 
Lieve pap en mam, jullie hebben ons altijd aangemoedigd om onze talenten te 
benutten en mede dankzij jullie steun ben ik zover gekomen. Ik vind het fijn om 
te zien dat jullie nog zoveel uit het leven halen, ook al kost dat soms meer moeite 
dan jullie zouden willen. Het optimisme en het doorzettingsvermogen dat daarmee 
gepaard gaat is een bron van inspiratie. Bedankt voor alles.
Allerliefste Ruth, het leven is met jou veel leuker. Het is heerlijk om samen te zijn; 
op de leukste plaatsen van de wereld, maar ook gewoon thuis. Jij hebt mij leren 
genieten van de kleine dingen en je betekent alles voor me. Ik kijk ontzettend uit 
naar wat de toekomst ons zal brengen.
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